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CHAPTER I 
 
INTRODUCTION 
  
Although diabetes mellitus was long considered a disease of minor significance to 
world health, it is now the most common disease in the world.  The past two decades 
have seen an explosive increase in the number of people diagnosed with diabetes 
worldwide.  The epidemic is chiefly of type 2 diabetes and is largely due to the escalating 
rates of obesity.  Analyses by the International Obesity Task force indicate that 
approximately 58% of diabetes mellitus globally can be attributed to weight gain.  More 
specifically, in western countries, around 90% of type 2 diabetes cases are attributable to 
weight gain. 
Obesity and type 2 diabetes are thus causally linked.  Weight gain leads to insulin 
resistance and consequently hyperglycemia due to increase hepatic glucose production 
and decreased peripheral glucose uptake.  Insulin resistance places a greater demand on 
the pancreatic capacity to produce insulin, which also declines with age, leading to the 
development of clinical diabetes.  Although the primary cause of the disease is unknown, 
the major causative link between type 2 diabetes and obesity is an elevation of circulating 
FFA and intracellular lipids.  To optimize therapy with insulin sensitizing agents, it 
would be useful to understand how increased lipids contribute to insulin resistance.  
Therefore, the goal of this dissertation is to gain a better understanding of how changes in 
lipid metabolism alter glucose homeostasis.  This chapter will first provide an 
introduction to the following: the role of FFA in hormonal regulation of hepatic glucose 
1 
production and mechanisms by which elevated lipids alter insulin regulation of glucose 
homeostasis. 
 
Basic Glucose Metabolism 
A schematic of basic glucose metabolism in the hepatocyte is shown in Fig.1.1.  
Glucose entry into the cell occurs via facilitated diffusion using glucose transporters 
(GLUT-1 to -5).  While GLUT-1 is distributed ubiquitously, GLUT-2 is found in liver, 
pancreas, intestine and kidney, and GLUT-4 in muscle and adipose tissue, GLUT-3 and -
5 are found in brain and testis, and intestinal epithelial cells, respectively.  Although 
GLUT-1 is also expressed in the liver, GLUT-2 is considered to be the most significant 
hepatic glucose transporter because of its kinetics.  GLUT-2 is a membrane bound 
glucose transporter with a high Km relative to physiological blood glucose levels.  As 
GLUT-2 is a high capacity transporter, rapid equilibration occurs between the plasma and 
intracellular compartments, and therefore cellular glucose transport is virtually a linear 
function of the circulating glucose level (66). Thus, GLUT-2-mediated glucose transport 
is not thought to be a regulatory site for glucose uptake but rather a glucose sensor, 
consequently allowing β-cells and hepatocytes to respond accordingly (172).  In contrast, 
insulin stimulates translocation of GLUT-4 from intracellular vesicles to the plasma 
membrane: therefore it is an important determinant in glucose uptake in muscle and 
adipose tissue. 
Once glucose enters the cell it is phosphorylated by either glucokinase (GK) in 
the liver and pancreatic β-cells or hexokinase (HK) in muscle and adipose tissue, 
producing glucose-6-phosphate (G6P).  After phosphorylation glucose enters into either 
2 
 Figure 1.1:  Basic glucose metabolism in the hepatocyte. Transporter: glucose 
transporter -2 (GLUT-2). Substrates: glucose-6-phosphate (G6P); glucose-1-phosphate 
(G1P); uridine diphosphate-glucose (UDP-Glc); fructose-6-phosphate (F6P); fructose-
2,6-bisphosphate (F2,6P2); fructose-1,6-bisphosphate (F1,6P2); dihydroxyacetone 
phosphate (DHAP); glyceraldehyde-3-phosphate (GAP); phosphoenylpyruvate (PEP); 
oxaloacetate (OAA); glycerol-3-phosphate (G3P). Enzymes:  glucokinase (GK); 
Glucose-6-phosphatase (G6Pase); glycogen synthase (GS); glycogen phosphorylase 
(GP); 6-phosphofructo-1-kinase (PFK-1); fructose-1,6-bishposphatase (F1,6P2); 
phosphofructo-2-kinase/fructose-2,6-bisphosphatase (PFK-2/F2,6P2ase); L-type pyruvate 
kinase (PK); pyruvate carboxylase (PC); lactate dehydrogenase (LDH); pyruvate 
dehydrogenase (PDH); phosphoenolpyruvate carboxykinase (PEPCK); glycerol kinase 
(GlycK); glyceraldehyde-3-phosphate dehydrogenase (G3PDH).  cytosolic, (c); 
mitochondrial, (m). 
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glycogen synthesis or glycolysis (6, 56).  In the liver and kidney the carbon in G6P may 
also be released into the plasma after removal of phosphate by glucose-6-phosphatase 
(G6Pase).   
Glucose channeled into glycogen, provides a carbohydrate reserve.  Glycogen is a 
branched polymer of glucose which consists of two types of glycosidic linkages, chains 
of α1→4-linkages with α1→6-branches spaced about 4 to 6 residues along the α1→4 
chain. Glycogen synthesis is initiated by the conversion of G6P to glucose-1-phosphate 
(G1P) by phosphoglucomutase.  G1P is then activated to uridine diphosphate (UDP)-
glucose by UDP-glucose pyrophosphatase.  Glycogen synthase, the regulatory enzyme of 
glycogen synthesis, then transfers the glucosyl residue of UDP-glucose to the 
nonreducing end of a glycogen branch.  As glycogen synthase is unable to form α1→6 
bonds these branches are formed by either glycogen-branching enzyme amylo-(1→4 to 
1→6)-transferase or glycosyl-(4→6)-transferase.   
When levels of G6P are in excess, (i.e. beyond that needed to replenish 
carbohydrates reserves) G6P is then channeled into glycolysis for energy production and 
conversion into triglycerides.  In glycolysis, a six-carbon molecule of glucose is degraded 
by a series of enzyme catalyzed reactions to produce 2 three-carbon molecules of 
pyruvate.  First G6P is converted to fructose-6-phosphate (F6P) which in turn is 
phosphorylated by phosphofructokinase (PFK-1) to yield fructose-1,6-bisphosphate 
(F1,6P2).  F1,6 P2 is next split into two three carbon molecules, dihydroxyacetone 
phosphate (DHAP) and glyceraldehyde-3-phosphate (GAP).  Only GAP continues 
through glycolysis, however DHAP is isomerized into GAP so that both three-carbon 
molecules can be metabolized to pyruvate.  Of note, although DHAP does not continue 
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through glycolysis, it can enter another metabolic pathway, de novo lipogenesis, and thus 
contributes to the intracellular lipid content.  Through a series of reactions, GAP is then 
converted to phosphoenylpyruvate (PEP) which in turn is phosphorylated by pyruvate 
kinase to produce pyruvate.  Under anaerobic conditions, pyruvate is converted to lactate 
by lactate dehydrogenase whereas under aerobic conditions, pyruvate is oxidized to 
acetyl-CoA via pyruvate dehydrogenase and utilized for lipid synthesis (cytosol) or for 
energy production entering the tricarboxylic acid (TCA) cycle (mitochondria). 
Under fasting conditions, glucose is produced by the liver and kidney via two 
mechanisms: gluconeogenesis and glycogenolysis.  Gluconeogenesis is the de novo 
synthesis of glucose from three-carbon molecules such as amino acids (alanine, 
glutamine) from muscle proteolysis, lactate from glycolysis, and glycerol from lipid 
catabolism.  FFA also provide energy for gluconeogenesis (will be discussed later in this 
chapter).  Gluconeogenesis is conceptually the opposite of anaerobic glycolysis.  Alanine 
and lactate are converted into pyruvate by alanine aminotransferase and lactate 
dehyrdrogenase, respectively.  Pyruvate then enters the mitochondria and is carboxylated 
by pyruvate carboxlase to produce oxaloacetate, which in turn is decarboxylated by 
phosphoenolypyruvate carboxykinase (PEPCK) yielding PEP.  Through a series of 
reactions, PEP is converted to F1,6P2.  Glycerol enters the gluconeogenic pathway after 
being phosphorylated by glycerol kinase as DHAP which is then converted to F1,6P2.  
Fructose-1,6-bisphosphatase (F1,6P2ase) then converts F1,6P2 to F6P which is in 
equilibrium with G6P.  Gluconeogenesis is primarily regulated by fructose-2,6-
bisphosphate (F2,6P2), which, in the liver, allosterically activates PFK-1 and inhibits 
P1,6P2ase.  F2,6P2 levels are regulated by the bifunctional enzyme 6-phosphofructo-2-
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kinase/fructose-2,6-bisphosphatase (PFK-2/F2,6P2ase).  F2,6P2 is produced via 
phosphorylation of F6P by PFK-2 and this reaction is reversed by F2,6 P2ase.  
Phosphorylation of the bifunctional enzyme activates F2,6P2ase while at the same time 
inhibiting FPK-2, and thus reduces F2,6P2 levels.  This therefore relieves inhibition of 
P1,6P2ase and decreases PFK-1 activity, thereby simultaneously stimulating 
gluconeogenesis and hindering glycolysis. 
The second mechanism of glucose production is the degradation of glycogen into 
glucose, or glycogenolysis.  External α1→4-linked residues of glycogen are removed by 
glycogen phosphorylase forming G1P, which in turn is converted to G6P by 
phosphoglucomutase.  The rate-limiting regulatory step in glycogenolysis is glycogen 
phosphorylase as G1P and G6P are in equilibrium. 
The final reaction in glucose production, by either gluconeogenesis or 
glycogenolysis is the conversion of G6P to free glucose by glucose-6-phosphatase 
(G6Pase).  The liver and kidney are the only two sites which are known to express 
G6Pase (228) but it has been suggested that the gluconeogenic pathway exists in the gut 
(179).  Free glucose is then released into the plasma via GLUT-2. 
 
The Role of FFA in Hormone Regulation of Hepatic Glucose Production (HGP) 
 
Regulation of Hepatic Glucose Production 
 The liver plays a central role in maintaining glucose homeostasis.  This is due to 
both its anatomical location (it receives portal supply of absorbed nutrients) as well as its 
ability to consume and produce glucose (183). Following an overnight fast (in the post 
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absorptive state), the liver is the major contributor of endogenous glucose production 
with the only other contributing organ being the kidneys. Contribution of the kidneys to 
endogenous glucose production has been estimated to be 5-23% in the overnight fasted 
human (41, 88, 269), and 10%  (176) or less (118) in the overnight fasted dog leaving the 
remaining 90% to be produced by the liver. Therefore it is the liver that is primarily 
responsible for delivering glucose to both the non-insulin-sensitive (nervous, red blood 
cells, skin, smooth muscle) and the insulin sensitive (muscle and fat) tissues. Thus, the 
factors which regulate hepatic glucose production (HGP) are particularly important to 
glucose homeostasis. 
HGP is tightly controlled on a minute-to-minute basis by systemic levels of 
hormones and substrates.  When plasma glucose levels rise, the rate of glucose produced 
by the liver decreases, and vice versa.  The simplest regulator of HGP is the plasma 
glucose level itself, which has direct effects on the liver.  However, the endocrine 
pancreas plays the most significant role in controlling rates of HGP.  Pancreatic β- and α-
cells respond to circulating glucose levels by modifying their secretion of insulin and 
glucagon, respectively.  Glucagon stimulates glucose production, while insulin inhibits it.  
The brain also regulates HGP by modulation of liver and pancreatic function via 
sympathetic and parasympathetic signals, as well as release of epinephrine from the 
adrenal medulla.  Hormones which chronically regulate HGP are cortisol, growth 
hormone, and thyroid hormone.  Recently, the role of the adipocyte in maintaining 
glucose homeostasis has become evident not only through its effect on the plasma FFA 
levels but also via the release of adipocyte secreted proteins, such as leptin, resistin, 
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tumor necrosis factor-α, and adiponectin, to name a few.  However, the function(s) of 
these hormones are not completely understood and will not be discussed in detail here.   
Each hormone mentioned above directly and/or indirectly regulates HGP in a 
specific manner.  The first goal of this dissertation is to describe the direct and indirect 
mechanisms by which insulin, epinephrine, and glucagon acutely regulate HGP 
(gluconeogenesis and glycogenolysis) and how FFA play a role in regulating their 
physiological actions at the liver in vivo. 
 
Inhibition of HGP by Insulin 
 
Insulin Signaling 
 
 Insulin signaling regulates cell growth and differentiation, and promotes energy 
storage of substrates in fat, liver, and skeletal muscle by stimulating lipogenesis, 
glycogen and protein synthesis, and inhibiting lipolysis, glycogen and protein breakdown. 
The effects of insulin are rapid occurring within seconds to minutes after it binds to the 
insulin receptor and are mediated through a complex network of signaling pathways.  The 
insulin receptor is present in almost all cell types, although the numbers vary from only a 
few in the erythrocyte to a very significant quantity in insulin-sensitive cells found in 
liver, skeletal muscle, and adipose tissue.  
 The insulin receptor is a tetrameric protein that consists of two extracellular α-
subunits and two intracellular β-subunits (236, 275). It belongs to a subfamily of receptor 
tyrosine kinases, which also includes the insulin-like growth factor I receptor and the 
insulin receptor-related receptor (203). Each of these receptor tyrosine kinases are the 
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products of separate genes, in which the two subunits are derived from a single chain 
precursor or proreceptor that is processed by a furin-like enzyme to produce a single α-β-
subunit complex.  Two of the α−β dimers are linked with disulfide bonds to form the 
tetramer.  Likewise, an additional receptor isoform can be created by the linkage of α−β 
dimers of the insulin receptor and insulin-like growth factor which form a hybrid 
complex.  Functionally, the insulin receptor acts like an allosteric enzyme in which the α-
subunit inhibits the tyrosine-kinase activity of the β-subunit. Upon binding of insulin to 
the α-subunits, the kinase of the β-subunits is activated.  Immediately following 
activation, the β-subunits undergo transphosphorylation which in turn leads to a 
conformational change and a further increase in kinase activity.   
 Upon activation of the insulin receptor, the β-subunits phosphorylate insulin 
recepotor substrates (IRS) that are linked to two main signaling pathways: the 
phosphatidylinositol 3-kinase (PI3-K) - AKT/protein kinase B (PKB) pathway and the 
Ras-mitogen-activated protein kinase (MAPK) pathway.  The PI3K/PKB pathway is 
responsible for most of the metabolic actions of insulin whereas the MAPK pathway 
regulates cell growth and differentiation.  As the focus of this dissertation is the hormone 
regulation of lipid and glucose metabolism, only the PI3K/PKB pathway will be 
discussed here (Fig.1.2).   
In general, after phosphorylation of tyrosine residues by the insulin receptor, 
activated IRS proteins bind to intracellular proteins containing Src homology-2 (SH2) 
domains, such as the regulatory subunit(s) of PI3K.  Binding of PI3K to 
phosphotyrosines on IRS proteins leads to the production of the lipid second messenger 
phosphatidylinositol-3,4,5-triphosphate (PIP3) from PIP2 at the plasma membrane.  PIP3
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Figure 1.2:  Insulin receptor-signaling pathway.  Important steps in the insulin 
pathway are the insulin receptor, the insulin receptor substrates (IRS) 1-6, and the 
phosphatidylinositol 3-kinase (PI3K) with its multiple isoforms of its regulatory and 
catalytic subunits, phosphoinositide-dependent kinase (PDK) and protein kinase B 
(PKB).  Negative regulators include c-Jun-N-terminal kinase (JNK), protein tyrosine 
phosphatase (PTP), phosphotase and tensin homoloque (PTEN), and Src-homology-2 
domain-containing inositol phosphatase-2 (SHIP-2). Downstream or intermediate 
effectors, as well as modulators of these steps atypical protein kinase C (aPKC)  and 
phosphatidylinositol 4,5-biphosphate (PIP2), and phosphatidylinositol 3,4, 5 triphosphate 
(PIP3). From reference (276). 
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Then recruits phosphoinositide dependent kinase (PDK) and PKB at the membrane where 
PKB is phosphorylated by PDK.  Activated (phosphorylated) PKB is released into the 
cytosol where it then mediates many metabolic actions of insulin.  The specific metabolic 
actions of the PI3K/PKB signaling pathway result from differences in the tissue 
distribution, subcellular localization, and downstream targets of the many isoforms of 
IRS proteins, PI3K, and PKB (276).   
There are six members of the IRS family which have been shown to be activated 
by the insulin receptor and insulin growth factor-1 receptor kinases (35, 93, 157, 273, 
274).   IRS-1 and -2 are widely distributed, IRS-3 is largely restricted to adipocytes and 
brain, IRS-4 is expressed primarily in embryonic tissues, and IRS-5 and -6 have limited 
tissue expression.  Although the IRS proteins are highly homologous, studies in knockout 
mice and cell lines indicate that the isoforms are not redundant but have harmonizing 
roles in insulin signaling.  IRS-1 knockout mice have impaired insulin action largely in 
muscle (9).  IRS-2 knockout mice have greater defects in insulin signaling in the liver, 
and show altered growth in neurons and pancreatic β-cells (155).  More specifically, 
tissue specific knockdown of hepatic IRS-1 and IRS-2 using adenovirus short hairpin 
RNAs in vivo has demonstrated that IRS-1 mediates expression of genes involved in 
gluconeogenesis whereas IRS-2 mediates the expression of genes involved in lipogenesis 
(277).  The functional roles of IRS proteins 3-6 have not been investigated extensively, 
however it has been shown that IRS-3 and -4 cannot activate MAPK or PI3K to the same 
degree as IRS-1 and IRS-2 (282).  Isoforms of IRS proteins also differ in their cellular 
compartmentalization (136) and activation kinetics (199).   
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 Studies have demonstrated a pivotal role of PI3K in mediating the metabolic 
actions of insulin.  Inhibitors or dominant negative constructs of PI3K block almost all of 
insulin’s metabolic actions including stimulation of glucose transport, glycogen 
synthesis, and lipid synthesis.  Additionally, PI3K has been shown to play an important 
role in other insulin-regulated processes such as protein synthesis and attenuation of 
PEPCK (3) and G6Pase (73) gene expression.  The PI3K enzyme consists of a SH2-
containing regulatory subunit of ~85 kDa and a catalytic subunit of ~110 kDa, each of 
which occurs in several isoforms.  Several isoforms of the regulatory subunit of PI3K 
have been identified.  These isoforms are derived from three separate genes, Pik3r-1, -2, 
and -3 (8).  Pik3r-1 encodes 65-75% of the regulatory subunits, mostly in the form of 
p85-α, but is also responsible for producing the splice variants, p55-α and p50-α.  Tissue 
distributions of these specific isoforms vary where p85-α is expressed ubiquitously, p55α 
is limited to skeletal muscle, and p50α is restricted to the liver.  Pik3r-2 produces p85-β 
and accounts for ~20% of the regulatory subunits in the cell. Pik3r-3 encodes p55PIK 
and is expressed at low levels in most tissues.  Under normal circumstances, the levels of 
regulatory subunits are in excess of the catalytic subunits and phosphorylated IRS 
proteins and therefore free monomeric regulatory subunits compete with the p85-p110 
heterodimer for binding to the phosphotyrosines on IRS proteins.  Additionally, it has 
been shown that free p85-α sequester IRS-1 and compartmentalize PI3K activity (167). 
 The three catalytic isoforms, p110-α, -β, and -δ are derived from three different 
genes and show different tissue distribution (245).  p110-α and -β are expressed in most 
tissues whereas -δ are limited to leukocytes.  Studies over-expressing p110-α and –β 
suggest p110-β is more important in mediating insulin-stimulated glucose uptake than 
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p110-α (10).  Dimerization of the catalytic subunits to regulatory subunits stabilizes p110 
because free p110 is unstable and quickly degraded (301).  Binding of p110 to the 
regulatory subunits also allosterically inhibits enzymatic function until the heterodimer 
binds to phosphorylated IRS proteins, which relieves its inhibition (301).    
PKB has three isoforms, each encoded by a different gene, PKB-α, -β, and –γ 
(also known as AKT 1-3).  PKB-α and –β are widely distributed with PKB-β highly 
expressed in insulin-sensitive tissues whereas PKB-γ is predominantly expressed in the 
nervous system.  Although PKB-α and –γ do not seem to play a significant role in 
glucose homeostasis (51, 281), PKB-β deficient mice display insulin resistance and 
develop diabetes due to the ability of insulin to decrease hepatic glucose output and 
induce glucose untilization (50).   Additionally, PKB-β has been found to be co-localized 
with GLUT-4-containing vesicles, a characteristic not observed by PKB-α and –γ (37).   
 Another downstream effecter in the PI3K pathway in mediating the metabolic 
effects of insulin is the activation of aPKC.  In contrast to conventional or novel PKCs, 
aPKCs are not senstitive to the second messengers, calcium and diacylglycerol (DAG).  
The mechanisms of aPKCs are similar to PKB, in that they require PIP3 and 
phosphorylation by PDK-1 (262).  aPKCs have been shown to play a role in insulin-
stimulated glucose uptake and GLUT-4 translocation in adipocytes and muscle (94).  
aPKCs are also involved in the regulation of lipid synthesis in the liver by increasing 
sterol-regulatory-element binding protein 1-c expression (95).  The PKC isoenzymes -ζ 
and -λ are encoded by two different genes, and their levels of expression vary, PKC-λ is 
the main aPKC in skeletal muscle and adipose tissue of mouse whereas PKC-ζ is more 
prominent in humans (94).   
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 There is negative regulation of the PI3K pathway at the levels of the insulin 
receptor, IRS proteins, PI3K, and PKB.  One class of regulatory proteins involved is the 
protein tyrosine phosphatases (PTPs), the most studied of which is PTP-1B.  PTB-1B 
interacts directly with the insulin receptor and dephosphorylates important tyrosine 
residues, thereby reducing activity (89).  IRS proteins are also negatively regulated by 
PTPs, serine phosphorylation, and ligand-induced downregulation.  Many kinases that 
can phosphorylate IRS proteins on serine residues, such as c-Jun-N-terminal kinase 
(JNK)(178), extracellular signal-regulated kinase (ERK) (31), and S6 kinase (122) are 
activated by insulin, which suggests that serine phosphorylation of IRS proteins might 
represent a negative-feedback mechanism for the insulin-signaling pathway.  PI3K can be 
negatively regulated by phosphatase and tensin homologue (PTEN) (292) and SH2-
containing inositol 5’-phosphatase-2 (SHIP-2) (258), which dephosphorylates and 
inactivates PIP3.  PKB activity is regulated by several inhibitory molecules including 
protein phosphatase-2A and the PH-domain leucine-rich repeat protein phosphatase 
(PHLPP) (102), which directly dephosphorylates and deactivates PKB.  Another 
regulator, tribbles-3 (TRB-3), binds to unphosphorylated PKB and inhibits its 
phosphorylation and therefore activation (81).  Cross-talk from other pathways have also 
been shown to negatively regulate insulin signaling, however this will be discussed later 
in this chapter.  
Insulin Action In Vivo 
 Acute inhibition of HGP primarily involves suppression of glycogenolysis (GLY) 
with only a modest effect on gluconeogenesis (GNG).   It was previously thought that 
insulin completely suppressed GNG, however, this concept was based on in vitro studies 
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where insulin suppresses expression and activity of key GNG enzymes (138, 166).  More 
recently, in vivo studies in humans (25, 106) and dogs (83) indicate that insulin only 
moderately reduces GNG.  During a 4-h hyperinsulinemic-euglycemic clamp in over-
night-fasted normal subjects, Boden et al. (25) showed GNG to fall from 1.5 to 0.67 
mg/kg/min after 4-h of hyperinsulinemia (P < 0.05).  Under similar conditions, 
Gastaldelli et al. (106) reported that GNG decreased from 1.2 to 0.8 mg/kg/min during a 
2½-h hyperinsulinemic-euglycemic clamp (P < 0.05).  Although significant decreases 
were observed, both of these studies utilized the 2H2O method to approximate rates of 
GNG, which overestimates the effects of insulin on GNG (by underestimating GNG 
because of glycogen cycling), indicating that insulin only has a modest impact on GNG.  
Using three techniques to assess GNG, one of which being the 2H2O method, Edgerton et 
al. (83) reported no significant drop in GNG flux during a 3-h intraportal infusion of 
insulin (twofold basal) in over-night-fasted dogs.  However, peripheral insulin levels 
were significantly lower compared to the human studies mentioned above.  In a 
subsequent study, Edgerton et al. (85) showed that insulin at levels fourfold above basal, 
did not significantly inhibit of GNG, even in the absence of appreciable glycogen 
breakdown.  In these same studies, rates of GLY (mg/kg/min) fell from 1.3 to -0.3 in the 
Boden study (25), from 0.8 to -0.2 in the Gastaldelli study (106), and from 1.0 to 0.4 in 
the Edgerton study (83) (values of 2H2O method).  Taken together, insulin inhibits HGP 
primarily by suppressing GLY, since only a small fraction of GNG accounted for the fall 
in HGP. 
 The traditional view has been that insulin, being secreted directly into the liver via 
the portal vein, was responsible for the hormone’s inhibitory effect on the liver.  Work 
15 
from our lab has shown that the liver sinusoidal insulin level does indeed potently 
regulate HGP.  Studies were carried out in overnight-fasted, pancreatic clamped 
conscious dogs in which the insulin level was either increased (253) or decreased (256) in 
the portal vein (thus resulting in a rise or fall in hepatic sinusoidal insulin levels, 
respectively) in the absence of any change in the arterial plasma insulin level.  Glucose 
was infused peripherally in order to maintain euglycemia and glucagon was successfully 
clamped at basal values in both studies.  Net hepatic glucose output (NHGO) fell 40% by 
30 minutes in response to a rise in hepatic sinusoidal insulin whereas NHGO increased 
fourfold by 15 minutes in response to a decline in hepatic sinusoidal insulin.  Our lab has 
also shown that this effect is independent of the route (hepatic artery vs. portal vein) by 
which insulin enters the liver (254).  Taken together, these studies clearly show that HGP 
is rapidly and sensitively regulated by the direct action of insulin at the liver.  
Additionally, as net hepatic lactate output did not increase or decrease in response to a 
selective rise or fall of hepatic sinusoidal insulin respectively, and there was no 
significant change in GNG in either study, these studies provide further evidence that 
insulin suppresses HGP primarily by inhibiting GLY.   
 In 1987, Prager et al. (215) was the first to suggest that peripheral insulin could 
suppress HGP in the absence of any change in the portal insulin level, and thus 
implicated an indirect mechanism of inhibition.  This concept has been supported by 
many investigators (1, 16, 109, 162) but the indirect mechanisms by which insulin 
suppresses HGP is probably best demonstrated in an elegant study performed by Sindelar 
et al. (253).  This study suggested that HGP is inhibited by selective increases in the 
portal vein or arterial insulin level.  A greater than 50% reduction in NHGO was 
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observed in response to either a 14 μU/ml rise in the portal insulin level (no change in 
arterial insulin) or a 14 μU/ml rise in the arterial insulin level (no change in portal 
insulin).  Although the extent by which insulin inhibited HGP was similar in both groups, 
the time required to detect a marked suppression was significantly different.  The rise in 
portal insulin quickly (~30 min) suppressed NHGO whereas 1-h was necessary to detect 
significant suppression following a rise in the arterial insulin.  Most interestingly, the 
above studies also showed that the direct effect of insulin on HGP resulted from a rapid 
decrease in GLY, whereas the indirect effect of insulin resulted primarily from a 
reduction of GNG flux.  This decrease in GNG resulted from a fall in net hepatic uptake 
of gluconeogenic precursors due a reduction in gluconeogenic amino acids from muscle, 
glycerol from adipose tissue, and the diversion of carbon derived from glycolysis to 
lactate within the hepatocyte.  Furthermore, Sindelar et al. (254) went on to show that 
equimolar increments in arterial and portal insulin levels resulted in an additive effect on 
the liver. 
 Insulin can also indirectly affect HGP by acting on the pancreatic α cell to inhibit 
the secretion of glucagon, a known potent stimulating hormone of glucose production.  In 
fact, the suppression of glucagon secretion is dose dependently regulated by insulin 
starting as low as 10 μU/ml (189).  It is thought that the architecture of the murine 
pancreatic islet where α-cells reside in the periphery of the β-cell core, is unique in that 
blood flows from the β-cells to the α-cells, allowing insulin to inhibit glucagon secretion. 
However, the pattern of cell distribution in the pancreatic islet architecture of humans, 
non-human primates, and dogs is such that the α-cell is dispersed throughout the islet 
(33).   Nevertheless, it has been shown in both humans (161) and dogs (108) that insulin-
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inhibited glucagon secretion can explain a fraction of the indirect effects of insulin on the 
liver.   Additionally, it has been thought that insulin has an indirect effect on the liver via 
its action on the brain. Our lab has previously shown that under hypoglycemic conditions, 
insulin acts on the brain to rapidly stimulate sympathetic outflow, increasing circulating 
levels of epinephrine, glucagon, and cortisol, and ultimately enhancing HGP (70).  
Furthermore, studies from the Rossetti group, showed that a chronic decrease in 
hypothalamic insulin receptors and hepatic vagotomy both resulted in a 50% decrease of 
insulin-suppressed glucose production (196, 213).  Subsequent work by this group 
suggests that insulin acts in the medial hypothalamus via adenosine triphosphate (ATP)-
sensitive potassium channels to inhibit hepatic gluconeogenesis (197, 213).  However, in 
the overnight-fasted conscious dog, in the presence of arterial hyperinsulinemia and 
hepatic insulin deficiency, an acute fourfold rise in the head insulin level did not bring 
about any inhibition of HGP (86).  Compared to chronic manipulation of the “brain-liver’ 
circuit, it is possible that an acute rise in insulin is not sufficient to cause a change in the 
hypothalamic signal to the liver, and thus does not play a role in the acute regulation of 
HGP.  Additionally, it is likely that the significance of insulin’s indirect action on the 
liver via the brain varies among species.  Differences in rates of basal HGP in rats (~6 
mg/kg/min), mice (15-20 mg/kg/min), and dogs and humans (~2-3 mg/kg/min) may be 
due to dissimilarities in neural drive to the liver.  Therefore, insulin action in the brain 
may be essential to regulate HGP in rodents but not species with lower rates of basal 
HGP.   
 In summary, it is clear that insulin regulates HGP by both direct action on the 
liver, inhibiting GLY and indirect actions on skeletal muscle, adipose tissue, and perhaps 
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the brain, reducing GNG.  As insulin is secreted from pancreatic β-cells directly into the 
portal vein, and 50% of the insulin that survives first pass degradation by the liver 
subsequently acts on peripheral tissues, it seems logical for insulin to quickly inhibit 
GLY (predominant contributor to HGP except under extreme fasting conditions), 
whereas GNG is reduced at a much slower rate.   
 
Role of FFA in Mediating Insulin Inhibition of HGP 
 In the study by Sindelar et al. (253) in which the direct and indirect mechanisms 
of insulin on HGP were addressed, they found that the only ~20% of the suppression of 
HGP could be explained by the change in hepatic gluconeogenic precursor uptake.  
Additionally, a correlation between the time course of peripheral insulin’s suppressive 
effect on HGP and the suppression of lipolysis was observed.  One hour following a 
selective rise in peripheral insulin (no change portal insulin), levels of plasma FFA were 
maximally suppressed and NHGO was significantly reduced.  Bergman and colleagues 
also noted a strong correlation between the effects of a rise in systemic insulin on the 
liver and its effects on the adipocyte (2, 14).  To determine the extent of contribution of 
FFA suppression to insulin’s overall action on the liver, Sindelar et al. (255), again 
brought about a selective rise in the arterial plasma insulin concentration in the overnight-
fasted conscious dog. In one group, the fall in FFA and glycerol was prevented by an 
Intralipid (triglyceride emulsion) and heparin infusion, while in the other group, FFA and 
glycerol were allowed to fall.  When plasma FFA levels were prevented from falling, 
50% of insulin’s indirect inhibition of HGP was eliminated.  As expected, a small 
increase in net hepatic glycerol uptake occurred due to the mild elevation of glycerol that 
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occurred during the Intralipid/heparin infusion.  However, this change in glycerol uptake 
in the liver could only account for small fraction of the reduction of the fall in NHGO.  
Therefore, the main substrate responsible for the reduction in insulin’s indirect effect on 
HGP was FFA.  In agreement with this, Bergman and colleagues also showed that the 
inhibitory effect of a rise in systemic insulin on HGP could be partially reduced by 
preventing the fall in plasma FFA (225).   
 In the original studies by Sindelar et al. (253), addressing the direct and indirect 
effects of insulin on HGP, they suggested that the indirect action resulted primarily from 
a reduction of GNG.  Although net hepatic GLY and GNG were not assessed in their 
study in which falls of FFA and glycerol were prevented, the data suggest that a decrease 
in FFA relieves the inhibition of glycolysis and in turn reduces the net rate of GNG.  The 
fall in plasma FFA levels and therefore hepatic FFA uptake correlated almost perfectly 
with an increase in net hepatic lactate production that was not evident when the FFA 
level was clamped.   
 In a normal overnight-fasted dog, basal HGP results primarily (~60%) from GLY.  
When glycogen is being degraded, some of the carbon derived appears to be routed down 
the glycolytic pathway to pyruvate and then exits the liver as lactate.   Increased cellular 
FFA uptake and subsequent increases in fatty acid oxidation can alter enzymatic activity 
of glucose metabolic pathways. Active β-oxidation during fasting leads to increased 
intracellular NADH and acetyl-CoA in the mitochondria. An elevation of NADH would 
favor the activation of lactate dehydrogenases, converting the gluconeogenic precursors 
to pyruvate.  Acetyl-CoA also supports activation of the gluconeogenic pathway as it is 
an essential activator of pyruvate carboxylase .  Additionally, NADH and acetyl-CoA are 
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known allosteric inhibitors of pyruvate dehydrogenase.  This inhibition blocks the 
utilization of pyruvate for energy metabolism and directs pyruvate, lactate, and alanine 
toward the synthesis of glucose.  Furthermore, inhibition of PDH promotes formation of 
oxaloacetate (OAA) (107) and citrate (221).  An increase in intracellular citrate levels 
leads to the inhibition of PFK, a rate limiting enzyme in the glycolytic pathway, thus 
impeding glycolysis and further promoting gluconeogenesis.   
 When FFA levels were allowed to fall in the study by Sindelar et al. (255), the 
ratio of β-hydroxybutyrate (β-OHB) to aceteoacetate (Acac) fell from 1 to 0.5 indicating 
that less fatty acids were being oxidized by the liver.  In contrast, when the FFA level 
was clamped, the β-OHB/Acac ratio did not change.  Therefore, it is possible that the fall 
in FFA, resulted in a decrease in hepatic β-oxidation, lowering intracellular NADH, 
acetyl-CoA, and citrate levels.  This in turn decreased the promotion of gluconeogenesis 
and relieved the inhibition of glycolysis, redirecting glycogenolytically derived carbon 
within the hepatocyte.  Indeed, the increase in hepatic lactate output corresponded to the 
decrease in NHGO.   
 Although the work shown here suggests that the indirect effects of insulin on the 
adipocyte mediate the hormone’s ability to suppress GNG, it is possible that decreased 
FFA may also enhance insulin’s ability to suppress GLY.  In fact, it has been shown that 
elevated FFA produce hepatic insulin resistance by inhibiting insulin suppression of GLY 
(25).  Additionally, it has been suggested that increases in plasma FFA impair insulin 
signaling in the liver.  However, the mechanisms by which FFA alter hepatic insulin 
sensitivity will be discussed later in this chapter under FFA-Induced Insulin Resistance.   
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Stimulation of HGP by Epinephrine and Glucagon 
 
Epinephrine and Glucagon Signaling 
 To stimulate HGP, epinephrine and glucagon bind to the adrenergic receptors and 
the glucagon receptor, respectively, all of which belong to the G-protein coupled 
superfamily of receptors.  G-proteins are heterotetrameric, plasma-membrane, guanosine-
nucleotide-binding proteins that are closely associated with hormone receptors bound to 
the inner surface of the plasma membrane and consist of three subunits, α, β, and γ.   G-
proteins are classified according to the different α-subunits.  For example, Gαs stimulates 
adenylate cyclase which lead to in increase in intracellular cAMP, Gαq activates 
phospholipase C and ultimately releases stored intracellular Ca2+, and Gαi decreases 
adenylate cyclase activity and therefore lowers intracellular cAMP levels. In the resting 
state, guanosine diphosphate (GDP) is bound to the GTPase on the α-subunit.  Binding of 
a hormone results in a conformational change of the receptor and recruits G-proteins 
stimulating exchange of GDP for guanosine triphosphate (GTP) on the Gα-subunit.  GTP 
binding leads to release of the β- and γ-subunits, allowing the subunits to either positively 
or negatively influence a variety of signaling pathways.   
 Adrenergic receptors are classified into two classes, α and β.  The α class is 
subdivided into α1 and α2 adrenergic subclasses.  According to the present classification, 
subclasses α1 and α2 have been further subdivided into α1A, α1B, and α1D which belong to 
the Gαq coupled receptors and α2A, α2B, α2C, and α2D which belong to the Gαi coupled 
receptors, respectively (127).  The β class are Gαs coupled receptors and consists of 
β1, β2, and β3 (and perhaps β4) subtypes (29).  The distribution of adrenergic receptor 
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subtypes in dog and human liver are primarily α1 and β2 (144, 160, 164).  It has been 
shown that epinephrine acts primarily on hepatic β2-receptors in the dog (55) and human 
(18, 72, 227).  Like the β2-adrenergic receptor, the glucagon receptor is mainly coupled to 
Gαs proteins.  Therefore, epinephrine- and glucagon-stimulated HGP is mediated by 
increases in intracellular levels of cAMP (91, 271).  Since epinephrine and glucagon act 
on the same pathway, although through different receptors, the rise in cAMP presumably 
results in similar changes in cellular mechanisms following hormone binding.  Evidence 
has been provided that concomitant administration of the hormones at doses giving 
maximal activity results in an increase in glycogenolysis that was no larger than with 
either individual hormone, implying that both hormones act via the same pathway (182).   
Following hormone binding, active Gαs stimulates adenylate cyclase, increases 
cAMP levels, and activates protein kinase A (PKA) which in turn initiates a series of 
protein phosphorylation reactions (Fig. 1.3).  As a single receptor can activate many α-
subunits, the hormone response is amplified and results in a substantial increase in the 
strength of the signal.  Within seconds of recognition of the hormone, this chain of 
reactions leads to subsequent changes in glycogenolysis, glycogen synthesis, 
gluconeogenesis and glycolysis.   
 Epinephrine and glucagon signaling promote hepatic GLY, while at the same 
time, opposing hepatic glycogen synthesis.  Activated PKA phosphorylates and activates 
glycogen phosphorylase kinase (GPK) which subsequently phosphorylates glycogen 
phosphorylase (GP), leading to its activation.  Activation of GP then phosphorylates  
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Figure 1.3: Glucagon /adrenergic receptor–signaling pathway.  Glucagon (GGN); 
Adrenergic receptor (AR); adenylate cyclase (AC); adenosine 3’, 5’ –cyclic 
monophosphate (cAMP); protein kinase A (PKA); glycogen synthase (GS); glycogen 
phosphorylase kinase (GPK); glycogen phosphorylase (GP); inhibitor 1 (I-1); protein 
phosphatase 1 (PP1); peroxisome proliferators-activated receptor-γ coactivator-1 (PGC-
1); phospoenolpyruvate carboxykinase (PEPCK); glucose-6-phosphatase (G6Pase); 6-
phosphofructo-2-kinase/fructose-2,6-bisphosphatase (PFK-2/F2,6P2ase); L-type pyruvate 
kinase (PK);.phospholipase C (PLC); phosphatidylinositol 4,5-biphosphate (PIP2); 
phosphatidylinositol 3,4, 5 triphosphate (PIP3). From reference .(140) 
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glycogen, which results in hepatic glycogenolysis and the production of G6P.  PKA also 
directly phosphorylates and inactivates glycogen synthase (GS) in the liver (134, 135).  
Another target of PKA is Inhibitor-1, which is activated upon phosphorylation.  
Activation of this protein inhibits protein phosphatase-1 (PP1), which  
is turn reduces inhibition of GP and activation of GS.  Taken together, activated PKA 
alters the activity of many enzymes involved in glycogen metabolism, simultaneously 
stimulating glycogenolytic flux and inhibiting glycogenic flux.  
In addition to their effects on glycogen metabolism, epinephrine and glucagon 
stimulate HGP by increasing gluconeogenesis and inhibiting glycolysis.  Phosphorylation 
of the bifunctional enzyme, PFK-2/F2,6P2ase, by PKA results in inhibition of the kinase 
and activation of the bisphosphatase, causing a decrease in the intracellular levels of 
F2,6P2.  Likewise, isolated hepatocytes treated with either β-adrenergic agonists or 
glucagon results in a rapid decrease in F2,6P2 levels .  Reduction of intracellular levels of 
F2,6P2 decreases PFK-1 activity and relieves inhibition of P1,6P2ase, and therefore 
simultaneously inhibits glycolytic flux and promotes gluconeogenic flux . Additionally, 
glucagon has been shown to increase hepatic gene expression of PEPCK, a rate-limiting 
enzyme of GNG (114).  PKA activation by cAMP leads to phosphorylation of a cAMP 
response element-binding (CREB) protein which in turn binds to a cAMP response 
element (CRE) in the promoter region of the transcriptional coactivator, peroxisome 
proliferator-activated receptor-γ coactivator-1 (PGC-1), and up-regulates its transcription.  
Together with another transcription factor, hepatocyte nuclear factor-4, PGC-1 increases 
PEPCK transcription (298).  An increase in cAMP also results in phosphorylation and 
inactivation of pyruvate kinase.  In fact, it has been shown that glucagon strongly inhibits 
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carbon flux through pyruvate kinase, whereas epinephrine was only marginally effective 
(45, 97, 231).  Inactivation of pyruvate kinase would lead to an inhibition of glycolytic 
flux and an increase in gluconeogenic flux.  These findings suggest that as both glucagon 
and epinephrine increase levels of cAMP and therefore activate PKA, these changes in 
phosphorylation and/or expression of the enzymes mentioned here may be possible 
mechanisms by which they stimulate hepatic GNG.   
Concurrent stimulation of GLY/GNG fluxes and inhibition of glycogenic 
/glycolytic fluxes raises the amount of G6P available for dephosphorylation by G6Pase, 
thereby increasing the pool of glucose for HGP.  It has been shown that both glucagon 
and cAMP induce stimulate gene expression of the catalytic subunit of G6Pase in the dog 
(129). Furthermore, recent studies suggest that the up-regulation of G6Pase by glucagon 
is at least partially due to increased transcription of the G6Pase gene in a PKA-dependent 
manner involving PGC-1 (298). It has also been shown that cAMP signals via a CRE 
located in the promoter region of G6Pase (129).  Therefore it could be suggested that 
epinephrine and glucagon activation of PKA increases G6Pase activity, and thereby 
promote GLY as well as GNG. 
 Furthermore, both epinephrine and glucagon are known to activate and stimulate 
signal transduction of the Gαq class of G-proteins.  The activation of Gαq leads to the 
activation of phospholipase C, production of PIP3, and subsequent release of intracellular 
calcium (Fig. 1.3) (271).  As mentioned above, α1-receptor, a Gαq coupled receptor, is 
also expressed in dog and human liver.  Thus, epinephrine can technically increase 
intracellular calcium levels.  However, activation of α-adrenergic receptors are not 
thought to be the primary site through which the catecholamine exerts its effects in the 
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dog (55, 91) and human (18, 72, 227).  Although glucagon has been shown to affect 
glucose production by increasing intracellular calcium (153) the relevance of this 
observation is currently unclear.  For instance, some investigators found that calcium 
increases only in the presence of supra-physiological glucagon levels (268), while others 
found that calcium can increase with physiological glucagon concentrations (153).   
 
Epinephrine and Glucagon Action In Vivo 
 
 Although epinephrine and glucagon presumably stimulate liver glucose 
production via the same signaling pathway, their actions at liver in vivo are considerably 
different.  Both hormones increase HGP in a rapid, time-dependent manner, however, 
sensitivities of each hormone at the liver differs on the molar basis. Additionally, the 
mechanism (GLY vs. GNG) by which the hormones stimulate HGP are dissimilar as a 
result of their differential direct and indirect actions on the liver.  
Earlier studies in human and dog showed that the effect of epinephrine on HGP is, on 
a molar basis, much less potent than that of glucagon (265, 266).  To establish an equal 
effect on HGP requires a fifty-fold rise in epinephrine but only a four-fold rise in 
glucagon.  However, despite its low potency, epinephrine plays a critical role in 
glucoregulation during stress, as circulating levels of the hormone can increase by 100- to 
200-fold. 
The stimulatory effect of epinephrine on HGP has been shown to arise from both 
indirect actions on muscle and adipose tissue and direct action on the liver.  Release of 
epinephrine from the adrenal medulla results in the stimulation of adipose tissue lipolysis, 
muscle glycogenolysis, and HGP.  Early studies in the human suggested that increases in 
27 
circulating epinephrine stimulate HGP by increasing GNG via mobilization of alanine 
and lactate from muscle and FFA and glycerol from adipose tissue (56, 61, 177, 234).  
Epinephrine is also known to cause a release of lactate from adipose tissue (74).  Studies 
in the conscious dog have shown that increases in net hepatic uptake of alanine, lactate, 
and glycerol are secondary to the effects of the hormone on peripheral tissues; thus 
further suggest that the indirect effects of epinephrine stimulate HGP by increasing GNG 
(46, 234).  Additionally, Chu et al. (57) showed that the direct effects of epinephrine on 
HGP are a result of increases in GLY alone.  The concept that epinephrine increases HGP 
by indirect and direct stimulation of GNG and GLY respectively, was elegantly 
demonstrated in a study by Chu et al (56).  The study was carried out in over-night fasted, 
pancreatic clamped conscious dogs in which epinephrine was infused either intraportally 
or peripherally.  The hepatic sinusoidal epinephrine levels were indistinguishable (~565 
pg/ml) whereas the arterial levels differed significantly (Δ~1000 pg/ml) between the two 
groups.  Intraportal infusion of epinephrine resulted in an increase in GLY but not GNG, 
suggesting epinephrine had no direct effect on GNG.  In contrast, peripheral infusion of 
the hormone resulted in increased gluconeogenic precursor supply to the liver, and 
thereby stimulated HGP primarily by increasing GNG.  Interestingly, this rise in GNG 
was accompanied by a compensatory decrease in GLY, despite equal levels of hepatic 
sinusoidal epinephrine in the two groups, which implies a reciprocal relationship between 
the two processes.  Subsequent studies by Chu et al. (55) showed that the direct 
stimulation of GLY by epinephrine was completely inhibited by adrenergic blockade and 
that this effect was specific to β2-adrenergic receptors.  Furthermore, in a different study, 
peripheral infusion of epinephrine showed that portal delivery of adrenergic blockers 
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inhibited the GLY effect of epinephrine, but not its GNG effect (58).  Taken together 
these studies clearly demonstrate that epinephrine stimulates HGP indirectly by 
increasing hepatic GNG and directly increases hepatic GLY. 
The stimulatory effect of glucagon on HGP has been shown to arise from its direct 
action on the liver, with a half-maximal activation occurring in ~4.5 minutes (77).  
Glucagon-stimulated HGP results primarily in an increase in GLY and to a lesser extent 
in a modest and slower rise in GNG (48).  Studies have also shown, however, that 
glucagon can stimulate both the transcription and activation of enzymes involved in 
hepatic GNG in vitro (91, 154, 211, 212) and that it can increase hepatic gluconeogenic 
flux in vivo (175, 266), yet the contribution of the rise in GNG to the overall increase in 
glucose production is small.  The hormone can only cause a transient, modest increase in 
hepatic gluconeogenesis presumably because it has no effect on gluconeogenic substrate 
release from muscle and little or no effect on lipolysis in adipose tissue.  Thus, any 
enhancement of gluconeogenic flux would transiently increase GNG.  However, 
eventually plasma gluconeogenic substrate concentrations would fall, and the 
gluconeogenic contribution to total HGP would return toward its basal rate. 
Taken together, it is clear that the actions of epinephrine and glucagon on the liver 
differ considerably despite the fact that they both trigger a rise in intracellular cAMP 
within the hepatocyte.  Although the hormones are not equally potent at the liver, the 
main difference in the actions of the two hormones is their ability to act on peripheral 
tissues.  Both epinephrine and glucagon act directly on the liver to stimulate GLY.  
However, unlike glucagon, epinephrine acts on muscle and adipose tissues to mobilize 
gluconeogenic precursors to the liver.  Given the fact that glucagon is secreted from 
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pancreatic α-cells directly into the portal vein, and only a small percentage of glucagon 
survives first pass degradation by the liver, it would be expected that the hormone acts 
solely on the liver to stimulate HGP.  Therefore, it could be hypothesized that during 
stress (i.e. hypoglycemia) when secretion of both glucagon and epinephrine is increased, 
the peripheral release of epinephrine from the adrenal medulla, augments HGP largely by 
stimulating GNG.  In fact, our lab has shown that when glucagon and epinephrine are 
raised concurrently, they have additive effects and amplify hepatic glucose production by 
increasing both GLY and GNG (116). 
  
Role of FFA in Mediating Epinephrine and Glucagon Stimulation of HGP 
 It has been well established that epinephrine simultaneously increases HGP and 
lipolysis.  Epinephrine released from the adrenal medulla results in a concomitant rise in 
epinephrine levels in the hepatic sinusoids and the arterial circulation, with the latter 
causing an elevation in the plasma FFA level.  As mentioned above, portal administration 
of epinephrine increased GLY but had no effect on GNG, whereas peripheral 
administration resulted in a rise in GNG that was accompanied by a compensatory 
decrease in GLY.  A substantial increase in arterial levels (78%) and net hepatic uptake 
(122%) and fractional extraction (50%) of FFA occurred during the peripheral infusion of 
epinephrine that was not observed when the hormone was infused into the portal vein.  In 
a different study (54), the authors showed that increases in plasma FFA resulted in a 
stimulation of GNG and inhibition of GLY, similar to that observed by the indirect action 
of epinephrine.  Therefore, epinephrine stimulation of lipolysis could explain a 
significant portion of the indirect action of the hormone on the liver.   
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To determine the effect of elevated FFA on the glycogenolytic and gluconeogenic 
effects of epinephrine, Chu et al. (53) carried out a study in the over-night fasted, 
pancreatic clamped conscious dog in which the hormone was infused intraportally in the 
presence or absence of a simulated rise in lipolysis brought about by a peripheral infusion 
of Intralipid and heparin.   The necessary hyperglycemic/hyperlipidemic control data 
were also obtained.  As expected, the effect of intraportal administration of epinephrine 
on HGP arose solely from an increase in GLY.  Interestingly, a rise in FFA and glycerol 
significantly limited epinephrine’s glycogenolytic effect while at the same time 
augmenting its gluconeogenic action at the liver.  This increase in GNG flux (230%) was 
greater than that observed in the hyperglycemic/hyperlipidemic control, despite similar 
increases in net hepatic uptake of FFA.  Therefore it was clear that the increase in FFA 
potentiated the gluconeogenic effect of epinephrine.  Notably, the arterial blood level and 
net hepatic of glycerol increased during the infusion of Intralipid/heparin.  However, if all 
of the glycerol taken up by the liver was converted to glucose, it could only account for 
22-25% of the observed increase in the net gluconeogenic flux.  Taken together, this 
study strongly suggests that the indirect actions of epinephrine alter the mechanisms by 
which glucose is produced by the liver and that this result from its ability to release FFA 
from adipose tissue.  
 It is likely that elevated FFA mediate the effects of epinephrine on the liver by 
their ability to hamper glycolytic flux and promote gluconeogenic flux, which in turn 
could possibly result in an inhibition of glycogenolytic flux.  In response to epinephrine-
stimulated GLY, an increase in net hepatic lactate output (NHLO) occurs presumably 
because some of the carbon produced by glycogen breakdown enters the glycolytic 
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pathway and exits the liver as lactate.  Indeed, in the study by Chu et al. (53) mentioned 
above, the rise in plasma FFA completely blocked epinephrine’s increase in NHLO and 
actually resulted in a substantial increase in the uptake of lactate by the liver.   As 
discussed in Role of FFA in Mediating the Effects of Insulin on HGP earlier in this 
chapter, increased cellular FFA uptake and subsequent increases in β-oxidation can lead 
to elevated intracellular levels of NADH, acetyl-CoA, and citrate which in turn 
collectively result in the inhibition of glycolytic flux and the promotion of gluconeogenic 
flux.  Therefore, the subsequent increases in G6P could possibly result in the inhibition of 
GLY. 
Although glucagon receptors are located on adipocytes and glucagon has been 
shown to stimulate lipolysis in vitro, the hormone has little to no effect on adipose tissue 
in vivo.  However, if glucagon was simultaneously elevated with FFA (as seen 
postprandially in type 2 diabetes), it might be hypothesized that FFA would alter 
glucagon action in a similar manner to that seen with epinephrine. Therefore the goal of 
Specific Aim I was to determine the effects of physiological incremental increases in 
glucagon and FFA on the contributions of GLY and GNG of HGO.    
 
 
The Effects of Elevated Lipids on Insulin Regulation of Glucose Homeostasis 
 
 Glucose homeostasis reflects a delicate balance between glucose production and 
glucose uptake. This balance is best demonstrated during periods following food 
consumption and fasting when plasma glucose levels remain in a narrow range.  As it was 
alluded to earlier in this chapter, insulin serves as the primary regulator of plasma glucose 
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levels.  Insulin rapidly suppresses hepatic glucose production and 50% of secreted insulin 
that survives first pass degradation by the liver subsequently acts on peripheral tissues to 
stimulate glucose uptake.  Insulin action in peripheral tissues also alters lipid and protein 
metabolism and secretion of other glucoregulatory hormones (i.e. glucagon) which then 
indirectly mediate its actions on glucose homeostasis.  When insulin-sensitive tissues 
become less responsive to the hormone, because of insulin resistance and/or insulin 
deficiency, as seen with type 2 diabetes, profound dysregulation of substrate metabolism 
and hormone secretion produces elevations in fasting and postprandial glucose levels.   
Increased adiposity is strongly associated with insulin resistance and type 2 
diabetes.  Interestingly, not all fat is created equal; increased visceral adiposity shows a 
stronger correlation with insulin resistance than an increase in subcutaneous adiposity 
(63, 105).   Because visceral adipocytes have a higher rate of lipolysis, they are thought 
to be less sensitive to the anti-lipolytic effects of insulin and therefore may release more 
FFA than subcutaneous adipocytes.  Furthermore, increased visceral adiposity is thought 
to lead to greater FFA delivery to the liver.  It is also thought that an increased mass of 
stored triglyceride in adipose tissue leads to enlarged adipocytes further worsening 
resistance (especially in visceral adipose tissue) to the ability of insulin to suppress 
lipolysis.  This results in increased release and circulating levels of FFA.   
Although it is not yet entirely understood why obesity results in insulin 
resistance/type 2 diabetes, FFA have emerged as a major causative link.  There is strong 
evidence for increased fasting and postprandial plasma FFA levels both in individuals 
with diabetes and in those at risk for the disease.  It has been estimated that elevated 
plasma FFA account for the entire insulin resistance in non-diabetic obese patients and 
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~50% of the insulin resistance in obese patients with type 2 diabetes (19).  Acute 
elevations of FFA have been shown to induce insulin resistance (20, 26, 229, 257) in a 
dose-dependent manner (24). Chronic increases of FFA, as seen in most obese patients, 
also induce insulin resistance (20, 237).   Moreover, Santomauro et al. (237)  normalized 
chronically elevated FFA overnight in obese subjects and improved insulin sensitivity.  
Additionally, acute elevations of FFA results in stimulation of insulin secretion (67, 96, 
111, 204) whereas, chronically elevated FFA impair insulin secretion (235). Thus, it is 
plausible that FFA-induced insulin resistance precedes the development of type 2 
diabetes.  In fact, it has been shown in individuals with impaired glucose tolerance that 
plasma FFA are increased despite normal glucose levels (12, 207, 224). 
A second causative link between obesity and type 2 diabetes it that of lipotoxicity, 
or the accumulation of triglyceride in non-adipose tissues, such as the liver, skeletal 
muscle, and pancreas.  Interestingly, lipotoxicity in skeletal muscle shows a stronger 
correlation with insulin resistance than elevated levels of plasma FFA (152, 195, 202). 
Lipotoxicity in the liver, or hepatic steatosis, has a very robust association with hepatic 
insulin sensitivity; in fact, studies have indicated that insulin resistance is more closely 
related to changes in hepatocellular than intramyocellular triglyceride content (11, 173, 
242).  Additionally, lipotoxicity in the pancreas has been implicated in β-cell apoptosis 
(143, 152). 
For many decades the importance of insulin sensitivity and insulin deficiency as 
pathogenic factors which lead to the development of type 2 diabetes has been debated.  
Deletion of the insulin receptor in skeletal muscle (34) does not cause diabetes, 
suggesting that insulin resistance alone is not sufficient to cause diabetes.  In fact, 
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population studies have confirmed that both impaired insulin action and β-cell 
dysfunction are observed in groups at risk for the disease (163).  The remainder of this 
chapter will focus on the mechanisms by which elevated lipids induce insulin resistance 
and alter β-cell function.   
 
The Effects of Elevated Lipids on Insulin Sensitivity 
 
FFA-Induced Insulin Resistance 
 
Substrate Competition 
 In 1963, Randle et al. were the first to propose that FFA play a role in the 
development of insulin resistance in obesity and type 2 diabetes and demonstrated that 
FFA compete with glucose for substrate oxidation in rat heart muscle and diaphragm 
(221).  They speculated that an increase in FFA levels result in an elevation of the 
intramitochondrial acetyl-CoA/CoA and NADH/NAD+ ratios, with subsequent 
inactivation of PDH.  This in turn causes citrate levels to increase in the cytoplasm, 
leading to inhibition of PFK, a rate limiting enzyme in glycolysis.  Inhibition of 
glycolysis, and subsequent increases in G6P levels would inhibit hexokinase II activity, 
which would result in an increase in the intracellular glucose pool and decrease muscle 
glucose uptake.  Consistent with this, hyperinsulinemic-euglycemic and –hyperglycemic 
clamps in healthy humans have shown that increased plasma FFA levels inhibit whole-
body glucose disposal (98, 146, 229, 278, 297).  A similar mechanism could operate the 
liver, however, with the caveat that glucokinase, rather than hexokinase II, is the primary 
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hepatic enzyme involved in glucose phosphorylation.  In fact, our laboratory has shown 
that FFA-inhibition of net hepatic glucose uptake was associated with a shift in net 
hepatic lactate balance from output to uptake, suggesting an inhibition of glycolysis 
(185).   
Randle’s hypothesis of substrate competition can also apply in terms of FFA 
ability to stimulate GNG.  As proposed in the Role of FFA in Mediating the Effects of 
Insulin on HGP section of this chapter, a rise in hepatic β-oxidation could result in 
elevated intracellular NADH, acetyl-CoA, and citrate levels, which subsequently results 
in increased P1,6P2ase and decreased PFK-1 activities, thereby simultaneously 
stimulating gluconeogenesis and hindering glycolysis.  Early evidence supported FFA 
regulation of GNG (92).  However, due to the reciprocal relationship between GNG and 
GLY, a concept known as autoregulation, stimulation of GNG might not result in the 
overproduction of glucose by the liver.  Our laboratory has shown that an acute rise in 
FFA inhibited GLY and stimulated GNG without altering the overall production of 
glucose by the liver (54).  It has also been reported that a rise in FFA did not alter HGP in 
healthy (230) or type 2 diabetic subjects (141).  In agreement with this, Boden et al. (21) 
showed that increasing and decreasing plasma FFA stimulated and suppressed GNG, 
respectively, but did not change glucose production.    
 
Hexosamine Pathway 
As the entry of F6P in the glycolytic pathway could be limited by the inhibition of 
PFK by FFA, carbon flux could be increased via the hexosamine pathway (F6P → 
glucosamine-6-P), a route of glucose metabolism, although quantitatively small, which 
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has been implicated in the development of insulin resistance (233).  Saturated fatty acids 
have been shown to increase the expression of glutamine-fructose-6-phosphosphate 
aminotransferase, the rate-limiting enzyme in this pathway (288).  Additionally, Hawkins 
et al. (123) demonstrated that prolonged increases of plasma FFA led to elevated UDP-
GlcNAc (end-product of hexosamine pathway) which preceded muscle insulin resistance.  
However, Choi et al. (52) later showed that elevations of FFA at more physiological 
levels induced insulin resistance with no increase of end products of the hexosamine 
pathway.  Thus, the role of the hexosamine pathway in FFA-induce insulin resistance 
remains uncertain. 
 
Insulin Signaling 
 Studies by Boden et al. suggest that the mechanism of substrate competition alone 
cannot account for the effects of FFA on glucose disposal.  They reported a 3-h lag 
before FFA-induced inhibition of glucose uptake was manifest, which is more consistent 
with a translational or post-translational event than with allosteric regulation as suggested 
by Randle (221).  Additionally, Roden (229) and Boden (26) have shown that impaired 
insulin-stimulation of glucose uptake by FFA results in a decrease (rather than a increase) 
in intracellular G6P and that this precedes reduced rates of glucose oxidation and 
glycogen synthesis.  These studies showed that one-third of the acute FFA-inhibition of 
glucose uptake occurs from substrate competition where as the remainder results via non-
oxidative mechanisms.  Indeed, human studies from the Shulman group have shown that 
increased plasma FFA inhibit insulin-stimulated glucose transport as a consequence of 
decreased IRS-1-associated PI3K activity (80, 252).  These findings led to an alternative 
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hypothesis that increased delivery of FFA to skeletal muscle and subsequent elevations of 
intracellular FFA and/or FA metabolites [diacylglycerol (DAG), fatty acyl CoA, and 
ceramides] suppress insulin signaling upstream of, or directly at the level of PI3K.  The 
Shulman group went on to show in rats that lipid infusion resulted in a reduction of 
insulin-stimulated IRS-1 tyrosine phosphorylation and was associated with activation of 
protein kinase C (PKC)-θ (115), a well-known serine kinase that has been shown to be 
potently activated by DAG.    Subsequent studies from this group showed that PKC- θ 
knockout mice are protected from lipid-induced insulin resistance in skeletal muscle 
(149).  Additionally, the Boden group, has shown in humans that FFA increased the 
translocation of PKC isoforms βII and δ from the cytosol to the membrane fraction(137). 
PKC has been shown to cause insulin resistance by decreasing tyrosine phosphorylation 
of IRS-1 and of the insulin receptor (103, 222, 300).  Additionally, rats on a high fat diet 
show increases in the content of long-chain fatty acyl CoA and alter the PKC isozymes θ 
and ε in muscle (241). 
FFA produce hepatic insulin resistance by inhibiting insulin suppression of GLY 
(25).  Currently very little is known about the biochemical mechanisms by which FFA 
inhibit insulin signaling in the liver.  However, it has been shown that the development of 
hepatic insulin resistance occurs within a 2 to 4-h delay after elevation of plasma FFA 
(24-26) suggesting that impaired insulin action at the liver may be similar to that seen in 
muscle.  The fact that liver-specific insulin receptor knockout mice demonstrate severe 
hepatic insulin resistance (99) suggests that an impairment of insulin signaling could 
result in increased HGP.  Additionally, Lam et al. have reported that FFA-induced 
hepatic insulin resistance is associated with activation of PKC-δ in liver of rats (156).   
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Of note, specific metabolic actions of the PI3K-mediated insulin signaling 
pathway results from differences in tissue distribution, subcellular localization, and 
downstream targets of the many isoforms of IRS proteins, PI3K, and PKB.  Therefore, it 
is possible that only some metabolic pathways are impaired by FFA while others remain 
unaltered or even hyper-stimulated. 
 
Inflammation 
 Adipose tissue has received a great deal of recognition in the pathogenesis of 
obesity-induced insulin resistance not only because of increased release of FFA but also 
because of its dysregulated production of cytokines which reflects an inflammatory state 
of the organ.  In obesity, accumulation of lipid in adipocytes, initiates the activation of 
two classic inflammatory signaling pathways, the c-Jun N-terminal kinase (JNK) 
pathway and the IkB/NFκB pathway.  Both pathways are thought to play important roles 
in insulin resistance but do so via dissimilar mechanisms.  JNK has been shown to 
promote insulin resistance through the serine phosphorylation of IRS-1 (4, 128).  Under 
resting conditions, nuclear factor-κB (NFκB) is bound to its inhibitor IκB.  
Phosphorylation of IkB by its kinase (IKK) leads to the degradation of IκB, releasing 
NFκB for translocation to the nucleus.   Unlike JNK, IKK does not phosphorylate IRS-1 
but rather does so through the transcriptional activation of NFκB, which targets gene 
products with potential involvement in insulin resistance (251).  Stimulation of JNK and 
IkB/NFκB pathways regulate protein phosphorylation and transcriptional events which 
subsequently lead to the release of pro-inflammatory cytokines such as tumor necrosis 
factor-a (TNF-a) and interleukon-6 (IL-6).  By mechanisms not completely understood, 
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macrophages then infiltrate the adipose tissue which also produce pro-inflammatory 
cytokines, further promoting local and potentially systemic inflammation.   
As enlarged adipocytes are also resistant to the anti-lipolytic effects of insulin, 
increased FFA could potentially activate these pathways and induce-inflammation.  
Indeed, Olefsky and colleagues have demonstrated in 3T3-L1 adipocytes that FFA-
impaired insulin signal transduction and decreased insulin stimulated GLUT-4 
translocation was associated with activated JNK and IKK-β and increased secretion of 
TNF-α (194).  Lipid accumulation in adipocytes also activates the unfolded protein 
response to increase endoplasmic reticulum (ER) stress in adipose tissue (200) which has 
been shown associated with the activation of JNK (200) and NFκB (133).  
The Boden group (137) has found acute FFA-induced insulin resistance to be 
associated with the activation the IkB/NFκB pathway.  High doses of salicylate, which 
block IKK activity (296), can ameliorate insulin resistance in diabetes and obesity (150, 
302).  It has also been shown in rats, that pretreatment with salicylate prevented the 
deleterious effects of elevated FFA in skeletal muscle and that this was associated with 
decreased serine/threonine phosphorylation of IRS-1 and increased IRS-1-associated 
PI3K activity (150).  More over, mice lacking IKK-β are protected from lipid induced 
insulin resistance (150).  In humans, FFA-induced insulin resistance in skeletal muscle 
was associated with increased DAG, PKC, and decreased IκB-α (137).  Additionally, 
saturated fatty acids may also promote the synthesis of ceramides in muscle which may 
correlate with the degree of insulin resistance (267).  Ceramides can also activate 
inflammatory pathways including JNK and NFκB (272).  Taken together, these studies 
suggest that increased FFA delivery and subsequent increases in intracellular FA 
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metabolites leads to the activation of JNK and/or IKK which in turn decreases PI3K 
activity and thus glucose uptake.   
Although not much is known in terms of FFA-activation of inflammation in the 
liver, transcriptional targets of NFκB are activated in the liver with increasing adiposity.   
Transgenic mice with liver-specific constitutively active IKK-β have profound hepatic 
and moderate systemic insulin resistance (36).  Interestingly, hepatic production of pro-
inflammatory cytokines IL-6, IL-1β and TNF-α was increased and this was accompanied 
by activated Kupffer cells (resident liver macrophages).  Systemic neutralization of IL-6 
and treatment with salicylate both improve insulin sensitivity in these mice.  These results 
suggest that sub-acute hepatic inflammation by low-level activation of NFκB leads to 
local and systemic insulin resistance. 
 Of note, high-fat diet-induced and obesity-induced insulin resistance does not lead 
to macrophage infiltration (289) or activation of IKK-β/NFκB (232) in skeletal muscle.  
Additionally, deletion of IKK-β or inhibition of NFκB specifically in muscle does not 
normalize insulin resistance in obese mice.  Therefore, even though inflammation can be 
activated in skeletal muscle, it appears that in obesity-associated insulin resistance, 
skeletal muscle is a target of inflammation rather than a site of initiation. 
 
Vascular Function 
 It has been demonstrated that endothelial-dependent vasodilation is reduced in 
states of insulin resistance, including type 2 diabetes (264).  Baron and colleagues have 
provided extensive evidence that insulin increases blood flow in skeletal muscle and they 
have implicated that the effect is mediated via the nitric oxide (NO) system (13).  This 
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same group has shown that an 8-h infusion of Intralipid and heparin reduced the effect of 
insulin on blood flow by ~50% (263).  Additionally, elevation of FFA causes an 
impairment of endothelial-dependent and insulin-mediated vasodilation associated with a 
small increase in systolic arterial pressure (264).  Furthermore, postischemic flow-
mediated dilation of the brachial artery was impaired after 2-h of lipid infusion and 
associated with activation of NFκB in mononuclear cells (280).  FFA have also been 
shown to directly activate NFκB in cultured endothelial cells.  Taken together these 
findings suggest that increased FFA in vivo might reduce insulin action by lowering 
blood flow in insulin-sensitive tissues and thus decreasing insulin availability. 
 
Insulin Clearance 
 Insulin clearance, the plasma volume cleared of insulin in a unit of time, is 
characterized by the binding of insulin to its receptor, its internalization and degradation 
by the insulin degrading enzyme (IDE) or insulinase, or lysomal enzymatic processes 
(284).  Removal of insulin from the circulation may be involved in mediating some 
aspects of insulin action by decreasing its availability.  The main site for insulin clearance 
is the liver, removing ~50% following first-pass extraction (82, 239).  In obese subjects 
with hyperinsulinemia and high levels of FFA, hepatic insulin clearance is impaired.  
Yoshii et al. (299) have previously shown in conscious dogs that an intraportal (vs. 
peripherally) oleate infusion decreased hepatic insulin clearance.   Additional studies 
from this group using rats (156) have implied that activation of PKC-δ mediates the FFA-
induced decrease in hepatocyte insulin binding.  In fact, activation of PKC can increase 
insulin receptor internalization (39).  Additionally, others have suggested that FFA 
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directly bind to IDE, inhibiting its activation (120).  As insulin clearance is characteristic 
of all insulin-sensitive tissues (38, 40, 261), elevated FFA may decrease insulin 
availability to skeletal muscle and adipose tissue as well.   
 
Lipotoxicity 
 
Mechanisms of Lipotoxicity 
 The net content of intracellular triglyceride depends on the relative activities of 
enzymes involved in lipid metabolism that influence fatty acid uptake and synthesis 
versus those that influence fatty acid oxidation and export.  When input (uptake or 
synthesis) of fatty acids to a cell exceeds its output (degradation or export), triglycerides 
accumulate within the tissue.  The conventional explanation is that an impairment of fat 
deposition in adipose tissue due to either excess energy intake or decreased storage 
capacity result in increased release of FFA from adipocytes.  FFA must then be 
partitioned for storage in other tissues such as the liver, skeletal muscle, and pancreas.  In 
fact, Boden et al. have shown that raising blood FFA levels increased intramyocellular 
triglyceride in a time- and dose-dependent manner (27).   
Dietary substrates can also contribute to lipotoxicity.  Dietary fatty acids can 
serve as a direct source of substrate for tissue triglyceride via two mechanisms: spillover 
into the plasma FFA pool and through the uptake of lipoproteins [intestinally derived 
chylomicrons and very low density lipoproteins (VLDL, in which triglycerides are 
derived from either plasma FFA pool or dietary fatty acids)] and/or their remnants.  
Carbohydrates can be driven towards lipid synthesis by a process known as de novo 
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lipogenesis.  Carbohydrates provide two routes to formation of triglycerides: the glycerol 
backbone via triose phosphate and fatty acids via acetyl CoA (Fig. 1.1).  In the liver, 
fructose can directly contribute to both of these routes by two mechanisms: increased 
hepatic glucose uptake (an effect likely to be mediated by increased translocation of 
glucokinase) (198, 250) and bypassing the regulated conversion of F6P to F1,6P2 (119).  
It is thus a relatively unregulated source of substrate for triglyceride synthesis.  Dietary 
substrates are particularly relevant given the increased consumption of energy-dense diets 
(214).  Interestingly, it has been suggested that fructose consumption (essentially in soft 
drinks) may be a causal factor for the development of insulin resistance (32). 
The specific origin of the lipids that accumulate within non-adipose tissues 
remains unknown.  However, in one study, using a multiple-stable-isotope approach, 
Park and colleagues very elegantly demonstrated that plasma FFA (59%), de novo 
lipogenesis (26.1%), and dietary FFA (14.9 %) all contribute to hepatic triglyceride 
accumulation in obese patients with hepatic steatosis (79).  Contributions of these sources 
to muscle lipotoxicity are unknown although it is thought that lipid accumulation is 
largely due to increased delivery of plasma and dietary FFA to the tissue.     
Decreased oxidation of lipids due to a functional mitochondrial impairment could 
lead to an increased deposition of triglycerides.  Obese and type 2 diabetic individuals 
have smaller mitochondria in skeletal muscle (139, 145) and exhibit impaired activity of 
the respiratory chain (124).    Magnetic resonance studies have shown that insulin 
resistance in offspring of patients with type 2 diabetes is characterized by both elevated 
intramyocellular triglycerides and impaired mitochondrial ATP synthesis (210).  Peterson 
et al. (209) found similar defects in muscle and liver in lean elderly subjects with severe 
44 
insulin resistance compared to young controls.  Additionally, ultrastructural 
mitochondrial defects in patients with NAFLD may be indicative of defective oxidation 
as these patients also have reduced respiratory chain activity (205) and impaired ATP 
synthesis after a fructose challenge (64).  Collectively these studies suggests that 
impaired mitochondrial lipid oxidation can lead to the accumulation of triglycerides in 
myocytes and hepatocytes.   
In the liver, decreased lipid export via VLDL production could also contribute to 
elevated hepatocellular triglycerides.  The liver’s ability to mobilize triglycerides depends 
on adequate VLDL formation and export which requires normal production of 
apolipoprotein B (apoB)-100 and microsomal triglyceride transfer protein (MTP) activity. 
Abetalipoproteinemia which is caused by a variety of mutations in the gene for a subunit 
of MTP (191, 226, 244, 290), is a recessive human disease characterized by near 
complete absence of apolipoprotein-B (apoB)-containing lipoproteins (e.g. chylomicrons, 
VLDL, and LDL) in plasma.    MTP plays a pivotal, if not an obligatory role, in the 
assembly and secretion of triglyceride rich apoB-containing lipoproteins.  As expected, 
liver specific MTP knockout mice (218) exhibit hepatic steatosis and decreased hepatic 
triglyceride secretion while mice overexpressing hepatic MTP show an increase in in vivo 
hepatic triglyceride secretion (279).  Therefore, an impairment of hepatic triglyceride 
export could contribute to triglyceride accumulation in the liver.  In fact, it has been 
shown that apolipoprotein production is impaired in patients with NAFLD (43).   
Although insulin resistance is strongly correlated with liver and muscle 
lipotoxicity, triglyceride accumulation could be a result of conserved insulin sensitivity of 
lipogenic pathways.  One mechanism by which insulin stimulates lipogenesis is the 
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activation of a key transcription factor, sterol regulatory element-binding protein-1c 
(SREBP-1c), a well know stimulator of all lipogenic genes.  In states of insulin 
resistance, it might be expected that activation of SREBP-1c would be decreased.  
Surprisely, however, in two mouse models of profound insulin resistance, insulin 
stimulates hepatic SREBP-1c transcription, resulting in increased rates of de novo 
lipogenesis (249).  Although SREBP-1c expression has not been determined, hepatic de 
novo lipogenesis has also been shown to be increased in patients with NAFLD (76).   
Moreover, SREBP-1c can also activate acetyl-CoA carboxylase (130) and inhibit MTP 
expression which would in turn suppress fatty acid oxidation (174) and VLDL formation 
(240), respectively, further contributing to a positive triglyceride balance.  Therefore, 
while insulin signaling pathways regulating glucose metabolism may be impaired in 
states of insulin resistance, other metabolic pathways may be over-stimulated as a result 
of hyperinsulinemia. 
 
Lipotoxicity-Induced Insulin Resistance 
Although there is a strong correlation with lipotoxicity and type 2 diabetes it 
unclear as to whether the accumulation of intracellular lipid is a cause or effect of a 
decreased insulin response.  The mechanisms by which lipotoxicity could possibly bring 
about insulin resistance is not precisely understood.  It is hypothesized that the 
triglycerides themselves do not affect insulin action directly but rather represent a 
reservoir of FFA and/or fatty acid metabolites in which arise during esterification or 
hydrolysis of intracellular triglycerides and inhibit insulin signaling.  It is supposed that 
the general mechanism of FFA-induced insulin resistance as described above also occurs 
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with lipotoxicity.  Additionally, inflammatory gene expression increases in liver with 
adiposity (36).  Therefore as lipotoxicity is strongly associated with obesity, this suggests 
that triglyceride accumulation might activate resident macrophages and induce a sub-
acute inflammatory response similar to adipose tissue inflammation.  Additionally, 
hepatic lipid accumulation also activates the unfolded protein response to increase ER 
stress, which is well known to activate both JNK and NFκB. 
 
The Effects of Elevated Lipids on β-cell Function 
 
 It has been well-established that acute elevations in plasma FFA stimulate insulin 
secretion (67, 96, 111, 204).  The chronic effects, however, are controversial.  Ex vivo 
studies in animal islets or the perfused pancreas suggest a biphasic influence of FFA on 
insulin secretion in which elevated FFA stimulate insulin release for the first 6-h whereas 
after 24- to 48-h secretion is inhibited (235, 303).  In humans, however, a 48-h lipid 
infusion increased glucose-stimulated insulin secretion (23).  This suggested that it may 
take longer for FFA to suppress insulin secretion in humans.  When chronically elevated 
FFA were lowered in obese diabetic and non-diabetic subjects, the rates of insulin 
secretion decreased by 30-50%, supporting the concept that FFA serve as a insulin 
secretagogue (22, 237).  However, interpretations of these results are challenging.  
Bergman has proposed a hyperbolic relationship between insulin secretion and insulin 
sensitivity, such that a reduction in sensitivity can be compensated by a similar increase 
in β-cell responsiveness (15).  Indeed, when chronic elevations of FFA were lowered in 
the studies mentioned above, peripheral insulin sensitivity improved.  Therefore, it is 
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possible that the decrease in insulin secretion was not due to a direct effect of FFA on the 
β-cell but reduced peripheral insulin resistance.  Although prolonged elevations of FFA 
appear to have negative effects on the β-cell in vitro and in smaller animals, their effects 
on insulin secretion in humans is doubtful.  According to Boden and Carnell, even though 
most obese subjects have elevated FFA only 15-20% of them develop overt type 2 
diabetes, suggesting a genetic predisposition to β-cell failure. 
The concept of lipotoxicity in the β-cell has been put forward.  Increased 
esterification of triglycerides (including de novo lipogenesis) appears to be the major 
metabolic avenue as pancreatic β-cells do not have mechanisms to rid themselves of 
surplus triglyceride.  In vitro studies, forcing triglyceride synthesis impaired glucose-
stimulated insulin secretion (147).  Schwartz et al. (143) placed dogs on a high-fat diet 
(80%) and reported reduced insulin secretion after seven weeks, and putative β-cell 
lipotoxicity.  The severe impairment of insulin secretion in Zucker diabetic fa/fa rats is 
associated with lipotoxicity in β-cells, as triglyceride levels were elevated fifty-fold (246-
248, 283, 287).  It has been suggested that lipotoxicity in pancreatic islets might lead to 
β-cell apoptosis via de novo ceramide formation (168), activation of PKC (87), inhibition 
of PKB (294), excessive NO production (68, 247), or induction of NFκB (295).  
Kharroubi  et al. (148) have shown that apoptosis is the main mode of lipid-induced cell 
death however, the results implicate that this process is activated by an ER stress 
response independent of NFκB and NO. 
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Specific Aims 
 
As β-cell function is impaired in overt type 2 diabetes, lower plasma insulin levels 
during the postprandial period should result in a decreased insulin response at both the 
pancreatic α-cell and adipocyte and therefore cause glucagon and FFA levels to be 
elevated.   Indeed, in subjects with type 2 diabetes, it has been shown that glucagon 
secretion from α-cells is not suppressed and has even been shown to be elevated (75, 
243).  Additionally, FFA normally fall during the postprandial period, but in individuals 
with type 2 diabetes FFA levels remain elevated (223, 224).  As an insufficient decrease 
in HGP is involved in the postprandial hyperglycemia observed in type 2 diabetes, it is 
possible that elevated levels of glucagon and FFA could be responsible for the increase in 
hepatic glucose production by the liver in these patients.  Although it is well established 
that both glucagon and FFA are essential regulators of glucose production by the liver, it 
is unclear how they interact to acutely regulate HGP.   
Like glucagon, epinephrine directly stimulates HGP by increasing GLY.  
However, the indirect actions of epinephrine alter the mechanisms (stimulate 
GNG/inhibit GLY) by which glucose is produced by the liver and that this results from 
its ability to release FFA from adipose tissue. Since the direct actions of both epinephrine 
and glucagon on HGP are mediated by cAMP, it could be hypothesized that the elevated 
FFA, as seen postprandially in type 2 diabetes, would alter hepatic glucagon action in a 
similar manner to that seen with epinephrine.  Therefore the goal of Specific Aim I was 
to determine the effects of physiological increments in glucagon and FFA on the 
contributions of GLY and GNG of HGO.    
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Although there is a strong correlation with lipotoxicity (152, 195, 202)  and type 2 
diabetes it unclear as to whether the accumulation of intracellular lipid is a cause or an 
effect of a decreased insulin response.  The putative role of triglyceride accumulation in 
non-adipose tissues is based solely upon correlative results.  Therefore, one remains 
unconvinced regarding the importance of triglyceride accumulation as a direct cause of 
insulin resistance and a contributor to the pathogenesis of diabetes. Since our laboratory 
uses the conscious dog as an experimental model due to its good reflection of glucose 
metabolism in humans and allowance for invasive experimental design, the goal of 
Specific Aim II was to create a canine model of hepatic steatosis.    
The net content of triglyceride in the liver depends on the relative activities of 
enzymes involved in lipid metabolism that influence fatty acid uptake and synthesis 
versus those that influence fatty acid oxidation and export.  When input (uptake or de 
novo lipogenesis) of fatty acids to hepatocytes exceeds their output (degradation or 
export), triglycerides accumulate within the liver.  Therefore, in an attempt to induce fatty 
liver in the dog, lipid metabolism was altered by 3 different treatments: 1) a 10% fructose 
diet, 2) elevating hepatic FFA flux, or 3) elevating hepatic FFA flux while 
simultaneously inhibiting triglyceride export from the liver using the microsomal 
triglyceride transfer protein inhibitor, CP-346086. 
The goal of Specific Aim III was to examine whole body insulin sensitivity 
following treatment regimens to induce hepatic steatosis.  To assess whole body insulin 
sensitivity, a two-step hyperinsulinemic-euglycemic clamp was performed on the day 
immediately following completion of the treatment period used to induce hepatic 
steatosis in the dog.  
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CHAPTER II 
 
MATERIALS AND METHODS 
 
Animals and Surgical procedures 
 
Animal Care 
Experiments were conducted on fifty-two 18 h fasted conscious mongrel dogs 
(10-30 kg) of either gender that had been fed a standard diet of meat (Pedigree canned 
beef, Vernon, CA) and chow (Laboratory Canine Diet no. 5006, PMI Nutrition 
International, INC., Brentwood, MO) once daily.  The diet totaled 33% protein, 12% fat, 
49.5% carbohydrates, and 5% fiber, based on dry weight.  Water was available ad 
libitum. Only dogs that had a good appetite, a leukocyte count < 18,000/mm3, a 
hematocrit >35%, and normal stools were used for studies.  The animal housing and 
surgical facilities met Association for Assessment and Accreditation of Laboratory 
Animal Care International standards. Protocols were approved by the Vanderbilt 
University Medical Center Animal Care Committee. 
 
Surgical Procedures 
Surgery was performed on each dog under general anesthesia (15 mg/kg pentothal 
sodium presurgery and 2.5% isofluorane during surgery) approximately 16 (Specific Aim 
I) or 25 (Specific Aim III) days prior to the metabolic study.  The dog was placed in a 
supine position on a surgical table with an 8.5 mm inner diameter (ID) endotracheal tube 
(Concord/Portex, Kenee, NH), and ventilated with a tidal volume of 400 ml at a rate of 
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14 breaths per minute.  A laparotomy was performed by making a midline incision 1.5 
cm caudal to the xyphoid process through the skin, subcutaneous layers and linea alba, 
and extending caudally 15-20 cm. 
Silastic catheters (0.03 inch internal diameter; Dow-Corning Midland, MI) were 
placed into splenic and jejunal veins for the intraportal infusions of glucagon, insulin, and 
Intralipid/heparin (Specific Aim III).  A portion of the spleen was retracted and a distal 
branch of the splenic vein was selected for cannulation.  By blunt dissection, a small 
section of the vessel was exposed and then ligated with 4-0 silk (Ethicon, Inc, 
Sommerville, NJ). A small incision was made in the vessel and a silastic infusion catheter 
(0.04 in ID; HelixMedical, Carpintera, CA) was inserted and advanced until the tip of the 
catheter lay 1 cm beyond the bifurcation of the main splenic vein.  Another silastic 
catheter (0.04 in ID) was inserted a branch of a jejunal vein and passed anterograde until 
the tip of the catheter lay approximately 1 cm proximal to the coalescence of two jejunal 
veins. The catheters were secured in place with 4-0 silk, filled with saline (Baxter 
Healthcare Corp, Deerfield, IL) containing 200 U/ml heparin (Abbott Laboratories, North 
Chicago, IL), knotted and placed in a subcutaneous pocket prior to closure of the skin. 
For Specific Aim III, an additional silastic catheter (0.04 inch ID) was placed into 
the splenic vein (as described above) for the daily 3 h infusion of Intralipid and heparin.  
Excess catheter was tunneled subcutaneously, and attached to a vascular-access-port 
(Access Technologies, Inc., Skokie, IL).  The vascular-access-port was sutured to the 
muscular bed between the scapulae.   
For blood sampling, silastic catheters (0.04 inch i.d.) were placed into the left 
hepatic vein, the hepatic portal vein, and left femoral artery.  The central and left lateral 
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lobes of the liver were retracted cephalically and caudally, respectively. The left common 
hepatic vein and the left branch of the portal vein were exposed. In the left branch of the 
portal vein, a 14-gauge angiocath (Benton Dickinson Vascular Access, Sandy, UT) was 
inserted 2 cm from the central lobe of the liver. In the hole created by the angiocath, a 
silastic catheter (0.04 in ID) was inserted and passed retrograde about 4 cm into the portal 
vein so that the tip of the catheter lay 1 cm beyond the bifurcation of the main portal vein.  
Another angiocath was inserted into the left common hepatic vein 2 cm from its exit from 
the left lateral lobe. A silastic sampling catheter was inserted and advanced anterograde 2 
cm. Both catheters were secured with three ties of 4-0 silk through the adventitia of the 
vessels and around the catheters.  The sampling catheters were filled with heparinized 
saline, knotted and placed in a subcutaneous pocket, with excess catheter looped within 
the peritoneum.   
A catheter was inserted into the left femoral artery for sampling of arterial blood.  
An incision (2 cm) was made parallel to the vessel and the femoral artery was isolated 
and ligated distally.  A 0.04 in ID silastic catheter was inserted and advanced 16 cm in 
order to place the tip of the catheter in the abdominal aorta.  The catheter was secured, 
filled with saline, knotted and placed in a subcutaneous pocket  
All catheters were filled with saline solution that contained 200 U/ml of heparin 
(Abbott Laboratories, North Chicago, IL).  Excess catheter was looped within the 
peritoneum for infusion and sampling (hepatic artery and portal vein) catheters.  With an 
exception of the silastic catheter attached to the vascular-access-port, venous catheters 
were knotted, secured to the abdominal wall, and placed in a subcutaneous pocket prior to 
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closure of the skin.  The arterial sampling catheter was also knotted and placed in a 
subcutaneous pocket prior to closure of the skin. 
Transonic flow probes (Transonic Systems, Ithaca, NY) were positioned around 
the hepatic artery and portal vein to determine liver blood flow during experiments.  The 
duodenum was laterally retracted to expose sections of the hepatic artery and portal vein.  
A small segment of the common hepatic artery was carefully exposed.  Taking care not to 
disturb the nerve bundle located around the portal vein, a small portion of the vessel was 
exposed by blunt dissection.  3 and 6 (or 8) mm ID ultrasonic flow probes (Transonic 
Systems Inc, Ithaca, NY) were secured around the hepatic artery and portal vein 
respectively.  To prevent blood from entering the portal vein beyond the site of the flow 
probe, the gastroduodenal vein was isolated and ligated.  Blood that would normally flow 
through the gastroduodenal vein was shunted through the caudal pancreatoduodenal vein 
draining the distal pancreas.  The ultrasonic flow probe leads were positioned in the 
abdominal cavity, secured to the abdominal wall, and placed in a subcutaneous pocket 
prior to closure of the abdominal skin.   
A continuous suture of 2-0 chromic gut (Ethicon, Inc.) was used to close the 
subcutaneous layer.  The skin was closed with horizontal mattress sutures of 3-0 
Dermalon (Ethicon, Inc.).  Immediately following surgery, the dogs received an 
intramuscular injection of penicillin G (Procaine; Anthony Products, Irwindale, CA, 106 
U) to minimize the possibility of infection.  Additionally, Flunixin (Meglumine 50 
mg/ml; Phoenix Scientific, Inc., St. Joseph, MO) was also injected intramuscularly (1 
mg/kg body weight) for acute pain relief.  Animals awoke from surgery within 2 h, were 
active, and ate normally approximately 8 h after surgery.  Post-operatively, each dog also 
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received 500 mg ampicillin (Principen; Bristol-Myers Squibb, Princeton, NJ) orally twice 
a day for 3-d.   
On the morning of the metabolic study, the transonic leads and catheters were 
removed from the subcutaneous pocket under local anesthesia (2% lidocaine; Abbott 
Laboratories, North Chicago, IL).  The contents of each catheter were aspirated, and they 
were then flushed with saline.  Blunt needles (18 gauge; Monoject, St. Louis, MO) were 
inserted into the catheter ends and stopcocks (Medex, Inc, Hilliard, OH) were attached to 
prevent the backflow of blood between sampling times.  Angiocaths (20 gauge; Beckton 
Dickson) were inserted percutaneously into the left and right cephalic veins and into a 
saphenous vein for the infusion of somatostatin, tracers, dye and glucose.  A continuous 
infusion of heparinized saline was started via the femoral artery at a rate to prevent any 
clotting in the line.  Each animal was allowed to rest quietly in a Pavlov harness for 30 
min prior to the start of the metabolic study. 
 
Collection and Processing of Samples 
 
Blood Samples 
Blood samples were drawn from the femoral artery and portal and hepatic veins at 
the predetermined sampling points indicated in the experimental protocols.  Prior to each 
sample taken, the respective catheter was cleared of saline by withdrawing 5 ml of blood 
into a syringe.  The blood sample was then drawn using a separate, pre-labeled syringe 
that had been flushed with heparinized saline (1 U/ml; Abbott Laboratories, North 
Chicago, IL).  After sampling, the blood taken during the clearing process was re-infused 
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into the animal, and the catheter was then flushed with heparinized saline (1U/ml; Abbott 
Laboratories, North Chicago, IL).  The total volume of blood withdrawn did not exceed 
20% of the animal’s blood volume.  Additionally, two volumes of saline (0.9% sodium 
chloride; Baxter Healthcare Co., Deerfield, IL) were given for each volume of blood 
taken.  There was no significant decrease in hematocrit using this procedure.     
Before the experiment started, a blood sample was drawn and centrifuged (3000 
rpm for 7 min). The plasma from this blood sample was used for the preparation of 
hormone infusates and the indocyanine green standard curve.  When samples were taken 
from all three vessels, arterial and portal blood samples were taken simultaneously 
approximately 30 s before collection of the hepatic vein samples to compensate for the 
transit time through the liver, and thus allow the most accurate estimates of net hepatic 
substrate balance (113).  Whenever the experimental design required a glucose clamp, 
small (~0.5 ml) arterial samples were drawn every 5 min in order to maintain the desired 
plasma glucose concentration.   
Immediately following each sample collection, the blood was processed.  A 20 μl 
aliquot of arterial whole blood was used for the immediate duplicate measurement of 
hematocrit using capillary tubes (0.4 mm ID; Drummond Scientific Co., Broomall, PA).  
The remaining blood was placed into tubes containing 1.6 mg/ml potassium EDTA 
(Sarsdedt, Numbrecht, Germany).  After gentle mixing, a 1 ml aliquot of whole blood 
was lysed with 3 ml 4% perchloric acid, centrifuged, and the supernatant was stored for 
later determination of metabolites (alanine, β-hydroxybuturate, glycerol, lactate).  90 μl 
aliquots of the supernatant were placed in 1 ml of 0.2 mol/l sodium acetate buffer with or 
without glutaminase (Sigma, St. Louis, MO) for the later analysis of whole-blood 
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concentrations of glutamine and glutamate, respectively.  A 1 ml aliquot was also used 
for the measurement of acetoacetate.  An aliquot (1 ml) of whole blood was placed in a 
tube containing 20 μl of glutathione (Sigma, St. Louis, MO), centrifuged, and the 
supernatant was stored for the future analysis of catecholamines, epinephrine and 
norepinephrine.  A forth aliquot (1 ml) of whole blood was lysed with 1 ml of 10% 
sulfosalicylic acid, centrifuged, and the supernatant was stored for the later determination 
of gluconeogenic amino acids (glycine, serine, threonine).  The remainder of the blood 
was centrifuged to obtain plasma. 
Four 10-μl aliquots of plasma were used for the immediate analysis of glucose 
using a Beckman glucose analyzer (Beckman Instruments, Fullerton, CA).  A 1 ml 
aliquot of plasma received 50 ml of 100, 000 KIU/ml Trasylol (FBA Pharmaceuticals, 
New York, NY) and was stored for the determination of glucagon concentrations.  5 μl of 
tetrahydrolipstatin (THL, Xenical; Roche Pharmaceuticals, Nutley, NJ) were added to a 
0.5 ml aliquot of plasma for FFA.  THL is an inhibitor of lipoprotein lipase and therefore 
inhibits in vitro lipolysis (9).  The remainder of the plasma was used for the analysis of 
cortisol, 3-[3H]-glucose, insulin, and triglycerides. Additionally, the plasma arterial and 
hepatic insulin samples were used for measurement of indocyanine green, as described 
below. 
After each sample was processed, it remained on wet ice for the remainder of the 
experiment.  Immediately following the completion of the experiment, the glutamine and 
glutamate samples were incubated at 37ºC for 45 min in a water bath, and then frozen at 
70ºC until the assay was completed.  Also at the end of the experiment, the 1 ml aliquots 
from the deproteinized metabolite samples were neutralized for assessment of whole-
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blood acetoacetate concentrations.  50-μl of Fisher Universal Indicator Solution (Fisher) 
was added.  In addition, 200-μl of 10% potassium hydroxide was added and the tubes 
were vortexed.  Small aliquots 35 μl aliquots of diluted potassium hydroxide solution 
(5:1 with water) were added, followed by vortexing.  The endpoint was reached when 
samples turned yellow-green.  If the endpoint was passed, 3% PCA diluted 3:1 (with 
water) was added in drop size manner.  After neutralization, the weight of the tubes was 
recorded and the pre-weight was subtracted.  Analysis was then performed the same day 
as described below in Sample Analysis.  Plasma samples for the assessment of 3-[3H]-
glucose were deproteinized according to the method of Somogyi-Nelson (259) 
Immediately after each experiment 1 ml aliquots of plasma were mixed with 5 ml of 
0.067 N Ba(OH)2 and 5 ml of 0.067 N ZnSO2 (Sigma Chemical).  Samples were stored at 
4°C for 1-3 days and then processed. 
 
Tissue Samples 
Within 2 min of the final sampling time point, each animal was anesthetized with 
pentobarbital (390 mg/ml Fatal-Plus; Vortech Pharmceutical Inc., Dearborn, MI) at 
1ml/5kg.  The animal was then removed from the Pavlov harness while the tracers, 
hormones, and or Intralipid/heparin continued to infuse.  A midline laporotomy incision 
was made, the liver exposed, and clamps cooled in liquid nitrogen were used to 
simultaneously freeze sections of hepatic lobes in situ. The hepatic tissue was then 
immediately cut free, placed in liquid nitrogen, and stored at -70°C.  Liver (~100 mg) 
collected for histological examination was placed in disposable vinyl specimen molds 
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(Sakura Finetek U.S.A., Inc., Torrance, CA) and frozen in embedding medium (O.C.T. 
Compound, Sakura Finetek U.S.A., Inc., Torrance, CA).   
 
Sample Analysis 
 
Whole Blood Metabolites 
 
Alanine, β-hydroxybutyrate, Glycerol and Lactate  
Whole blood concentrations of alanine, β-hydroxybutyrate, glycerol, and lactate 
were measured using methods developed by Llyod et al. (165) for the Technicon 
Autoanalyzer (Tarrytown, NY) and were modified to the Packard Multi Probe Robotic 
Liquid Handling System (Perkin Elmer; Shelton, CT). Enzymes and coenzymes for 
metabolic analyses were obtained from Boehringer-Mannheim Biochemicals (Germany) 
and Sigma Chemicals. The methods rely upon a reaction in which NAD is reduced to 
NADH. The reduced form (NADH) has a native fluorescence, which is not exhibited by 
the oxidized form.  Excess amounts of NAD and enzyme/coenzyme are added to the 
metabolite samples.  NAD becomes reduced to NADH upon oxidation of the metabolite.  
A fluorometer in the system detects changes in the florescence resulting from changes in 
NADH levels.  Therefore the concentration of the metabolite present is proportional to 
the NADH produced. 
Metabolites were measured in the PCA-treated blood samples as described in 
Collection and Processing of Samples. A standard curve was created for each metabolite 
using known concentrations prepared in 3% PCA. The Packard Multi Probe Robotic 
Liquid Handling System pipettes the sample into one well of a 96 well plate. After an 
59 
initial absorbance is read, the Packard Multi Probe Robotic Liquid Handling System 
pipettes enzyme solution into each well and shakes the plate to mix the sample and 
enzyme.  The reaction proceeds and after an allotted time the change in absorbance is 
determined. All assay reactions are reversible with an exception of glycerol kinase. The 
NAD and enzyme are in excess compared to the substrate, thus the reactions are 
essentially taken to completion and the substrate is the rate-limiting component. 
Therefore, all reactions below are written with a single direction arrow. All reactions are 
carried out at 23°C. 
 
Alanine 
 
The alanine assay involved the reaction: 
 
       alanine dehydrogenase  
L-alanine + NAD+ + H2O -------------------------------> Pyruvate + NADH + NH4+  (1) 
 
The enzyme buffer used was 0.05 M trizma base, 2 mM EDTA and 1 mM hydrazine 
hydrate, pH 10. To 10 ml of enzyme buffer, 4.6 mg of NAD and 3.4 Units (U) of alanine 
dehydrogenase were added. 
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ß-hydroxybutyrate 
 
 
The ß-hydroxybutyrate analysis involved the following reaction: 
 
                3-hydroxybutyrate dehydrogenase  
ß-hydroxybutyrate + NAD+ -----------------------------------> acetoacteate + NADH + H+ (2) 
 
The enzyme buffer was 0.2 M monopotassium phosphate, 3 mM EDTA and 1 mM 
hydrazine hydrate, pH 8.5. To 10 ml of enzyme buffer, 12 mg NAD and 2.1 U ß-
hydroxybutyrate dehydrogenase were added.  
 
 
Glycerol 
 
 
The glycerol assay involved the following reactions: 
glycerol kinase 
glycerol + ATP --------------------------------> glycerol-l-phosphate + ADP (3) 
 
    glycerol-3-phosphate dehydrogenase 
L-glycerol-l-phosphate + NAD+ -----> dihydroxyacetone phosphate + NADH + H+ (4) 
 
The enzyme buffer was 0.09 M glycine, 1 mM hydrazine, and 0.01 M MgC12, pH 9.5. To 
10 ml of the enzyme buffer, 15.4 g NAD, 15.4 mg ATP, 0.3 U glycerokinase, and 0.6 U 
glycerol-3-phosphate dehydrogenase were added. 
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Lactate 
 
The lactate assay involved the following reaction: 
                                 lactate dehydrogenase 
lactate + NAD+ ----------------------------------------> pyruvate + NADH + H+ (5) 
 
The enzyme buffer used was 0.24 M glycine and 0.25 M of hydrazine dihydrochloride 
and 7 mM disodium EDTA, pH 9.6. To 10 ml of enzyme buffer, 4.6 mg NAD and 0.1 U 
lactate dehydrogenase were added. 
 
Acetoacetate 
 Blood acetoacetate concentrations were determined by a spectrophotometric 
method (216) on the samples neutralized as explained in Collection and Processing of 
Samples).  1 ml of neutralized sample was placed into a plastic 4 ml cuvette.  1 ml of 
enzyme buffer (1:1, vol:vol, of 1 M dipotassium phosphate and 1 M monopotassium 
phosphate, diluted 1:5, vol:vol with water, pH 7.0) was then added to the cuvette.  In 
addition, 100 ml of 3 mg/ml NADH was added, the solution was mixed, and an initial 
absorbance reading was taken at 340 nm.  Next, 0.05 U of 3-hydroxybutyrate 
dehydrogenase was added, mixed, and incubated for 1 hour at room temperature.  Finally, 
a last absorbance reading was taken.  The difference between the initial and final readings 
correlates to the acetoacetate level in the samples.  Water blanks were used to normalize 
the data. 
The method is the reverse of that used to access β-hydroxybutyrate concentrations 
(reaction 2).  The analysis of acetoacetate involved the following reaction which is based 
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on the removal of NADH (rather than production in the β-hydroxybutyrate assay), and 
thus the loss of fluorescence: 
    3-hydroxybutyrate dehydrogenase 
acetoacetate + NADH + H+ ----------------------------> β-hydroxybutyrate + NAD+  (6) 
 
Glutamine and Glutamate 
Whole blood glutamine and glutamate concentrations were assessed using 
methods described by Bernt et al. (17) adapted to the Packard Multi Probe Robotic 
Liquid Handling System. As glutamine breaks down when frozen, glutamine samples 
were treated with glutaminase (as described in Collection and processing of samples) on 
the day of the study and consequently all glutamine was converted to glutamate. The 
glutamate samples were not treated with glutaminase and therefore resulted in the loss of 
glutamine when the samples were frozen. Glutamate concentrations were determined 
from both sets of samples with the difference in the two equaling the glutamine level. The 
analysis of glutamate was based on the following reaction: 
glutamate dehydrogenase  
L-glutamate + NAD+ + H2O ------------------> 2-oxoglutamate + NADH + NH3+ (7) 
 
The assay buffer consisted of 23 mM Trizma base, 0.22 M hydrazine hydrate, and 
0.7 mM EDTA, with a pH of 8.5. The enzyme solution was prepared in a phosphate 
buffer composed of 0.2 M dibasic sodium phosphate, 0.2 M monobasic sodium 
phosphate (4:1, v:v), 2 mg/ml NAD, and 36.5 μl/ml glutamate dehydrogenase. The 
glutaminase-treated sample and the corresponding untreated sample were converted to 
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concentrations by comparison with the standard curve constructed from monosodium 
glutamate. 
 
Serine, Glycine and Threonine 
The blood gluconeogenic amino acids serine, glycine and threonine were 
determined by reverse phase HPLC separation using pre-column derivatization with O-
phthalaldehyde (OPA) on SSA-treated blood samples (as described in Collection and 
Processing of Samples) (285). The OPA solution (pH 10.4) was prepared by dissolving 
12 mg OPA crystals (Pierce, Rockford, IL) in 200 ml of cold HPLC-grade methanol, 4.8 
ml of 1.0 M potassium borate buffer, 5 ml of deionized water, and 22 µl of 
mercaptoethanol. An auto injector withdrew 20 µl of standard, control, or sample and 20 
µl of OPA reagent. The sample and reagent were then mixed in the injector loop for 42 s 
before injection into a 1.5 ml/min mobile phase flow made up of elution buffers A and B. 
Elution buffer A (pH 7.2) was composed of 0.1 sodium acetate, HPLC grade methanol, 
and tetrahydorfuran (90:9.5:0.5; v:v:v). Elution buffer B was 100% HPLC grade 
methanol. The mobile phase flow was shifted from elution buffer A to elution buffer B 
over 30 min and samples or standards were detected using a fluorometer with an 
excitation filter of 338 nm and an emission filter of 425 nm. The sample concentration 
was determined from the standard curve taking into account the two-fold dilution during 
deproteinization. The detection range is from 5-5000 µmol/l for each amino acid. 
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Plasma Metabolites 
 
Plasma Glucose 
 
Plasma glucose concentrations were determined by the glucose oxidase method  
using a Beckman glucose analyzer (Beckman Instruments, Fullerton, CA).  The reaction 
sequence was as follows: 
                                       glucose oxidase 
ß-D-glucose + O2 ----------------------------------> gluconic acid and H2O2 (8) 
 
                                         catalase 
H2O2 + ethanol -------------------------------------> acetaldehyde + H2O  (9) 
 
                                        molybdate 
H2O2 + 2H+ +2I- ------------------------------------> I2 + H2O  (10) 
 
The glucose concentration is proportional to the rate of oxygen consumption.  The 
plasma glucose concentration in a sample (10 μl) is determined by comparing of the 
oxygen consumption in the sample with the oxygen consumed by a standard solution 
(150 mg/dl).  There is no end-product inhibition of the process, as reactions 8 & 9 remove 
all of the hydrogen peroxide.  Thus virtually all of the glucose in the sample is consumed.  
Glucose was measured a minimum of 4 times at each sampling time point for each vessel 
and a minimum of 2 times for samples drawn to clamp glucose. The glucose analyzer is 
accurate to 450 mg/dl.  
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Plasma 3-[3H]-glucose 
 For assessment of plasma 3-[3H]-glucose, samples were deproteinized according 
to the method of Somogyi-Nelson (192, 259, 260) as described in Collection and 
Processing of Samples.  For 1-3 days following the experiment the samples were stored 
at 4°C, after which they were centrifuged at 3000 rpm for 20 min.  5 ml of supernatant 
were pipetted into a glass scintillation vial and placed into a heated vacuum oven to 
evaporate 3H20.  The residue was reconstituted in 1 ml of deionized water and 10 ml 
liquid scintillation fluid (EcoLite (+); Research Product Division, Costa Mesa, CA). 
Tritium in the sample was determined using a Beckman LS 9000 Liquid Scintillation 
Counter (Beckman Instruments Inc, Irvine, CA) for double label counting.  The counter 
was programmed to correct the counts per minute (cpm) for quenching of the 
radioactivity in the sample caused by the deproteinization step.  Therefore the data were 
presented in disintegrations per minute (dpm). 
To assess for the loss of radioactive glucose during the deproteinization process, a 
recovery standard was created. The 3-[3H]-glucose infusate was diluted 1:250 (vol:vol) 
with saturated benzoic acid containing 1 mg/ml cold glucose.  Nine 1 ml aliquots of this 
diluted 3H infusate were placed into 3 sets of glass scintillation vials and were labeled as 
follows: chemical standard evaporated (CSE), chemical standard (CS), and chemical 
recovery standard (CRS).  The diluted infusate aliquots in the CSE vials were evaporated 
to dryness in a heated vacuum oven and reconstituted with 1 ml of deionized water.  The 
diluted infusate aliquots in the CS vials were not evaporated.  Te aliquots in the CRS 
vials were treated identical to the plasma samples.  10 ml of scintillation fluid were added 
to all standard vials and the standards were counted.  Comparison of the CS and CSE 
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determined the loss of 3H counts in the evaporation process.  The final amount of 
radioactivity per sample was determined by generating a recovery factor (ratio of 
radioactivity in the CSE compared to CRS) which accounted for the radioactivity lost 
during sample processing. 
 
 
Plasma Free Fatty Acids (FFAs) 
Plasma FFA levels were determined spectrophotometrically using the Packard 
Multi Probe Robotic Liquid Handling System (Perkin Elmer; Shelton, CT) and a kit from 
Wako Chemicals (Richmond, VA).  In the presence of acyl- Coenzyme A (CoA) 
synthetase, CoA is acylated by the fatty acids within the plasma sample. The acyl-CoA 
produced is oxidized by acyl-CoA oxidase, resulting in the production of H2O2. The 
addition of peroxidase, in the presence of H2O2, subsequently allows for oxidative 
condensation of 3-methyl-N-ethyl-N-(β-hydroxyethyl)-aniline with 4- aminoantipyrine 
(4-AAP) to form a purple colored adduct. The purple color adduct is measured at an 
optical density of 550 nm and is proportional to the plasma FFA concentration in the 
sample. The FFA concentrations were calculated using a calibration curve of known 
amounts of oleic acid. The assay was run at 37ºC. The specific reactions were as follows: 
Acyl-CoA synthetase 
FFA + ATP + CoA --------------------------------Æ Acyl-CoA + AMP + Ppi  (11) 
   Acyl-CoA oxidase 
Acyl-CoA + O2  --------------------------------Æ 2,3-trans-enoyl-CoA + H2O2 (12) 
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2 H2O2 + 3-methyl-N-ethyl-N-(β-hydroxyethyl)-aniline + 4-AAP 
Peroxidase      
-----------------------Æ Purple color adduct (13) 
 
Plasma Triglycerides 
Plasma triglyceride levels were assessed by the enzymatic measurement of 
glycerol, true triglycerides, and total triglycerides in plasma using the Spectramax Plus 
384 (Molecular Device Corp. Sunnyvale, CA) and The Serum Triglyceride 
Determination Kit (Sigma, St Louis, MI).  Assay was modified for a 96 well plate.  The 
procedure involves enzymatic hydrolysis of triglycerides by lipoprotein lipase to free 
fatty acids and glycerol.  Glycerol is then phosphorylated by glycerol kinase and 
adenosine-5’-triphosphate (ATP) resulting in the production of glycerol-1-phosphate 
(G1P) and adenosine-5’-diphosphate (ADP).  G1P is then oxidized by glycerol phosphate 
oxidase (GPO) to dihydroxyacetone phosphate (DAP) and hydrogen peroxide (H2O2).  
H2O2 is then coupled with 4-aminoantipyrine (4-AAP) and sodium N-ethyl-N-(3-
sulfopropyl)-anisiden (ESPA) producing quinoneimine dye (absorbance 540 nm).  The 
increase in absorbance is directly proportional to the triglyceride levels of the plasma 
sample.  The assay was run at 37ºC.  The triglyceride concentrations were calculated 
using a calibration curve of known amounts of glycerol. The specific reactions were as 
follows: 
Lipoprotein lipase 
Triglycerides  --------------------------------Æ Glycerol + FFA    (14) 
   Glycerol kinase 
Glycerol + ATP  --------------------------------Æ G-1-P + ADP   (15) 
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GPO 
G-1-P + O2  --------------------------------Æ DAP + H2O2    (16) 
         peroxidase 
H2O2+ 4-AAP + ESPA  -----------------------Æ quinoneimine dye + H2O  (17) 
 
 
Hormones 
 
Epinephrine and Norepinephrine 
Plasma epinephrine and norepinephrine levels were determined using a high-
performance liquid chromatography (HPLC) method as previously described by 
Goldstein et al. (112).  Catecholamines were measured from the glutathione-treated blood 
samples as described in Collection and Processing of Samples. 400 μl of each sample 
was partially purified by absorption to 10 mg of acid-washed alumina (Bioanalytical 
Systems, West Lafayette, IN) in 600 μl of Tris/EDTA(pH 8.6) and 50 μl of an internal 
standard, dihydroxybenzylamine (DHBA, 500 pg/ml, Sigma Chemical Co.).  Samples 
were shaken for 15 min, centrifuged for 4 min, and aspirated. The alumina pellet was 
rinsed with 2 ml water, the solution vortexed, centrifuged, and aspirated.  This process 
was repeated 3 times. The catecholamines were then eluted with 200 μl 0.1M perchloric 
acid (PCA) according to Anton and Sayre (7). 
 Each sample was injected onto an HR-80, reverse phase, 3 μm octadecylsilane 
column. The mobile phase consisted of 14.2 g of disodium phosphate, 43 ml of methanol 
37 mg of sodium EDTA (pH 3.4), and 440 mg of sodium octyl sulfate. The system 
employed a Coulchem II Detector, Model 5021 Conditioning Cell, and Model 5011 
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Analytical Cell (all obtained from ESA, Bedford, MA). Concentrations of epinephrine 
and norepinephrine were calculated using a linear calibration curve consisting of 5 
standards (ranging from 50-1000 pg/ml).  Standards were prepared from epinephrine 
bitartrate and (-)-arterenol bitartrate (norepinephrine) salts (Sigma Chemical Co.).  
Additionally, known amounts of epinephrine and norepinephrine were added to the first 
and last samples of each experiment to evaluate recovery, and to ensure precise 
identification of the peaks. 
 To identify peaks, data reduction was performed using ESA 500 Chromatograph 
and data station software. The ratio of the peak height of the internal standard to that of 
the catecholamine(s) was calculated, and the concentration of catecholamine(s) was 
determined by comparison with the standard curve. The limit of detection of the assay 
was 20 pg/ml for epinephrine and 5 pg ml for norepinephrine.  There was between 80-
100% recovery for both catecholamines. The interassay coefficient of variation (CV) was 
3-11 % for epinephrine; the low and high ends of the curve resulted in large variances. 
For norepinephrine, the interassay CV was 4-6 % . 
 
Cortisol, Glucagon, and Insulin 
The plasma levels of cortisol, glucagon, and insulin were measured using 
radioimmunoassay (RIA) techniques (291).  In essence, a plasma sample containing an 
unknown amount of hormone was incubated with a specific antibody for that hormone.  
A known amount of radiolabeled hormone was added to the mixture to compete with the 
antibody binding sites. A double antibody procedure (single antibody procedure for 
cortisol) which caused precipitation of the bound complex was used to separate unbound 
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hormone from the antibody-hormone complexes.  The radioactivity of the precipitate was 
measured via a Cobra II Gamma Counter (Packard Instrument Co, Meriden, CT). 
Binding of the radiolabeled hormone is inversely proportional to the amount of unlabeled 
hormone present, and a standard curve was constructed using known concentrations of 
the unlabelled hormone. 
 
Cortisol 
 Immunoreactive plasma cortisol was measured with a single antibody procedure 
(101) using a gamma coat RIA (Diagnostic Products Corporation, Los Angeles, CA).  25 
μl the plasma sample and 1 ml of 125I-labeled cortisol were pipetted into a cortisol 
specific antibody-coated tube. The reaction was allowed to continue for 1 hour in a 37°C 
water bath. The tubes were decanted and rinsed with 1 ml of deionized water. They were 
allowed to dry and were then counted in the Cobra II Gamma Counter for 1 minute.   
 The log of the amount of hormone in each sample was inversely proportional to 
the log of (bound label/free label). The cortisol concentration in each sample was 
determined by comparison to a standard curve using known amounts of unlabeled 
hormone. The sample detection range was 0.5-50 ug/dl. The antibody is 100% specific 
for cortisol, with only slight cross-reactivity with 11-deoxycortisol (6%) and 17-
hydroxyprogesterone (1%), and no cross reactivity (<0.4%) with corticosterone (<0.1 %), 
aldosterone, progesterone, deoxycorticosterone, and tetrahydrocortisone. The recovery 
for the assay was approximately 90%, and the interassay CV was in the order of 8-10% 
for the entire range of the dose response curve. 
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Glucagon 
 Immunoreactive plasma glucagon was measured using a double antibody RIA 
(Linco Research Inc., St. Charles, MO) (90). The protocol utilized primary and secondary 
antibodies specific for glucagon (kit with glucagon antibodies and 125I tracers from 
Linco). A 100 μl aliquot of the plasma sample and 100 μl of guinea pig specific antibody 
to glucagon were mixed and incubated for 24 h at 4ºC.  100 μl 125I-labelled glucagon was 
then added to the solution and incubated for an additional 24 h at 4ºC.  Next, the samples 
were incubated for 2 h at 4ºC with 100 μl goat anti-guinea pig IgG (2nd antibody) and 100 
μl IgG carrier. 1 ml of wash buffer was added and the tubes were centrifuged at 3000 
rpm. The samples were decanted and the portion of total radioactivity bound to the 
antibody (pellet) was counted in a Cobra II Gamma Counter. 
 The log amount of hormone in the samples was inversely proportional to the log 
of (bound label/free label). The glucagon concentration in each sample was determined 
by comparison to a standard curve using known amounts of unlabeled hormone. The 
samples were corrected for non-specific binding, and the sample detection range was 20-
400 pg/ml. The antibody is 100% specific for glucagon, with only slight cross reactivity 
with oxytomodulin (0.01%), and no cross reactivity with glucagon like peptide-1, human 
C-peptide, human insulin, human proinsulin, pancreatic polypeptide, or somatostatin.  A 
protein effect in the assay causes the 0 pg/ml glucagon standard to read as 15-20 pg/ml. 
This represents a stable, constant background in all samples. The recovery for the assay 
was between 80-100%, and the interassay CV was approximately 6-10% for the entire 
range of the dose response curve.  
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Insulin 
Immunoreactive plasma insulin was also measured using a double antibody RIA 
as described previously (187).  A 100 μl aliquot of the plasma sample, 200 μl of  125I- 
labeled insulin, and  100 μl of a guinea pig specific antibody to insulin were mixed and 
incubated for 18 h at 4ºC (both from Linco Research Inc., St. Charles, MO).  The samples 
were incubated for 30 min at 4ºC with 100 μl goat anti-guinea pig IgG (2nd antibody) and 
100 μl IgG carrier.  One ml of wash buffer was added, and tubes were centrifuged at 3000 
rpm.  The liquid portion of the samples was decanted and the remaining pellet containing 
the total radioactivity bound to the antibody was counted in a Cobra II Gamma Counter. 
The log of the amount of hormone in the samples was inversely proportional to 
the log of (bound label/fee label). The insulin concentration in each sample was 
determined by comparison to a standard curve obtained using known amounts of 
unlabeled hormone. The samples were corrected for non-specific binding, and the sample 
detection range was 1-150 μU/ml. The antibody is specific to porcine, canine, and human 
insulin, but cross-reacts with bovine insulin (90%), human proinsulin (38%), and the split 
proinsulin products Des 31,32 (47%) and Des 64,65 (72%).  In general, less than 15% of 
the basal insulin level is due to non-insulin material.  The antiboby also has no cross-
reactivity with C-peptide, glucagon, pancreatic polypeptide, or somatostatin. The 
recovery for the assay was between 90-100% and the interassay CV was approximately 
7-8% for the entire range of the dose response curve.  
 
 
 
73 
Hepatic Blood Flow 
Blood flow in the hepatic artery and portal vein was determined by use of trasonic 
flow probes implanted during surgery (as described in Surgical Procedures).  Total 
hepatic blood flow (the sum blood flow in hepatic artery and portal vein) was also 
assessed using the indocyanine green (ICG) dye method, as described by Leevy et al. 
(159).  The results presented in this document were calculated using ultrasonic-
determined flow (unless stated otherwise), as this method allows for the direct 
measurement of blood flow in the hepatic artery and portal vein.  Whereas the ICG dye 
method requires an assumption of the percent contribution of each vessel to total hepatic 
blood flow.  ICG-determined flow was used as a backup measurement in the case of 
ultrasonic flow probe failure. However, the same conclusions were drawn regardless of 
method used to calculate the data.  
 Ultrasonic flow measurements represented instantaneous variations in velocity 
and therefore provided blood flow in the individual vessels of interest. Each probe 
determined the mean transit time of an ultrasonic signal passed back and forth between 
two transducers within the probe which were located upstream and downstream of the 
direction of blood flow in the vessel. The transducers made of a piezoelectric material 
which is capable of receiving and transmitting an ultrasonic signal. The downstream 
transducer first emits an ultrasonic pulse into the blood vessel that is received upstream 
by the second transducer.  After the upstream transducer receives the ultrasonic signal, it 
re-emits the ultrasonic pulse signal back to the downstream transducer. The transit time 
of each ultrasonic beam as measured by the upstream and downstream transducers (ΔTup 
and ΔTdown, respectively) is defined by the following relationships: 
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ΔTup = D / (vo – vx)         (18) 
 
ΔTdown  = D / (vo + vx)         (19) 
 
where D is the distance traveled by the ultrasonic beam within the acoustic window of the 
probe, vo is the phase velocity, or the speed of sound, in blood, and vx represents the 
component of fluid velocity that is parallel or antiparallel to the phase velocity. The 
parallel component augments the phase velocity when the signal travels in the same 
direction of blood flow, while the antiparallel component is subtracted from phase 
velocity if the ultrasonic signal moves against the flow of blood in the vessel.  Combining 
the two expressions for transit time yielded the following equation: 
 
ΔTup - ΔTdown  = (D / (vo – vx))-( D / (vo + vx))     (20) 
 
Since the transit times measured by both transducers, the distance traveled by the beam, 
and the speed of sound in blood are all known quantities, this equation is used to 
calculate vx. Once vx is obtained, the transit velocity (V) of blood traveling through the 
vessel can be determined according to the following equation: 
 
V cos θ = vx          (21) 
 
where θ represents the angle between the centerline of the vessel and the axis of the 
ultrasonic beam.  Lastly, blood flow is the product of the transit velocity and the cross-
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sectional area of the vessel.  The cross-sectional area of the vessel was pre-determined by 
the size of the acoustic window according to the probe model.  Since transit time is 
sampled at all points across the diameter of the vessel, volume flow is independent of the 
flow velocity profile.   
If a flow probe failed during the experiment, the missing values were estimated by 
subtracting the values from the functional flow probe from the ICG determined total 
hepatic blood flow.  For example, values from the arterial flow probe were subtracted 
from the ICG values to yield estimates of the portal vein flow. 
 The ICG method is based on the Fick principle, in which the net balance of a 
substrate across an organ equals the concentration difference of the substrate across the 
organ multiplied by the blood flow through the organ. The equation can be rearranged to 
calculate hepatic blood flow by dividing hepatic ICG balance by the arteriovenous 
difference of ICG across the liver.  Because the liver is assumed to be the only site of 
ICG clearance, hepatic ICG uptake is equal to the ICG infusion rate in steady state 
conditions.  The extraction of ICG across the liver remains constant for brief infusions. 
However, if ICG is infused for longer than four hours, the level of dye in the plasma 
gradually increases, resulting in a slight overestimation (5-10%) of hepatic blood flow 
(125). 
 Arterial and corresponding hepatic vein plasma samples were centrifuged at 3000 
rpm for 30 min using no brake to pellet particulate matter. Absorbance was then 
measured on a Spectronic spectrophotometer at 810 nm. This process was then repeated, 
and the values obtained for each sample were averaged. A standard curve was 
constructed by adding successive 5 μl aliquots of diluted dye (1:10 dilution) to 1 ml of 
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plasma obtained from the animal before the dye infusion began.  Hepatic plasma flow 
(HPF) was then calculated as follows: 
 
HPF= (IR x 10 x SCMD)/(dog weight (kg) x (0.005) x (A-H))   (22) 
 
where IR is the ICG infusion rate (ml/min), SCMD is the standard curve mean difference 
per 5 μl increments, and A-H is the difference in absorbance between the hepatic arterial 
and venous samples. The value of 10 was used to correct for the dilution of ICG used in 
the standard curve, and 0.005 was the volume in ml used as increments in the standard 
curve. Hepatic blood flow (HBF) was derived from HPF: 
 
HBF = HPF/(1-hematocrit)        (23) 
 
Hematocrit was measured at every time point of each in which samples were taken from 
the hepatic artery and portal and hepatic veins.  Because this technique only determines 
total hepatic blood flow, an assumption was made regarding the contribution of blood 
flow in the vessels supplying the liver. The normal distribution of flow was assumed to 
be 20% artery and 80% portal vein at baseline.  In fact, the ultratransonic flow probe data 
obtained (0.22 ± 0.03 and 0.78 ± 0.03 for hepatic artery and portal vein, respectively) 
confirmed that the ratio of arterial and portal that we used was appropriate.   
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Tissue Analysis 
 
Hepatic Lipid Content 
 
Approximately 100 mg of tissue was homogenized in chloroform/methanol (2:1 
v/v) and the lipids were extracted using a modified method of Folch-Lees (100).  The 
homogenates were then filtered through sharkskin filter paper.  0.1 M potassium chloride 
was added to separate the chloroform and methanol layers.  The chloroform phase was 
removed, dried down, and the individual classes of lipids were separated by thin layer 
chromatography using a Silica Gel 60 A plate developed in acetic acid (80:20:1), ethyl 
ether, and petroleum ether and visualized by rhodamine 6G.  Phospholipids and 
acylglycerols bands were scraped from the plates and methylated using boron 
trifluoride/methanol as described by Morrison and Smith (188). Methylated fatty acids 
were extracted and analyzed by gas chromatography.  Gas chromatographic analysis were 
carried out on an HP 5890 gas chromatograph equipped with flame ionization detectors, 
an HP 3365 Chemstation, and a capillary column (SP2380, 0.25 mm x 30 m, 0.25 μm 
film, Supelco, Bellefonte, PA).  Helium was used as a carrier gas. The oven temperature 
was programmed from 160ºC to 230ºC at 4ºC/min.  Fatty acid methyl esters were 
identified by comparing the retention times to those of known standards.  Inclusion of 
lipid standards with odd chain fatty acids permitted quantification of the amount of lipid 
in the sample.  Standards used were dipentadecanoyl phosphatidylcholine (C15:0) and 
trieicosenoin (C20:1). 
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Histology: Oil Red O Staining 
Liver samples from each animal were embedded in OCT and kept at -70°C until 
sectioning. Serial sections of 10-µm thickness were cut and 3 sections were examined 
from each animal. Tissues were washed with propylene glycol for 2 minutes and stained 
with Oil Red O for 1 hour.  Tissues were washed briefly (1 min) in 85% propylene glycol 
and then rinsed in distilled water.  Next, the tissues were counterstained with hematoxylin 
(1 min), rinsed with tap water , and then rinsed again with distilled water.  A coverslip 
was added using an aqueous mounting medium. 
 
Hepatic Adenosine 3’, 5’- cyclic monophosphate (cAMP) Content 
Hepatic cAMP levels were assessed by a modified high-performance liquid 
chromatography method developed by Ally et al (5).  Liver samples (~500mg) frozen in 
liquid nitrogen were homogenized in ice cold 0.4 M perchloric acid containing 0.5 mM 
ethylene glycol-bis (β-aminoethyl ether) tetraacetic acid (EGTA).  After 1 min on ice, the 
acid extract was centrifuged at 2,500 g for 10 min at 4○C.  The supernatant, neutralized 
with ~360 μl of 0.5 M K2CO3 to pH 6.8 was centrifuged at 4○C for 5 min to precipitate 
insoluble KClO4.  The mobile phase consisted of elution buffer A (90:10, 100 mM 
potassium phosphate, pH 6.0, adjusted with K2PO4/methanol) and buffer B (80:20, 100 
mM potassium phosphate, pH 6.0, adjusted with K2PO4/methanol).  The chromatographic 
separation was carried out via auto-injection of 200 ul of sample onto a LC18-T column 
(25 cm x 4.6 mm I.D., 5 μm particle size, Supelco, Bellefonte, PA) protected with a C18 
guard column (Supelco, Bellefonte, PA). Elution occurred at a flow rate of 0.8 ml/minute 
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and a column temperature of 30○C.  Detection of cAMP was achieved with UV detection 
at 254nm (0.1 AUFS) and a retention time of ~20.0 min.   
Basal hepatic cAMP levels were assessed from 18-h fasted dogs with basal 
glucagon and insulin concentrations. 
 
Body Composition Assessment 
 
Magnetic Resonance Imaging (MRI) 
Prior to imaging, the dog will be anesthesized by a 1mg/lb dose of Telazol 
(Tiletimine/Zolzapam/Fort Dodge). To maintain anesthesia, 2% Aerrane 
(isoflurane/Baxter) will be used while on the ventilator.  Magnetic imaging scans will be 
performed.  3 plane abdominal slices (30cm x 5mm), 3D in-phase and out-of-phase axial 
abdominal slices will be obtained using a 3 Tesla whole–body General Electric/Magnex 
magnetic resonance imaging and spectroscopy system (Signa® Edipse 3.0T M4 Release 
software).  Images will be analyzed using software program designed for the 
quantification of fat tissue and other tissue in each slice.  Total abdominal fat and tissue 
will be estimated as the integrated fat or tissue across all slices.  Percent fat will then be 
calculated as the total abdominal fat divided by the total abdominal tissue.  In addition, 
visceral and subcutaneous distributions of fat will be quantified.  Visceral fat will be 
defined as intraabdominal fat bound by parietal peritoneum or transversalis fascia.  
Subcutaneous fat will be defined as the fat superficial to the abdominal and back muscles.  
Subcutaneous fat will be calculated by subtracting the intraabdominal fat area from the 
total fat area. 
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Magnetic Resonance Spectroscopy (MRS) 
All MRS data will be collected on a 3-Tesla whole–body General 
Electric/Magnex magnetic resonance imaging and spectroscopy system (Signa® Edipse 
3.0T M4 Release software).  A localized volume MR technique has on a PRESS 
sequence without water suppression will be used.  Prior to volume localization, an 
imaging protocol (as described above) will be performed that will include acquisition of 
anatomical images and positioning of the spectroscopic voxel in the area of the liver.  
Both the anatomical images and the spectroscopic data will be obtained while the dog is 
forced to hold its breath (the ventilator is turned off).  Three 2 x 2 x 2 (8cm3) voxels were 
examined in each time point during the study protocol.  64 transients with a repetition of 
2 seconds and an echo time (TE) of 25 ms will be acquired from each voxel and used to 
evaluate the spin density for water and fat contributions.   
The water and fat time-domain signals will each be modeled as a sum of 
exponentially decaying sinusoids.  The amplitude and frequency of each sinusoid will be 
optimally estimated (along with the decay rate and phase).  All frequencies (chemical 
shifts) will be measured relative to the principal water 1H resonance of ~4.7 ppm.  The 
water 1H resonance is a large peak located at ~4.5 ppm.  The lipid signal results from 
multiple chemically shifted 1H resonances corresponding to methyl and methylene groups 
occupying different positions on lipid molecules with frequencies found at around (0.9 – 
2.4 ppm) with a major peak at ~1.5 ppm corresponding to methylene groups (CH2)n 
chains.  The resonances are used to calculate a ratio/percent change in fat content in the 
liver.  
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Calculations 
 
 
Glucose Turnover 
Glucose turnover is the rate at which old glucose is replaced with new glucose.  
Tracer-determined total glucose production (Ra) and glucose utilization (Rd) were 
calculated using an isotope dilution method described by Wall (286), as simplified by 
DeBodo (71), and using a two-compartmental model described by Mari (63) with canine 
parameters established by Dobbins (78). The glucose pool was initially primed with an 
injection of 3-[3H]-glucose followed by a constant infusion of the tracer. By the 
beginning of the control period, the tracer (3-[3H]-glucose) and tracee (cold glucose) 
were in equilibrium so that the specific activity of glucose (SA = dpm/mg) was in a 
steady state.  Ra and Rd were calculated according to the following equations:  
Ra = [I - N (dSA/dt)]/SA, and   (24) 
Rd = Ra – (dN/dt) (25) 
where I is tracer infusion rate (dpm/min), N is the size of the glucose pool (mg) and t is 
time (min) (175). In a steady state, when dSA/dt = 0, the Ra equation is simplified to: 
Ra = I/SA (26) 
This method utilizes a one-compartment model of glucose kinetics as described 
by Steele (6). The one-compartment model assumes one compartment of glucose that 
consists of both a rapidly and slowly mixing pool of glucose.  Therefore, when rapid 
changes in cold glucose are induced in the system, the consequent changes in glucose 
specific activity would be unevenly distributed throughout the entire glucose 
compartment.  To compensate for this non-uniform mixing, a correction factor for the 
pool size is calculated as: 
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N = pVC  (27) 
where p is the pool fraction, V is the volume of distribution of glucose (ml) and C the 
cold glucose concentration (mg/dl).  The pool fraction (the rapidly mixing component of 
the glucose compartment) was estimated to be 0.65 (219), while V was assumed to be the 
extracellular volume, which is approximately 22% of the dog weight (65). 
The major limitation of the one-compartment model is that a rapid change in SA 
invalidates the method, so that a fall in SA, which occurs either by endogenous glucose 
production or exogenous glucose infusion in the presence of a constant 3-[3H]-glucose 
infusion, the change in SA would cause an error in the estimation of Ra (underestimation 
if SA drops, overestimation if SA increases) (62). In order to overcome this problem in 
the present studies, the data were calculated using a two-compartment model (171).  This 
model describes the glucose system more accurately under non-steady-state conditions.  
Ra was calculated as the sum of three terms: a steady-state term, a term for the first 
compartment, and a term for the second compartment.  The principle equations are as 
follows, where the expression of Ra, calculated at the equally spaced time instants t0, 
t1,…, tk, tk+1, is determined from the following formulas: 
Ra(tk) =(R*inf)(tk)/SA(tk)–V1[C(tk)dSA(tk)/dt] / SA(tk) – V2k22[SA(tk)G(tk) – G*(tk)]/SA(tk) 
 (28) 
G(tk+1) = b1G(tk) + b2C(tk) + b3C(tk+l) (29) 
G*(tk+l) = blG*(tk) + b2C*(tk) + b3C*(tk+l) (30) 
V2= V1k12k21/k222 (31) 
where tk and tk+l are time parameters, respectively; Ra(tk) and R*inf(tk) are the rate of 
appearance calculated with approximate two-compartment model (mg/kg/min) and tracer 
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infusion rate (dpm/kg/min), respectively; SA(tk) and dSA(tk) are specific activity 
(dpm/mg) and derivative of specific activity (dpm/mg/min), respectively. V1 and V2 
(ml/kg) are the volumes of the first and second compartments, respectively; C*(tk) and 
C(tk) are tracer and tracee concentrations, respectively; k12, k21, and k22 are constant rate 
parameters of the first and second compartments, respectively; G(tk) and G*(tk) are 
variables calculated recursively from tracee and tracer concentrations, respectively; bl, b2, 
and b3 are coefficients of recursive equations for calculating G(tk) and G*(tk).  Canine 
parameters were used for Vl, V2, and k22 in the present studies were those determined by 
Dobbins et al. (78).  It has been reported (78) that under non-steady state conditions 
where specific activity changes dramatically, glucose appearance determined using the 
two-compartment model is more accurate than the Steele equation (one-compartment 
model). 
When glucose was infused, endogenous glucose production (endo Ra) was 
determined by subtracting the glucose infusion rate (GIR), from total glucose production 
(Ra). 
 Of note, there are two major assumptions that are made when using this particular 
isotope dilution method to determine glucose kinetics.  First, the labeled and unlabeled 
glucose molecules are assumed to be metabolized in the same manner.  Secondly, the 
label is assumed be irreversibly lost (293).     
It should also be noted that, as the liver and the kidneys both produce glucose, 
whole body tracer-determined glucose production is slightly higher than the rate of 
hepatic glucose production.  Although net kidney glucose balance in the postabsorptive 
state is near zero, the kidney has been estimated to contribute 5-15% to whole body 
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glucose production. However, studies have suggested that the kidney is only a minor 
contributor to total glucose production (88).  
 
Net Hepatic Substrate Balance 
The net balance of a substrate across an organ, otherwise known as the 
arteriovenous (A-V) difference technique, utilized the Fick principle as described for the 
ICG-determination of blood flow (as described in Sample Analysis under Hepatic Blood 
Flow).  Briefly, net hepatic balance of a substrate (NHSB) was calculated as the 
difference between the substrate load leaving the liver (Loadout) and the substrate load 
entering the liver (Loadin), as shown in the equation below: 
NHSB = Loadout - Loadin  (32) 
The Loadout was calculated according to the equation: 
 
Loadout = [S]HV x HBF  (33) 
 
where [S]HV is the substrate concentration in the hepatic vein, and HBF is the total 
hepatic blood flow.  
The Loadin was calculated according to the equation: 
 
Loadin = ([S]A x HABF) + ([S]PV x PVBF)  (34) 
 
where [S]A and [S]PV are arterial and portal venous substrate concentrations, respectively, 
and HABF, PVBF are hepatic artery and the portal vein blood flows, respectively.  For all 
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glucose balance calculations, plasma glucose concentrations were converted to whole 
blood values using a previously determined correction factor (131, 201) which assumes 
blood glucose to be 73% of the plasma glucose values.  Blood flows were used for all 
substrate balance calculations except FFA balances.  FFA balances were calculated using 
plasma flow, determined by multiplying blood flow by (1-hematocrit).  A positive value 
for NHSB indicates net substrate production by the liver, whereas a negative value 
represents net hepatic substrate uptake.  In some cases, uptake is presented rather than 
balance, and when such is the case positive values are used. 
 Limitations of the A-V difference technique include: 1) imprecision in the 
measurement of local blood  flow, 2) measurement of net rather than absolute flux across 
the organ and 3) variability of vascular anatomy and heterogeneity of tissue structure and 
function.  In addition, transit time through the organ must be taken into account.  Because 
the A-V difference represents net flux across an organ, it is most valid during steady-state 
conditions. 
 
Hepatic Gluconeogenesis and Glycogenolysis 
Net hepatic gluconeogenic (NHGNG) flux and net hepatic glycogenolysis 
(NHGLY) were estimated in the present studies.  The synthesis and subsequent release of 
glucose from non-carbohydrate precursors is classically known as gluconeogenesis.  All 
carbon produced by the gluconeogenic pathway is not necessarily released by the liver.  
Some of the carbon may be stored as glycogen, oxidized, or released as lactate.  
Therefore, we made a distinction between gluconeogenic flux to glucose-6-phosphate (G-
6-P) and net hepatic gluconeogenic flux.   
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Hepatic gluconeogenic flux to G-6-P was determined by dividing the sum of net 
hepatic uptake of gluconeogenic precursors (alanine, glutamate, glutamine, glycerol, 
glycine, lactate, pyruvate, serine, and threonine) by two to account for the incorporation 
of the three-carbon precursors into the six-carbon glucose molecule. The net hepatic 
balance of pyruvate was assumed to be 10% of net hepatic lactate balance.  This method 
assumes that there is 100% conversion of gluconeogenic precursors taken up by the liver 
into G6P and that intrahepatic GNG precursors do not contribute significantly to GNG 
flux.  When net hepatic output of any precursor occurred, rather than uptake, the 
precursor was considered to be a product of the liver, and thus uptake was set to zero.   
NHGNG flux was determined by subtracting the sum of net hepatic output rates 
(when such occurred) of gluconeogenic precursors (in glucose equivalents) and hepatic 
glucose oxidation from the gluconeogenic flux to G-6-P.   When NHGNG flux is 
positive, there is net flux to glucose-6-phophate (G6P), whereas a negative number 
indicates net flux to pyruvate, or net glycolysis.  In the present studies, glucose oxidation 
was assumed to be 0.2 mg·kg-1min-1 in all groups (56, 121).  This parameter was not 
directly measured because it is difficult to differentiate between the small signal and the 
high inherent noise in the measurement. However, our lab has found glucose oxidation 
after an overnight fast to range from 0.1 to 0.2 mg·kg-1min-1.  While using this value may 
slightly overestimate or underestimate the absolute rate glucose oxidation, it is unlikely to 
differ by more than 0.1 mg/kg/min from the true value.  In previous studies hepatic GO 
did not change appreciably under euglycemic/hyperinsulinemic states (184).  
Additionally, it seems unlikely that glucagon would change hepatic glucose oxidation 
significantly.  Although, glucagon has been shown to inhibit pyruvate dehydrogenase, 
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and thus pyruvate oxidation(107, 221), the basal oxidation is so low that the noise of the 
measurement would be larger than the magnitude of the potential fall.  NHGLY was 
estimated by subtracting NHGNG flux from net hepatic glucose balance.  A positive 
value for NHGLY indicates net glycogen breakdown, whereas a negative value 
represents net glycogen synthesis. 
When using the A-V difference technique to estimate fluxes of NHGNG and 
NHGLY it is necessary to consider the limitations of this approach.  There is little to no 
hepatic production of gluconeogenic amino acids or glycerol however, such is not the 
case for lactate.  Our estimate of the rate of gluconeogenic flux to G-6-P will only be 
quantitatively accurate only if lactate flux is unidirectional at a given moment.  It has 
been suggested that there is spatial separation of metabolic pathways in that, 
gluconeogenic periportal hepatocytes primarily consume lactate and other non-
carbohydrate precursors for the synthesis of glucose and glycogen, while glycolytic 
perivenous hepatocytes predominantly consume plasma glucose which can be 
incorporated into glycogen, oxidized, or released as lactate or other glycolytic substrates 
(142, 220). Therefore, in a net sense it is possible that hepatic gluconeogenic and 
glycolytic flux occur simultaneously, with lactate output and uptake occurring in different 
cells.  To the extent that flux occurs in both directions simultaneously, the net hepatic 
balance method will result in an underestimation of gluconeogenic flux to G-6-P.  Of 
note, net hepatic gluconeogenic flux and net hepatic glycogenolytic flux can be 
calculated accurately without concern for the assumptions related to whether or not 
simultaneous gluconeogenic and glycolytic substrate flux occur.  Ideally the 
gluconeogenic flux rate would be calculated using unidirectional hepatic uptake and 
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output rates for each substrate, but this would be difficult, as it would require the 
simultaneous use of multiple stable isotopes which could themselves induce a mild 
perturbation of the metabolic state.  
 
Non-Hepatic Glucose Uptake 
Non-hepatic glucose uptake (non-HGU) was calculated over time intervals by the 
following formula: 
Non-HGU = average total glucose infusion between T1 and T2 + (T1NHGB + T2NHGB)/2) – 
glucose mass change in the pool       (35) 
  
where T1 and T2 indicates the time points for which glucose is being measured. The 
((T1NHGB + T2NHGB)/2) term will be a negative number in the presence of net hepatic 
glucose uptake. The glucose mass change in the pool is calculated using the following 
equation: 
Glucose mass change in the pool = ((([GA]T2 - [GA]T1) / 100) * 
((0.22 * body wt in kg * 1000 *0.65) / body wt in kg)) / (T2-T1)  (36) 
 
where [GA] is the plasma glucose concentration, T1 and T2 are the time points of the 
interval, 0.22 represents the volume of extracellular fluid (the volume of distribution) or 
22% of the dog’s weight (6), and 0.65 represents the fraction of the pool (65). 
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Sinusoidal Hormone Concentrations 
 Because the liver is supplied by blood flow from both the hepatic artery and the 
portal vein, neither represents the true inflowing hepatic blood flow supply. For this 
reason, hepatic sinusoidal hormone levels (of insulin and glucagon) were calculated as 
follows: 
 
Hepatic Sinusoidal Hormone Level = [S]A x  (APF/TPF) +  [S]P x (PPF/TPF) (37) 
 
where A and P are arterial and portal vein plasma substrate concentration; APF and PPF 
are the arterial and portal vein plasma flow measured by the ultrasonic flow probes; TPF 
(total hepatic plasma flow) = APF + PPF.  Note this calculation represent the average 
inflowing hepatic sinusoidal hormone level, rather than the average sinusoidal level. 
 
 
Statistical Analysis 
 
Data are expressed as means ± standard error (SE).  Data were analyzed for 
differences both among groups and within groups (i.e. change from individual baselines).  
Statistical comparisons for time course data were made by two-way ANOVA with 
repeated measures design run on SigmaStat (SPSS Science, Chicago, IL).  Post hoc 
analysis was performed with Tukey’s test.  When only two values were compared an 
independent t-test was used (SigmaStat, SPSS Science, Chicago, IL).  For Specific Aim I, 
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statistical comparisons of β-OHB and individual and total gluconeogenic amino acid data 
were made by two-way ANOVA.  Statistical significance was accepted at P < 0.05.   
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CHAPTER III 
 
THE EFFECT OF AN ACUTE ELEVATION OF FFA LEVELS ON 
GLUCAGON-STIMULATED HEPATIC GLUCOSE PRODUCTION 
 
 
Aim 
As β-cell function is impaired in overt type 2 diabetes, lower plasma insulin levels 
during the postprandial period should result in a decreased insulin response at both the 
pancreatic α-cell and adipocyte and therefore cause glucagon and FFA levels to be 
elevated.   Indeed, in subjects with type 2 diabetes, it has been shown that glucagon 
secretion from α-cells is not suppressed and has even been shown to be elevated (75, 
243).  Additionally, FFA normally fall during the postprandial period, but in individuals 
with type 2 diabetes FFA levels remain elevated (223, 224).  As an insufficient decrease 
in HGP is involved in the postprandial hyperglycemia observed in type 2 diabetes, it is 
possible that elevated levels of glucagon and FFA could be responsible for the increase in 
hepatic glucose production by the liver in these patients.  Although it is well established 
that both glucagon and FFA are essential regulators of glucose production by the liver, it 
is unclear how they interact to acutely regulate HGP.   
Like glucagon, epinephrine directly stimulates HGP by increasing GLY.  
However, the indirect actions of epinephrine alter the mechanisms (stimulate 
GNG/inhibit GLY) by which glucose is produced by the liver.  This results from its 
ability to release FFA from adipose tissue. Since the direct actions of both epinephrine 
and glucagon on HGP are mediated by cAMP, it could be hypothesized that the elevated 
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FFA, as seen postprandially in type 2 diabetes, would alter hepatic glucagon action in a 
similar manner to that seen with epinephrine.  Therefore the goal of Specific Aim I was 
to determine the effects of physiological incremental increases in glucagon and FFA on 
the contributions of GLY and GNG of HGO.    
 
Experimental Design 
First Study   
Each experiment consisted of a tracer and dye equilibration period (-140 to -40 
min), a basal period (-40 to 0 min), and an experimental period (0 to 195 min).  At -140 
min, a priming dose of [3-3H] glucose (33.3 μCi) was given and a constant infusion of [3-
3H] glucose (0.35 μCi/min) was begun to allow the assessment of hepatic glucose 
production.  Constant infusions of indocyanine green (0.077 mg/min), to assess hepatic 
blood flow, and somatostatin (0.8 μg/kg/min), to inhibit endogenous insulin and glucagon 
secretion were also started at -140 min.  A constant intraportal infusion of glucagon (0.55 
ng/kg/min) was given (t = -140 min) to replace basal endogenous glucagon secretion.  
Endogenous insulin was replaced intraportally at a variable rate beginning at -140 min.  
The plasma glucose level was monitored every 5 min, and euglycemia was maintained by 
adjusting the rate of insulin infusion.  Once the plasma glucose level had been stabilized 
at euglycemia for 30 min, basal sampling was started (-40 min) and the infusion rate of 
insulin remained unchanged thereafter.  The average insulin infusion rate was 234 ± 23 
μU/kg/min.   
 The first study included five protocols:    
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Protocol 1 (GGN, n = 6):  At 15 min, the intraportal glucagon infusion was increased 
from 0.55 ng/kg/min to three times the basal rate (1.65 ng/kg/min).   
Protocol 2 (HG, n = 5):  To control for the effects of hyperglycemia on HGO, a 
hyperglycemic clamp was performed.  20% dextrose was infused via a leg vein to clamp 
the arterial glucose at the levels seen in the groups receiving three times basal glucagon.  
Protocol 3 (FFA + GGN, n = 7):  A constant Intralipid (0.02 ml/kg/min, 20% fat 
emulsion; Baxter Healthcare Corporation, Deerfield, IL) plus heparin (0.5 U/kg/min) 
infusion was started at 0 min via a leg vein.  After a FFA/glycerol equilibration period 
(15 min), the intraportal glucagon infusion was increased from 0.55 ng/kg/min to 1.65 
ng/kg/min as seen in protocol 1.       
Protocol 4 (GLYC + GGN, n = 5):  To control for the rise in glycerol, a constant 
glycerol infusion (via a leg vein) of 0.95 mg/kg/min was started at 0 min.  After a 
glycerol equilibration period (15 min), the intraportal glucagon infusion was increased 
from 0.55 ng/kg/min to 1.65 ng/kg/min as seen in protocol 1.   
Protocol 5 (FFA + HG, n= 5):  In order to control for the increase in FFA, glycerol, and 
glucose, a constant 20% Intralipid (0.02 ml/kg/min) plus heparin (0.5 U/kg/min) infusion 
was started at 0 min in the presence of a hyperglycemic clamp.  20% dextrose was 
infused via a leg vein to clamp the arterial glucose at the levels seen in the groups 
receiving three times basal glucagon.    
The glucagon infusion rate was increased by 7% every hour in groups 1, 3, and 4 
to compensate for aggregation occurring in the infusion syringe.  
Arterial blood samples were taken every 10 min during the basal period and every 
15 min during the experimental period.  In the FFA + HG and HG groups, arterial blood 
94 
samples were also taken every 5 minutes in order to monitor glucose levels.  The total 
blood volume withdrawn did not exceed 20% of the dog’s total blood volume and each 
volume of blood was replaced with two volumes of saline.  
Second Study 
 The equilibration period (-140 to -40 min) and basal period (-40 to 0 min) in the 
second study were identical to those in the first study (described above).   The average 
insulin infusion rate for this study was 264 ±28 μU/kg/min.  The experimental period (0 
to 45 min) was not only shortened to 45 min but the FFA/glycerol equilibration period 
was extended 15 min and the glucagon and Intralipid/heparin infusion rates were 
increased by 33% and 50%, respectively, compared to the first study. 
The second study included only two protocols:    
Protocol A (GGN, n = 3):  At 30 min, the intraportal glucagon infusion was increased 
from 0.55 ng/kg/min to four times the basal rate (2.2 ng/kg/min). 
Protocol B (FFA + GGN, n = 3):  A constant Intralipid (0.03 ml/kg/min, 20% fat 
emulsion; Baxter Healthcare Corporation, Deerfield, IL) plus heparin (0.75 U/kg/min) 
infusion was started at 0 min via a leg vein.  After a FFA/glycerol equilibration period 
(30 min), the intraportal glucagon infusion was increased from 0.55 ng/kg/min to 2.2 
ng/kg/min as seen in protocol A. 
Arterial blood samples were taken every 10 min during the basal period, every 10 
min during the FFA/glycerol equilibration (0 to 30 min), and every 5 min after the 
glucagon infusion was increased to four times the basal rate (30 to 45 min).  The total 
blood volume withdrawn did not exceed 20% of the dog’s total blood volume and each 
volume of blood was replaced with two volumes of saline.  
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Immediately following the final blood sample, each animal was anesthetized with 
pentobarbital sodium.  The animal was then removed from the harness while the 
hormones and Intralipid/heparin continued to be infused.  A midline laporotomy incision 
was made, and clamps cooled in liquid nitrogen were used to freeze sections of left and 
right central and left lateral lobes of the liver in situ.  The hepatic tissue was then cut free, 
placed in liquid nitrogen, and stored at –70°C.  Approximately 2 min elapsed between the 
time of anesthesia and the time of tissue clamping. All animals were then euthanized. 
 
Results 
 
Hormone levels and hepatic blood flow.  Arterial plasma levels of insulin remained basal 
in all groups throughout the study (Tables 3.1 and 3.2).  During the basal period, arterial 
and portal vein plasma glucagon levels were ~45 ± 2 and 60 ± 2 pg/ml, respectively (data 
not shown).  During the experimental period, glucagon infusion at three times the basal 
rate (1.65 ng/kg/min) caused increases of ~ 40 and 100 pg/ml in arterial and portal vein 
plasma glucagon levels, respectively (all P < 0.05; Fig. 3.1, Table 3.2).  In the HG and 
FFA + HG groups, arterial and portal vein plasma glucagon levels remained basal and 
stable during the experimental period (Fig. 3.1).  Arterial plasma cortisol, arterial blood 
epinephrine and norepinephrine, and hepatic blood flow remained basal in all groups 
throughout the study (data not shown). 
Arterial levels and net hepatic uptakes of plasma FFA and blood glycerol.  Peripheral 
infusions of Intralipid and heparin increased the arterial plasma FFA level from ~ 545 to 
~ 1650 μmol/l by the end of the study (P < 0.05, Fig. 3.2).  The arterial plasma FFA level 
remained unchanged in the GLYC + GGN (Table 3.2), GGN, and HG groups (Fig. 3.2).  
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Net hepatic uptake of FFA increased from ~ 2 to ~ 4 - 5 μmol/kg/min by the last hour in 
the FFA+GGN and FFA + HG groups (P < 0.05, Fig. 3.2).   Net hepatic uptake of FFA 
remained basal and unchanged in the GLYC + GGN (Table 3.2), GGN, and HG groups 
(Fig. 3.2). 
 Peripheral infusions of Intralipid and heparin increased the arterial blood glycerol 
level from ~ 70 to ~ 200 μmol/l by the end of the study in the FFA + GGN and FFA + 
HG groups, respectively (P < 0.05, Fig. 3.2).  In the GLYC + GGN group, a peripheral 
glycerol infusion of 0.95 mg/kg/min increased the arterial blood glycerol level from 74 ± 
9 to 195 ± 21 μmol/l (P < 0.05, Table 3.2).  The arterial blood glycerol level remained 
basal and unchanged in the GGN and HG groups (Fig. 3.2).  Net hepatic glycerol uptake 
increased from ~ 1.5 to 3.5 μmol/kg/min in the FFA + GGN, GLYC + GGN, and FFA + 
HG groups (all P < 0.05; Fig. 3.2, Table 3.2).  Net hepatic uptake of glycerol remained 
basal and unchanged in the GGN and HG groups (Fig. 3.2). 
Glucose metabolism.  In all five groups, plasma glucose levels rose from just over 100 to 
~ 200 mg/dl (Fig. 3.3, Table 3.2).  In response to a portal infusion of glucagon (1.65 
ng/kg/min), net hepatic glucose output (NHGO) increased by 5.4 ± 1.6 and 4.8 ± 1.0 
mg/kg/min (both P < 0.05, NS between groups) in GGN and GLYC + GGN groups, 
respectively, by 15 min of glucagon infusion (min 30, Fig. 3.3, Table 3.2).  In the 
presence of Intralipid and heparin infusions, glucagon-stimulated NHGO only increased 
by 3.2 ± 1.1 mg/kg/min (P < 0.05 vs. GGN and GLYC + GGN groups, Fig. 3.3).  
Hyperglycemia alone (HG) and peripheral infusions of Intralipid and heparin in the 
presence hyperglycemia (FFA+HG) resulted in a decrease in NHGO from 1.6 ± 0.3 to -
0.4 ± 0.5 and  2.2 ± 0.2 to 0.2 ± 0.7 mg/kg/min, respectively, by the last hour of the 
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experimental period (Fig. 3.3).  Changes in tracer-determined endogenous glucose 
production (Ra) paralleled the changes in NHGO (Table 3.3, Table 3.2).  Elevation in 
circulating FFA blunted glucagon-stimulated endogenous glucose production by 50% (Δ 
2.2 mg/kg/min, P< 0.05, GGN minus HG vs. FFA + GGN minus FFA + HG at min 30, 
Table 3.3). 
Net hepatic glycogenolysis and gluconeogenesis.  In response to a portal infusion of 
glucagon (1.65 ng/kg/min), net hepatic glycogenolysis (NHGLY) had increased by 5.4 ± 
1.6 and by 5.7 ± 1.4 mg/kg/min in GGN and GLYC + GGN groups, respectively, 15 min 
after initiation of the glucagon infusion (min 30, both P < 0.05, Fig. 3.4, Table 3.2).  In 
the FFA + GGN group, NHGLY had only increased by 3.2 ± 1.1 mg/kg/min by 15 min 
(min 30, P < 0.05 vs. GGN and GLYC + GGN groups, Fig. 4).  In the HG and FFA + HG 
groups, NHGLY decreased from 2.2 ± 0.5 to -0.03 ± 0.4 and 3.0 ± 0.5 to 0.08 ± 0.4 
mg/kg/min (last 30 minutes of the experimental period; Fig. 3.4). 
 Net hepatic gluconeogenic (NHGNG) flux had fallen by 0.9 ± 0.2, 0.7 ± 0.4, and 
0.8 ± 0.4 15 min after the start of glucagon infusion (min 30) in the GGN, FFA + GGN, 
and GLYC + GGN groups, respectively (Fig. 4).  By the last 30 min of the study, 
NHGNG flux had returned to basal rates in the GGN and GLYC + GGN groups (Fig. 4, 
Table 3.2).  However, in the FFA + GGN and FFA + HG groups, peripheral infusions of 
Intralipid and heparin resulted in an increase in NHGNG flux of 0.8 ± 0.2 and 0.8 ± 0.3 
mg/kg/min, respectively, by the end of the study (P < 0.05, Fig. 3.4).  NHGNG flux fell 
slightly in response to hyperglycemia alone (NS, Fig. 3.4).     
Arterial blood levels and net hepatic balances of β−OHB and acetoacetate. Peripheral 
infusions of Intralipid and heparin tended to cause a rise in arterial blood β-
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hydroxybutyrate (β-OHB)  levels (~20 to 27 μmol/l, last h) even though there was no 
significant increase in net hepatic β-OHB output (NS, data not shown).  In the absence of 
elevated FFA, there was no significant change in arterial levels or net hepatic output of β-
OHB (data not shown).  The arterial blood levels of acetoacetate remained unchanged 
regardless of treatment despite the tendency for net hepatic output of acetoacetate to 
increase over time in the GGN, FFA + GGN, and FFA + HG groups (~ Δ 0.5 μmol 
/kg/min) and decrease in the GLYC + GGN and HG groups (~Δ -0.2 μmol /kg/min, NS, 
data not shown).  
Arterial blood levels and net hepatic outputs of lactate.  After the first 75 min of the 
experimental period, three times basal glucagon caused an initial modest increase in 
arterial blood lactate levels, due to an rise in net hepatic lactate output (NHLO, Fig. 3.5, 
Table 3.2).  An elevation in plasma FFA decreased NHLO by the end of the study in both 
the FFA + GGN and FFA + HG groups (P < 0.05, Fig. 3.5).  In the presence of 
hyperglycemia (HG), arterial blood lactate levels rose significantly (716 ± 176 to 1142 ± 
269 μmol/l; 195 min, P < 0.05) over time as a result of an increase in NHLO (Fig. 3.5).   
Arterial blood levels, net hepatic balances, and fractional extraction of gluconeogenic 
amino acids.  Portal infusion of glucagon (1.65 ng/kg/min), had no effect on arterial 
blood levels, net hepatic balance, or fractional extraction of individual or total amino 
acids by 30 min after the initiation of glucagon infusion (data not shown).  By the end of 
the study, individual (excluding glutamine and glutamate) and total amino acid fractional 
extraction increased in response to three times basal glucagon (P < 0.05, data not shown).  
This in turn resulted in a fall in arterial blood levels and some decrease in net hepatic 
uptake of the gluconeogenic amino acids (NS, data not shown).  However, an elevation of 
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FFA levels did not alter glucagon’s effect on amino acid fractional extraction at any time 
point throughout the experiment (data not shown).  In the HG and FFA + HG groups, 
individual and total amino acid arterial blood levels, net hepatic balances, and fractional 
extractions remained constant throughout the study.   
Hepatic cAMP levels at the peak of glucagon action.  To determine if elevated plasma 
FFA inhibit the rise in cAMP caused by glucagon in vivo, we repeated the GGN and FFA 
+ GGN protocols (n=3/group) and terminated the experimental period at the peak of 
glucagon action (15 min after the increase in the glucagon infusion rate) and collected 
tissue to assess hepatic cAMP levels.  In addition to shortening the experimental period, 
we extended the FFA/glycerol equilibration period by 15 min and the glucagon and 
Intralipid/heparin infusion rates were increased by 33% and 50%, respectively, compared 
to the first study. 
 Arterial plasma levels of insulin remained basal (~6.0 μU/ml) in both groups 
throughout the study.  Arterial and portal plasma glucagon levels (pg/ml) increased by ~ 
50 and 140 pg/ml in both groups, respectively (P < 0.05, Fig. 3.6).  Arterial plasma 
cortisol, arterial blood catecholamines, and hepatic blood flow remained basal in both 
groups (data not shown).  Arterial plasma FFA (570 ± 36 μmol/l) and blood glycerol (55 
± 7 μmol/l) remained basal in the GGN group throughout the study.  In the FFA + GGN 
group, peripheral infusions of Intralipid and heparin increased the arterial plasma FFA 
and blood glycerol levels from 419 ± 51 to 1482 ± 241 and 42 ± 9 to 252 ± 47 μmol/l, 
respectively (P < 0.05).  Arterial glucose levels (mg/dl) rose from 106 ± 4 to 125 ± 2 in 
the GGN group and from 108 ± 2 to 135 ±7 in the FFA + GGN group (P < 0.05).   
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In response to a portal infusion of glucagon (2.2 ng/kg/min), NHGO increased 
from 1.9 ± 0.2 (0 to 30 min) to 10.1 ± 1.8 (min 45) mg/kg/min (P < 0.05 vs basal, Fig. 
3.6).  However, in the FFA + GGN group, elevated FFA and glycerol blunted glucagon 
stimulated NHGO, where NHGO rose from 1.9 ± 0.5 (0 to 30 min) to 8.0 ±1 mg/kg/min 
(min 45, P < 0.05 vs basal, Fig. 3.6).  Similarly, four times basal glucagon increased 
NHGLY (mg/kg/min) from ~2.0 (0 to 30 min) to 12.3 ± 2.5 in the GGN group and to 
only 8.4 ±1.7 in the FFA + GGN group at min 45 (P < 0.05 vs. basal, Fig. 3.6).  NHGNG 
flux (mg/kg/min) decreased from -0.6 ± 0.4 to -2.2 ± 0.7 after 15 min of four times basal 
glucagon infusion (P < 0.05, Fig. 3.6).  However, in the FFA + GGN group, NHGNG 
flux did not change in response to glucagon (Fig. 3.6).   
In the GGN group, there was a slight increase in arterial lactate levels from 721 ± 
254 to 1103 ± 247 μmol/l due to a dramatic rise in NHLO (μmol/kg/min) from 9.7 ± 4 to 
31 ± 8 (P < 0.05, Fig. 3.6).  Elevated FFA and glycerol completely inhibited glucagon’s 
increase in NHLO (Fig. 3.6).  Hepatic cAMP levels (ng/mg of tissue) increased from a 
basal level of 96 ± 16 to 178 ± 9 and 176 ± 24 in the GGN and FFA + GGN groups, 
respectively (n=3/group, data not shown). 
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Discussion 
 
 The present study determined the effects of physiological increments in glucagon 
and FFA on HGO in the presence of basal insulin and matched glycemia in the conscious 
dog.  Glucagon was elevated to levels approximately one-half those needed for the 
hormone’s maximal effect on HGO (266) so that we would be able to detect any change 
caused by FFA.  Intralipid and heparin were infused at rates needed to achieve FFA 
levels identical to those seen in our previous studies in which we assessed the ability of a 
simulated rise in lipolysis to alter epinephrine’s hepatic glycogenolytic and 
gluconeogenic effects (265, 266).  Since the direct actions of both glucagon and 
epinephrine on HGO are mediated by cAMP, we hypothesize that elevated FFA will alter 
glucagon-stimulated HGO as it does on epinephrine action at the liver.  Although the 
results from the present studies showed that an increase in FFA did in fact limit the initial 
increase in glucagon-stimulated HGO by blunting glycogenolysis, the elevation of FFA 
did not increase gluconeogenic flux. 
The present studies confirmed previous findings that stimulation of HGO by 
glucagon primarily results from an initial rapid, potent, and time-dependent increase in 
glycogenolysis (48, 49, 116, 117, 169).  In the first and second studies, the increments in 
portal glucagon levels increased NHGLY by 5.5 ± 1.6 mg/kg/min and 7.2 ± 1.4 
mg/kg/min, respectively, within 15 min (Figs. 4 and 6).  However, in the first study, 
combined Intralipid and heparin infusion blunted glucagon’s initial increase in NHGO 
(40%) and NHGLY (40%, P < 0.05, Figs. 3.3 and 3.4).  A trend for the inhibition of 
NHGO (20 %) and NHGLY (30%) was also observed in the second study but the small 
number of animals used prevented statistical significance from being achieved 
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(n=3/group, Fig. 6).  In the presence of an isolated rise in glycerol equivalent to that seen 
with Intralipid (0.02 ml/kg/min) and heparin (0.5 U/kg/min), the rise in portal glucagon 
stimulated a similar increase in NHGLY (5.6 ± 1.4 mg/kg/min) by 15 min to that seen 
with glucagon administration alone in study one (Table 3.2 and Fig. 3.4).  Thus, the 
inhibition of glycogenolysis and consequently HGO seen in response to Intralipid and 
heparin must have been solely due to elevated plasma FFA.  As expected, hyperglycemia 
suppressed NHGLY and NHGO to approximately zero in the HG and FFA + HG groups 
(Fig. 3.3 and 3.4).  Therefore, these findings indicate that elevated FFA inhibit the 
glycogenolytic effects of glucagon as they do those of epinephrine.  However, this effect 
was short-lived (1 h) compared to that of increased FFA on epinephrine-induced net 
hepatic glycogenolysis, which lasted for a 2 h period (53). 
Consistent with our earlier findings (48, 116, 117) glucagon administration 
resulted in an immediate but brief decrease in NHGNG flux in the GGN and GLYC + 
GGN groups (Table 3.2 and Fig. 3.4 and 3.6).  The initial decrease corresponds to and 
presumably results from the hormone’s rapid effect on NHGLY, in which some of the 
glucose produced by the breakdown of glycogen enters the glycolytic pathway and exits 
the liver as lactate (48, 49).  In fact, the increase in net hepatic lactate output mirrored the 
initial increase in NHGLY in the GGN and GLYC + GGN groups (Table 3.2 and Fig. 
3.4, 3.5, and 3.6).   Over the first 75 min of the experimental period, Intralipid and 
heparin infusion showed a tendency to blunt the increase in net hepatic lactate output 
caused by glucagon (Fig. 3.5).  Lack of statistical significance of this blunting effect was 
due to one outlier.  If this particular dog was omitted, the initial change in net hepatic 
lactate output  
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(μmol/kg/min) would be 3.8 ± 1.5 in the FFA + GGN group as opposed to 10.4 ± 1.1 in 
the GGN group (min 30).  In the second study, the fall in NHGNG flux and rise in net 
hepatic lactate output was completely inhibited in the FFA + GGN group (P< 0.05, 
n=3/group, Figs. 3.6).   Thus, the glucose and lactate data from both the first and second 
studies collectively indicate that elevated FFA blunt glucagon-stimulated NHGO by 
inhibiting NHGLY. 
Because overall NHGNG flux did not change in the GGN group (Fig. 3.4), the 
present data are consistent with our previous findings that glucagon has little to no acute 
effect on hepatic gluconeogenesis.  On the other hand, NHGNG flux increased from -0.08 
± 0.4 to 0.67 ± 0.3 mg/kg/min by the end of the study in the FFA + GGN group (Fig. 
3.4).  Although an increase in NHGNG was observed in this group, it cannot be 
interpreted as an augmentation of glucagon action since an identical increase in NHGNG 
flux was observed in the FFA + HG group (Fig. 3.4).  In both Intralipid/heparin 
protocols, the almost three-fold rise in blood glycerol levels (Fig. 3.2), giving rise to 
increases in net hepatic glycerol uptake, contributed to the increase in hepatic 
gluconeogenesis.   However, the rate of NHGNG flux in the GLYC + GGN group was 
identical to that seen with glucagon treatment alone.  Arterial NHGNG flux did not 
significantly change in the presence of hyperglycemia alone.  It seems most likely, 
therefore, that the rise in hepatic gluconeogenesis was largely due to the increase in 
hepatic FFA uptake.  In contrast to the interaction of FFA and epinephrine (53), elevated 
plasma FFA did not augment glucagon’s ability to stimulate hepatic gluconeogenesis. 
Elevated FFA blunt the early response of hepatic glycogenolysis to both glucagon 
and epinephrine.  A rise in plasma FFA has been shown to result in an increase in fatty 
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acid metabolites (fatty acyl CoA, diacylglycerol, ceramides) in liver and muscle (42), 
which have been suggested to activate protein kinase C (PKC, (115, 156, 241).  
Bouscarel et al have shown that activated PKC inhibits glucagon-induced cAMP 
formation in hepatocytes (30).  Activated PKC can also phosphorylate and inactivate Gs 
(126),  resulting in a subsequent desensitization of the glucagon or β2-adrenergic receptor 
(206).  Therefore it could be hypothesized that an increase in fatty acid metabolites 
directly inhibit the glucagon and epinephrine signaling pathways via the activation of 
PKC, which would inactivate Gs, and in turn inhibit adenlyate cyclase, resulting in a 
decrease in cAMP.  Our finding that hepatic cAMP content at the peak of glucagon-
stimulated glycogenolysis was not blunted by high levels of FFA (data not shown) does 
not support this hypothesis.  
FFA have been shown to directly inhibit glucose-6-phophatase (180, 181), which 
subsequently increases glucose-6-phosphate (G6P) which can stimulate glycogen 
synthase and inhibit hepatic glycogenolysis.  Using liver samples from the first study, 
Hornbuckle et al have shown that FFA did not alter mRNA expression of the catalytic 
subunit or transporter of glucose-6-phosphatase (129).  However, these liver samples 
were collected at the end of the study, when FFA had no effect on HGO.  It remains 
possible that FFA could directly inhibit glucose-6-phosphatase activity, thereby blunting 
the initial response to glucagon.   
A more likely hypothesis is that elevated FFA blunted the early rise in hepatic 
glycogenolysis by inhibiting glycolysis.  It has been proposed (132, 186, 221) that 
increased FFA levels could raise intracellular citrate levels leading to an inhibition of 
phosphofructokinase, thus at the same time limiting glycolysis, and consequently 
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increasing G6P, which would in turn blunt NHGLY. Our current studies, particularly the 
second, of the two sets of experiments show that a rise in FFA blunted glucagon’s 
immediate, brief increase in net hepatic lactate output, suggesting inhibition of net 
hepatic glycolysis.  In response to hyperglycemia or glucagon- and epinephrine-
stimulated glycogenolysis, an increase in net hepatic lactate output occurs (49, 53, 84, 
116, 117, 193, 265), most likely because some of the glucose taken up by the liver and 
produced by glycogen breakdown, respectively, enters the glycolytic pathway and exits 
the liver as lactate.  Intralipid and heparin infusions result in net hepatic lactate uptake 
consistent with inhibition of glycolysis or stimulation of gluconeogenesis (54).  In 
agreement with this, hyperinsulinemia which reduces plasma FFA results in an increase 
in net hepatic lactate output (84, 255) that is not evident when the FFA level is clamped 
(255).  Additionally, in the present (Fig. 3.5) and previous studies (53, 54), an elevation 
of plasma FFA decreased the ability of hyperglycemia to cause net hepatic lactate output.  
Although it has been suggested that elevated FFA results in an increase in hepatic 
gluconeogenesis which then inhibits hepatic glycogenolysis (44, 54, 59, 60, 158, 217), 
these and other studies have shown that by the time the rise in glycogenolysis was fully 
manifest (30 min) a small decrease had occurred in hepatic gluconeogenic flux (53, 116, 
117).   
Although FFA have a similar effect on the initial action of both glucagon and 
epinephrine on HGO, FFA temporally affect each hormone differently.  With time, an 
elevation in plasma FFA did not alter the overall rate of epinephrine-mediated HGO but 
enhanced the hormone’s ability to stimulate gluconeogenesis and inhibited its action on 
glycogenolysis (53).   In contrast, by the end of the present study the rise in FFA did not 
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alter glucagon-stimulated glucose production by the liver or the mechanisms by which it 
was produced.  Thus, the autoregulation, which took place in presence of epinephrine, did 
not occur in the presence of glucagon.   One possible explanation for this lies in that the 
potency of glucagon to stimulate glycogenolysis and thus force carbon down the 
glycolytic pathway is greater than that of epinephrine.  This would override FFA’s ability 
to inhibit glycolysis or fuel gluconeogenesis.  When epinephrine is administered 
peripherally, and therefore has both direct and indirect (i.e. stimulation of lipolysis) 
effects on the liver, hepatic lactate uptake occurs (57, 116, 117, 265), whereas net hepatic 
lactate output takes place following portal administration of epinephrine (53, 56, 57). 
In conclusion, these findings indicate that elevated FFA inhibit the glycogenolytic 
effects of glucagon, as they do the glycogenolytic effect of epinephrine.  However, this 
effect is short-lived compared to epinephrine.  In contrast to epinephrine, an increase in 
FFA does not augment glucagon-stimulated hepatic gluconeogenesis.  Although 
postprandial levels of glucagon and FFA are elevated in individuals with type 2 diabetes, 
our results suggests that their interaction alone does not potentiate HGO nor does FFA 
alter the mechanisms by which glucagon stimulates HGO.   
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Figure 3.1:  Arterial and portal vein levels of plasma glucagon.  Change in arterial 
plasma (A) and portal vein (B) glucagon levels during basal (-40 to 0 min) and 
experimental (0 to 195 min) periods in the presence of a pancreatic clamp.  A break was 
set in the x axis between 0 and 16 min.  Protocols were performed in conscious 18 h 
fasted dogs.  Values are means ± SE.  * P < 0.05 vs. respective basal levels for both 
groups receiving three times basal glucagon (GGN and FFA + GGN).   
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Figure 3.2:  Arterial plasma FFA and blood glycerol levels and net hepatic uptake.  
Arterial plasma FFA levels (A), net hepatic FFA uptake (B), arterial blood glycerol levels 
(C), and net hepatic glycerol uptake (D) during basal (-40 to 0 min) and experimental (0 
to 195 min) periods in the presence of a pancreatic clamp.  Protocols were performed in 
conscious 18 h fasted dogs.  Values are means ± SE.  * P < 0.05 vs. respective basal 
levels for both groups receiving 20% Intralipid plus heparin infusions (FFA+GGN and 
FFA+HG).   
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Figure 3.3:  Arterial plasma levels of glucose and net hepatic glucose balance.  
Arterial plasma levels of glucose (A) and net hepatic glucose balance (B) during basal (-
40 to 0 min) and experimental (0 to 195 min) periods in the presence of a pancreatic 
clamp.  A break was set in the x axis between 0 and 16 min.  Protocols were performed in 
conscious 18 h fasted dogs.  Negative and positive values of net hepatic balance represent 
net hepatic uptake and output, respectively.  Values are means ± SE.  * P < 0.05 vs. 
respective basal values for all groups.  There were no significant differences between the 
groups for arterial plasma glucose.  & P < 0.05 FFA+GGN vs. GGN. 
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Figure 3.4:  Net hepatic glycogenolysis (GLY) and gluconeogenic (GNG) precursor 
flux.  Net hepatic glycogenolytic (A) and gluconeogenic flux (B) during basal (-40 to 0 
min) and experimental (0 to 195 min) periods in the presence of a pancreatic clamp.  A 
break was set in the x axis between 0 and 16 min.  Protocols were performed in conscious 
18 h fasted dogs.  Negative and positive values of net hepatic GNG flux represent net 
glycolysis and net gluconeogenesis, respectively.  Values are means ± SE.  * P < 0.05 vs. 
respective basal values for all groups.  & P < 0.05 FFA+GGN vs. GGN. 
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Figure 3.5:  Arterial blood levels and net hepatic output of lactate.  Arterial blood 
levels (A) and change in net hepatic balance (B) of lactate during basal (-40 to 0 min) and 
experimental (0 to 195 min) periods in the presence of a pancreatic clamp.  A break was 
set in the x axis between 0 and 16 min.  Protocols were performed in conscious 18 h 
fasted dogs.  Values are means ± SE.  * P < 0.05 vs. respective basal levels. 
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Figure 3.6:  Net hepatic glucose balance, glycogenolysis (GLY) and gluconeogenic 
(GNG) flux, and lactate balance in the second study.  Net hepatic glucose balance (A), 
glycogenolysis (B), gluconeogenic flux (C), and lactate balance (D) during basal (-40 to 0 
min) and experimental (0 to 45 min) periods in the presence of a pancreatic clamp.  
Protocols were performed in conscious 18 h fasted dogs.  Values are means ± SE.  * P < 
0.05 vs. respective basal levels.  & P < 0.05 FFA+GGN vs. GGN. 
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TABLE 3.1
Arterial plasma concentrations of insulin during basal (-40 to 0 min) and experimental (0 to 195 min) periods in the presence of
a pancreatic clamp in conscious 18 h fasted dogs.
Basal period Experimental period (min)
 -40 - 0 30 45 75 105 135 165 195
Arterial Plasma 
Insulin (μU/ml)
GGN 6 ± 1 6 ± 1 6 ± 1 6 ± 1 6 ± 2 6 ± 2 6 ± 2 6 ± 2
FFA + GGN 5 ± 1 6 ± 1 6 ± 1 6 ± 1 6 ± 1 6 ± 1 6 ± 1 7 ± 1
HG 5 ± 1 5 ± 1 5 ± 1 5 ± 1 5 ± 1 6 ± 2 5 ± 1 6 ± 1
FFA + HG 4 ± 1 4 ± 1 4 ± 1 4 ± 1 5 ± 1 5 ± 1 5 ± 1 5 ± 1
Values are means ± SE.  Basal period values are an average of samples taken at -40 and 0 min. There were no significant differences among groups.    
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TABLE 3.2
Plasma hormone levels, arterial concentrations and net hepatic uptakes of plasma FFA and blood glycerol, arterial blood concentrations 
 and net hepatic output of lactate, glucose metabolism, and net hepatic glycogenolysis and gluconeogenic flux for the GLYC+GGN group 
during basal (-40 to 0 min) and experimental (0 to 195 min) periods in the presence of a pancreatic clamp in conscious 18 h fasted dogs.
Basal period Experimental period (min)
 -40 - 0 30 45 75 105 135 165 195
Plasma Hormone Concentrations
Insulin (μU/ml)
Arterial 4 ± 1 3 ± 1 3 ± 1 3 ± 1 3 ± 1 3 ± 1 3 ± 1 3 ± 1
Δ Glucagon (pg/ml)
Arterial 0 ± 1 37 ± 12* 43 ± 14* 39 ± 11* 41 ± 10* 41 ± 12* 37 ± 11* 41 ± 12*
Portal 0 ± 1 90 ± 18* 85 ± 26* 90 ± 21* 89 ± 23* 77 ± 24* 85 ± 20* 87 ± 30*
Arterial Concentrations and Net Hepatic Uptakes of Plasma FFA and Blood Glycerol
Arterial Plasma 615 ± 82 471 ± 43 364 ± 45 349 ± 51 334 ± 60 347 ± 61 397 ± 64 427 ± 63
FFA (μmol/l)
Net Hepatic FFA  -2.5 ± 0.4 -1.9 ± 0.3 -1.5 ± 0.3 -1.7 ± 0.3 -1.4 ± 0.5 -1.3 ± 0.4  -1.7 ± 0.6  -1.5 ± 0.6
Balance (μmol/kg/min)
Arterial Blood 74 ± 9 198 ± 27* 181 ± 19* 191 ± 18* 188 ± 24* 198 ± 25* 206 ± 25* 203 ± 15*
Glycerol (μmol/l)
Net Hepatic Glycerol  -2.2 ± 0.4 -4.1 ± 0.4* -3.7 ± 0.4* -3.8 ± 0.4* -3.8 ± 0.5* -4.0 ± 0.6*  -4.3 ± 0.5*  -4.3 ± 0.6*
Balance (μmol/kg/min)
Arterial Blood Concentrations and Net Hepatic Output of Lactate
Arterial Blood 1027 ± 243 1342 ± 256 1470 ± 234 1429 ± 238 1370 ± 278 1440 ± 277 1396 ± 280 1369 ± 299
Lactate (μmol/l)
Δ Net Hepatic Lactate 0.0 ± 0.3 12.0 ± 2.5 10.2 ± 2.6 6.0 ± 3.4 5.5 ± 2.6 4.4 ± 3.2 2.0 ± 2.9 1.6 ± 2.8
Output (μmol/kg/min)
Glucose Metabolism
Arterial Plasma 93 ± 1 110 ± 4* 142 ± 8* 168 ± 10* 176 ± 10* 183 ± 11* 187 ± 11* 193 ± 13*
Glucose (mg/dl)
Net Hepatic Glucose 1.4 ± 0.2 6.3 ± 1.0 4.8 ± 0.8 2.5 ± 0.4 2.1 ± 0.5 2.3 ± 0.3 2.2 ± 0.6 1.5 ± 0.5
Output (mg/kg/min)
Ra (mg/kg/min) 3.1 ± 0.4  6.9 ± 0.6*  7.2 ± 0.7*  6.0 ± 0.5* 4.6 ± 0.5 3.9 ± 0.4 4.2 ± 0.6 4.4 ± 0.8
Net Hepatic Glycogenolysis and Gluconeogenesis
Net Hepatic GLY 1.9 ± 0.4 7.5 ± 1.4*! 5.9 ± 0.8* 3.3 ± 0.4 2.6 ± 0.4 2.8 ± 0.2 2.4 ± 0.5 1.7 ± 0.4
(mg/kg/min)
Δ Net Hepatic GNG  0.0 ± 0.1  -0.81 ± 0.4*  -0.66 ± 0.2  -0.25 ± 0.4  -0.12 ± 0.3  -0.03 ± 0.3  0.24 ± 0.2  0.25 ± 0.2
Flux (mg/kg/min)
Values are means ± SE.  Basal period values are an average of samples taken at -40 and 0 min.  * P < 0.05 vs. respective basal concentrations.  $ P  < 0.05    
FFA+HG.  ! P < 0.05 FFA+GGN.  FFA+GGN, n=6.  GGN, n=6.  FFA+HG, n=5.  HG, n=5.  Negative values indicate net uptake. Ra, tracer determined  
endogenous glucose production.  GLY, glycogenolysi.  GNG, gluconeogenesis.  
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TABLE 3.3
Tracer determined endogenous glucose production (R a ) during  basal (-40 to 0 min) and experimental (0 to 195 min) periods 
in the presence of a pancreatic clamp in conscious 18 h fasted dogs.  
Basal period Experimental period (min)
 -40 - 0 30 45 75 105 135 165 195
Ra (mg/kg/min) 
GGN 2.8 ± 0.1  6.5 ± 0.7* 6.5 ± 0.7* 5.1 ± 0.5* 4.0 ± 0.3 3.8 ± 0.3 3.8 ± 0.4 3.9 ± 0.5
FFA + GGN 2.5 ± 0.2   5.5 ± 1.0*  5.6 ± 0.9* 4.8 ± 0.4* 3.9 ± 0.2 3.6 ± 0.3 3.4 ± 0.3 3.3 ± 0.3
HG 2.4 ± 0.2 2.0 ± 0.3 1.7 ± 0.2 2.0± 0.1 1.4 ± 0.4 2.1 ± 0.3 1.2 ± 0.3 1.3 ± 0.3
FFA + HG 2.4 ± 0.2 3.2 ± 0.4 2.5 ± 0.2 1.8 ± 0.4 1.5 ± 0.2 1.6 ± 0.3 1.3 ± 0.2 1.1 ± 0.3
Values are means ± SE.  Basal period values are an average of samples taken at -40 and 0 min.  * P < 0.05 vs. respective basal rates.  & P  < 0.05 
FFA+GGN vs. GLYC+GGN and GGN.  FFA+GGN, n=7.  GGN, n=6.  FFA+HG, n=5.  HG, n=5.  
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CHAPTER IV 
 
INDUCTION OF HEPATIC STEATOSIS IN A CANINE MODEL 
 
Aim 
Specific Aim II was to induce fatty liver (hepatic steatosis) in the dog. The net 
content of triglyceride in the liver depends on the relative activities of enzymes involved 
in lipid metabolism that influence fatty acid uptake and synthesis versus those that 
influence fatty acid oxidation and export.  When input (uptake or de novo lipogenesis) of 
fatty acids to hepatocytes exceeds their output (degradation or export), triglycerides 
accumulate within the liver.  Therefore, in an attempt to induce fatty liver in the dog, 
lipid metabolism was altered by 3 different treatments: 1) a 10% fructose diet, 2) 
elevating hepatic FFA flux, or 3) elevating hepatic FFA flux while simultaneously 
inhibiting triglyceride export from the liver using the microsomal triglyceride transfer 
protein inhibitor, CP-346086.   
 
Experimental Treatment Regimens 
Treatment 1:  10% fructose diet.  A 10% fructose diet was used to stimulate an 
increase in hepatic de novo lipogenesis.  Male mongrel dogs were fed once daily either a 
standard (SD, as described in Chapter II, n=2), a 10% fructose (FD, n=2) or carbohydrate 
(CD, 10% increase, n=2) diet for 4 months.  In the FD and CD groups, either 95g of 
fructose or maltodextrin was added to the standard meat/chow diet, respectively.  The 
daily caloric intake increased from ~1800 kcal/ to ~2200 kcal/d in both the HF and HC 
117 
groups.  Magnetic resonance imaging (MRI) and magnetic resonance spectroscopy 
(MRS) were performed at 0, 6, 12, and 16 weeks.  Approximately 24-h after the final 
feeding, a midline laparotomy incision was made following a two-step hyperinsulinemic-
euglycemic clamp (described in Chapter V).  Clamps cooled in liquid nitrogen were used 
to freeze sections of left and right central and left lateral lobes of the liver and skeletal 
muscle of the right sartorius in situ.  The tissue was placed in liquid nitrogen and stored at 
–70°C.  Approximately 2 min elapsed between the time of anesthesia and the time of 
tissue excision. All animals were then euthanized.  Tissue lipids were separated by TLC 
and then quantitated by gas chromatography as described in Chapter II. 
Treatment 2:  Increased hepatic FFA flux.  An intraportal infusion of 20% Intralipid 
(0.02 ml/kg/min) plus heparin (0.5 U/kg/min) or saline (0.02 ml/kg/min) was 
administered at ~2 PM immediately after feeding for 3-h/d for 15-d (n=7/group).  
Approximately 24-h after the final treatment, the same tissue sampling technique 
described above was carried out following a two-step hyperinsulinemic-euglycemic 
clamp.  Tissue lipids were separated by TLC and then quantitated by gas 
chromatography.  For histological examination, liver samples were frozen in embedding 
medium (Tissue-Tek, O.C.T. Compound) and stored at -70°C.   
In order to determine the metabolic and hormonal changes that occurred during 
the daily intraportal infusions, a subset of dogs received only one 3-h treatment.  
Following a basal period (-40 to 0 min), the dogs were fed a meal, and an intraportal 
infusion of Intralipid/heparin (n=4) or saline (n=4) was administered from 0 to 180 min.   
Arterial, portal vein, and hepatic vein samples were taken at -40, 0, 15, and 30 min and 
every 30 min thereafter.  Immediately following the study, the same tissue sampling 
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technique described above was carried out.  Tissue lipids were separated by TLC and 
then quantitated by gas chromatography. 
Treatment 3:  Increased hepatic FFA flux + inhibited VLDL secretion.  A 12 mg/kg 
dose of microsomal triglyceride transfer protein inhibitor, CP-346086, was administered 
orally (gelatin capsules No.00; Eli Lilly, Indianapolis, IN) 2-h prior to feeding (12 AM) 
for 17 days.  Starting on day 3, an intraportal infusion of 20% Intralipid (0.02 ml/kg/min) 
plus heparin (0.5 U/kg/min) was administered at ~2 PM immediately after feeding for 3-
h/d for 15-d (n=5).  Approximately 24-h after the final treatment, the same tissue 
sampling technique described above was carried out following a two-step 
hyperinsulinemic-euglycemic clamp.  Tissue lipids were separated by TLC and then 
quantitated by gas chromatography.  For histological examination, liver samples were 
frozen in embedding medium (Tissue-Tek, O.C.T. Compound) and stored at -70°C.   
The daily intraportal infusions were administered via the vascular access port 
using a Huber point needle (22 gauge, right angle, 1/2” tip-to-end; 6” tubing; Access 
Technologies, Inc., Skokie, IL) and aseptic accessing techniques as recommended by the 
manufacturer.  Each animal rested quietly in a Pavlov harness during the 3-h daily 
treatment.   
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Results 
Treatment 1:  10% fructose diet.  A 10% fructose diet did not result in an increase in 
triglyceride content after four months as determined by gas chromatography (Fig. 4.1).  
Despite numerous contacts to the Vanderbilt University Institute of Imaging Science we 
were unable to obtain the MRI and MRS data for analysis.    
Treatment 2:  Increased hepatic FFA flux.   
Metabolic and hormonal changes following one 3-h treatment. 
Hepatic blood flow.  Hepatic blood flow increased significantly (P < 0.05), in response to 
the meal primarily because of increase portal vein blood flow (P < 0.05 Lipid vs. control 
period, Table 4.1).  The increase in hepatic artery flow over control period rates reached 
statistical significance in the Saline but not Lipid groups, despite the fact the absolute 
increase was the same (Table 4.1).   
Arterial levels and net hepatic uptakes of plasma FFA and blood glycerol.  Intraportal 
infusions of Intralipid and heparin increased the arterial and portal plasma FFA levels 
from 536 ± 275 to 1842 ± 231 and 560 ± 280 to 2022 ± 202 μmol/l, respectively, by 90 
min and they remained elevated at these levels until the end of the study (P < 0.05 vs. 
control period, Fig. 4.2).  In the Saline group, after the meal, arterial and portal plasma 
FFA levels rapidly fell from ~630 to ~180 μmol/l by 30 minutes and remained unchanged 
thereafter (P < 0.05 vs. control period, Fig. 4.2).  Therefore, the hepatic FFA load 
(μmol/kg/min) increased by 46 ± 4 in the Lipid group and decreased by 5 ± 2 in the 
Saline group (last h, Fig. 4.2, P < 0.05 between groups).  Rates of net hepatic FFA uptake 
paralleled levels of plasma FFA throughout the study in both groups (Fig. 4.2).   Hepatic 
FFA fractional extraction did not differ between groups (Fig. 4.2).   
120 
Intraportal infusions of Intralipid and heparin rapidly (15 min) increased portal 
blood glycerol levels from 66 ± 22 to 184 ± 33 μmol/l, whereas arterial levels gradually 
rose from 56 ± 17 to 98 ± 8 μmol/l respectively by 90 min and remained elevated at that 
level until the end of the study (P < 0.05, Fig. 4.3).  In the Saline group, arterial and 
portal blood glycerol levels after the meal rapidly fell (15 min), reaching a nadir at one-
half their control period values and not changing significantly change thereafter (P < 
0.05, Fig. 4.3).  Therefore, the hepatic glycerol load (μmol/kg/min) increased by 6.7 ± 0.8 
in the Lipid group and decreased by 0.5 ± 0.4 in the Saline group (last h, Fig. 4.3).  Rates 
of net hepatic glycerol uptake paralleled levels of portal blood glycerol throughout the 
study in both groups (Fig. 4.3).   Hepatic glycerol fractional extraction was not 
significantly different between groups (Fig. 4.3).  
Of note, levels of plasma FFA and blood glycerol returned to basal values within 
an hour of terminating the lipid infusion (data not shown, n=1). 
Glucose metabolism. Arterial and portal plasma glucose levels increased rapidly after 
feeding, peaking at min 15 and remaining significantly elevated for the duration of the 
study (P < 0.05, Fig. 4.4).  The mean hepatic glucose load doubled as a consequence of 
the increases in the blood glucose level and blood flow (P < 0.05, Fig. 4.4).  In both the 
Lipid and Saline groups net hepatic glucose output was ~2.6 mg/kg/min during the 
control period; however, an hour after the meal, the liver had converted to net glucose 
uptake (~-1.7 mg/kg/min, Fig. 4.4).  Net hepatic uptake continued at approximately the 
same rate for the remainder of the study in the Saline group, whereas it tended to 
decrease in the Lipid group.  Hepatic glucose fractional extraction mirrored net hepatic 
glucose balance throughout the study in both groups (Fig. 4.4).    
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Hormone levels.  Arterial and portal plasma levels of insulin and glucagon rapidly (15 
min) increased following the meal and remained elevated throughout the postprandial 
period (Table 4.2).  Of note, the initial rise in arterial plasma insulin levels (μU/ml) 
tended to be 2-fold higher in the Lipid group (Δ 26 ± 9) compared to the Saline control 
(Δ 11 ± 5).  Due to the low statistical power and the apparent variability following the 
meal, few significant differences were observed. Arterial plasma cortisol levels remained 
basal in both groups throughout the study (data not shown). 
Tissue lipids.  Following a single 3-h infusion, hepatic triglycerides were 66% higher in 
the Lipid group than the Saline Control whereas muscle triglycerides were similar in both 
groups (Fig. 4.5). 
Tissue lipids following repeated brief elevations of FFA.  One day following the final 
infusion of the 15-d treatment regimen, liver triglyceride content (μg/mg tissue) was 
similar in the Saline (0.9 ± 0.1) and Lipid (1.3 ± 0.5) groups (Fig. 4.6).  Triglyceride 
content in skeletal muscle was similar in both groups (Fig. 4.6).  Additionally, there were 
no significant differences in liver or skeletal muscle diacylglyceride or phospholipid 
levels among groups(data not shown).   
Treatment 3:  Increased hepatic FFA flux + inhibited VLDL secretion.  Repeated 
elevations of FFA in the presence of the MTP inhibitor, CP-346086 for 3-h/d for 15-d 
resulted in nearly a 2-fold increase in liver triglycerides (1.9 ± 0.6 μg/mg tissue, P < 0.05 
vs. Saline, Fig.4.6).   Liver sections stained with oil red O confirmed that chronic 
treatment with Intralipid/heparin in the presence of CP-346086 resulted in hepatic lipid 
accumulation (Fig. 4.6).  Triglyceride content (μg/mg tissue) in skeletal muscle tended to 
be lower in the Lipid + CP-346086 group (8 ± 3) compared to Saline (15 ± 5) and Lipid 
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(11 ± 2).  Additionally, there were no significant differences in liver and skeletal muscle 
diacylglyceride or phospholipid levels (data not shown). 
 
Discussion 
Although there is a strong correlation with lipotoxicity (152, 195, 202) and type 2 
diabetes it is unclear as to whether the accumulation of intracellular lipid in liver and 
muscle is a cause or an effect of a decreased insulin response.  The putative role of 
triglyceride accumulation in non-adipose tissues is based solely upon correlative results.  
Therefore, one remains unconvinced regarding the importance of triglyceride 
accumulation as a direct cause of insulin resistance and a contributor to the pathogenesis 
of diabetes. Thus the aim of the present study was to create a canine model of hepatic 
steatosis.    
When input (uptake or synthesis) of fatty acids to hepatocytes exceeds their 
output (degradation or export), triglycerides accumulate within the liver.  The 
conventional explanation for lipotoxicity is that an impairment of fat deposition in 
adipose tissue due to either over storage of lipid or decreased storage ability results in 
increased release of FFA from adipocytes.  FFA must then be partitioned for storage in 
other tissues such as the liver, skeletal muscle, and pancreas.  However, in the liver, 
increases in dietary substrates for lipogenesis (FFA and carbohydrates) and decreases in 
VLDL export are also thought to contribute to the increased hepatocelluar lipid content.   
Dietary substrates are particularly relevant given the increased consumption of 
energy-dense diets (214).  The dietary substrate, fructose, is of particular interest as it has 
been suggested that its consumption (essentially in soft drinks) may be a causal factor for 
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the development of insulin resistance (32).  Fructose can directly contribute to hepatic 
lipid content via stimulation of de novo lipogenesis by two mechanisms: it increases 
hepatic glucose uptake (an effect likely to be mediated by increased translocation of 
glucokinase) (198, 250) and bypass the regulated conversion of F6P to F1,6P2 (119) .  It 
is thus a relatively unregulated source of substrate for triglyceride synthesis.  In fact, it 
has been shown that rats placed on a 10% fructose diet for one month had significant 
increases in hepatic fatty acid synthase, de novo fatty acid synthesis, fatty acid re-
esterification, and liver triglycerides (151).  Thus, our first attempt to induce hepatic 
steatosis was the use of a 10% fructose diet.  The 10% fructose diet did not increase liver 
triglycerides even after four months of treatment.  The protocol was terminated due to the 
insignificant effect on hepatic lipid metabolism.   
Parks and colleagues have elegantly demonstrated, using a multiple-stable-isotope 
approach, that plasma FFA account for 60% of the hepatic triglyceride accumulation in 
obese patients with hepatic steatosis (79).  Furthermore, it has been shown that insulin 
does not suppress lipolysis in patients with NAFLD to the same extent it does in healthy 
individuals (238).  Taken together, these findings suggest that elevated FFA flux to the 
liver results in an accumulation of hepatic triglycerides.  Therefore, in our second attempt 
to induce the fatty liver in the dog, hepatic FFA flux was repeatedly elevated for 3-h/d for 
15-d.  The lipid infusion was administered at the time of feeding to maximally increase 
rates of lipogenesis.   The rise in insulin which occurs in response to a meal should result 
in the stimulation of lipogenic enzymes and thus further promote the accumulation of 
triglyceride within the liver.   
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In order to determine the acute metabolic and hormonal changes that occurred 
during the daily intraportal infusions, a subset of dogs received only one 3-h treatment 
(Lipid, n=4; Saline, n=4).  Intraportal infusion of Intralipid and heparin resulted in a 4-
fold increase in plasma FFA levels in both the portal and arterial circulations.  In contrast, 
intraportal infusion of Intralipid and heparin resulted in a 3-fold rise in the blood glycerol 
level in the portal circulation and a 2-fold rise in the arterial circulation. Plasma insulin 
levels increased, as expected, in response to the meal in both groups (69).  The 
increments in hepatic glucose load were identical in the Saline and Lipid groups 
following the meal.  Within sixty minutes of meal consumption, a switch from net 
glucose output to uptake was observed.  Thus as plasma insulin, FFA, and glucose were 
elevated during the 3-h lipid infusion, hepatic lipogenesis should have been increased. 
Boden et al. (27) have shown that an acute elevation of FFA levels in humans 
increased intramyocellular triglyceride in a time- and dose-dependent manner.  In the 
present study, we demonstrated for the first time that an acute rise in FFA during the 
postprandial period results in a nearly 2-fold increase in hepatic triglycerides. 
Interestingly, no differences were observed in skeletal muscle triglycerides, despite the 
significant rise in arterial plasma FFA and insulin.   
Following the 15-d treatment regimen (elevated FFA for 3-h/d) neither hepatic 
nor muscle triglyceride levels were significantly higher in the Lipid group compared to 
the Saline group.  Since liver triglycerides were elevated following a single treatment but 
not after 15-d of lipid infusion, it seems that the liver compensated for the daily 
elevations of hepatic FFA flux and/or triglyceride synthesis by removing any excess 
hepatic lipids via increased β-oxidation or VLDL production.  In fact, when we inhibited 
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VLDL secretion by the liver using the MTP inhibitor, CP-346086, liver triglycerides 
were increased 2-fold following the 15-d lipid treatment.   
MTP is thought to play a pivotal, if not an obligatory, role in the assembly and 
secretion of triglyceride-rich apoB containing lipoproteins (VLDL and chylomicrons) 
from the liver and intestine.  In fact, the genetic manipulation of liver-specific MTP 
demonstrates its key functions in regulating liver triglyceride concentrations (279).  
Liver-specific MTP knockout mice exhibit hepatic steatosis and decreased hepatic 
triglyceride secretion, while mice over-expressing hepatic MTP show an increase in in 
vivo hepatic triglyceride secretion (218).  The human recessive disease 
abetalipoproteinemia, which is characterized by near complete absence of apoB-
containing lipoproteins, is caused by a variety of mutations in the gene for a subunit of 
MTP (191, 226, 244, 290).  Interestingly, polymorphisms of MTP are found with 
increased frequency in patients with NAFLD (190).  Therefore, our findings support the 
hypothesis that MTP plays a significant role in the regulation of hepatic triglycerides and 
that its inhibition may contribute to the accumulation of lipids in patients with hepatic 
steatosis.  (Of note, due to the discontinuation of CP-346086 manufacture, we were 
unable to determine the metabolic and hormonal changes that occurred during the daily 
intraportal lipid infusions in the presence of the inhibitor.) 
The goal of Specific Aim II was to induce fatty liver (hepatic steatosis) in the dog.  
In attempt to do so, lipid metabolism was altered by 3 different treatments: 1) a 10% 
fructose diet, 2) elevating hepatic FFA flux, or 3) elevating hepatic FFA flux while 
simultaneously inhibiting triglyceride export from the liver using the microsomal 
triglyceride transfer protein inhibitor, CP-346086.  A 10% fructose diet given over a four 
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month period and repeated elevations of FFA (3-h/d for 15-d) were not successful in 
elevating hepatic triglycerides.  However, as triglyceride levels were elevated 2-fold 
following the combined lipid and CP-346086 treatment. We were thus successful in 
creating a canine model of hepatic steatosis.  This model would provide an excellent 
research tool to determine the effects of elevated liver triglycerides on the actions of 
glucoregulatory hormones.  As hepatic steatosis has a very strong association with 
hepatic insulin resistance, it has of particular interest to determine whether the 
accumulation of intracellular lipid is a cause or an effect of a decreased insulin response.   
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 Figure 4.1: Hepatic triglycerides.  Hepatic triglyceride content in male mongrel dogs 
that were fed once daily either a standard (SD), a 10% fructose (FD) or carbohydrate 
(CD, 10% increase) diet for 4 months. n=2/group 
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Figure 4.2: Arterial and portal plasma levels, hepatic load, net hepatic uptake, and 
hepatic fractional extraction of FFA.  Arterial and portal plasma levels (A) hepatic load 
(B), net hepatic balance (C), and hepatic fractional extraction of FFA during control 
period (-40 to 0 min) and postprandial period (0 to 180 min).  An intraportal infusion of 
either Intralipid/heparin or saline was infused from 0 to 180 min.  Fractional extraction 
was calculated as net hepatic balance per load in.  Values are means ± SE.  * P < 0.05 vs. 
respective control period 
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Figure 4.3: Arterial and portal blood levels, hepatic load, net hepatic uptake, and 
hepatic fractional extraction of glycerol.  Arterial and portal plasma levels (A) hepatic 
load (B), net hepatic balance (C), and hepatic fractional extraction of glycerol during 
control period (-40 to 0 min) and postprandial period (0 to 180 min).  An intraportal 
infusion of either Intralipid/heparin or saline was infused from 0 to 180 min.  Fractional 
extraction was calculated as net hepatic balance per load in.  Values are means ± SE.   
* P < 0.05 vs. respective control period 
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 Figure 4.4: Arterial and portal plasma levels, hepatic load, net hepatic balance, and 
hepatic fractional extraction of glucose.  Arterial and portal plasma levels (A) hepatic 
load (B), net hepatic balance (C), and hepatic fractional extraction of glucose during 
control period (-40 to 0 min) and postprandial period (0 to 180 min).  An intraportal 
infusion of either Intralipid/heparin or saline was infused from 0 to 180 min.  Positive and 
negative values of net hepatic glucose balance represent net output and net uptake, 
respectively.  Fractional extraction was calculated as net hepatic balance per load in.  
Values are means ± SE.  * P < 0.05 vs. respective control period 
131 
 
 
Figure 4.5: Tissue triglycerides after a single infusion.  Liver (A) and skeletal muscle 
(B) triglycerides.  Tissue was excised immediately following a 3-h intraportal infusion of 
either Intralipid/heparin or saline which was administered during the postprandial state.   
* P < 0.05 vs. Saline 
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 Figure 4.6:  Tissue lipids after repeated infusion.  Liver (A) and skeletal muscle (B) 
triglyceride levels and oil red O staining of representative liver sections (C) following 
treatment with saline, Intralipid/heparin (Lipid), or Intralipid/heparin in the presence of a 
microsomal triglyceride transfer protein inhibitor, CP-346086 for 3-h/d for 15-d.  Tissue 
was excised immediately following a 2-step hyperinsulinemic-euglycemic clamp.  Values 
are means ± SE.  * P < 0.05 vs. Saline. 
133 
TABLE 4.1
Hepatic blood flow during control period (-40 to 0 min) and postprandial period (0 to 180 min).  An intraportal infusion of either   
Intralipid/heparin or saline was infused from 0 to 180 min.
Control period Experimental period (min)
 -40 - 0 15 30 60 90 120 150 180
Hepatic Blood Flow
Arterial
Saline 5 ± 0 6 ± 0* 6 ± 1* 6 ± 1 6 ± 1 6 ± 1 7 ± 2 6 ± 2
Lipid 5 ± 1 6 ± 0 6 ± 0 8 ± 2 8 ± 2 7 ± 2 7 ± 3 8 ± 2
Portal
Saline 22 ± 1 28 ± 4 32 ± 7 34 ± 7 33 ± 5 33 ± 5 32 ± 5 35 ± 6
Lipid 29 ± 3 40 ± 3* 44 ± 3* 44 ± 2* 45 ± 4* 39 ± 3* 38 ± 2* 38 ± 5*
Values are means ± SE.  Basal period values are an average of samples taken at -40 and 0 min.  * P < 0.05 vs. respective control levels.  
 
TABLE 4.2
Plasma hormone levels during control period (-40 to 0 min) and postprandial period (0 to 180 min).  An intraportal infusion of   
either Intralipid/heparin or saline was infused from 0 to 180 min.
Control period Experimental period (min)
 -40 - 0 15 30 60 90 120 150 180
Plasma Hormone Concentrations
Insulin (μU/ml)
Arterial
Saline 8 ± 1 19 ± 5* 33 ± 17 19 ± 7 25 ± 10 43 ± 10 36 ± 15 22 ± 5*
Lipid 9 ± 1 36 ± 8* 25 ± 8 34 ± 17 35 ± 18* 33 ± 18* 36 ± 18 31 ± 19
Portal
Saline 27 ± 11 50 ± 16 112 ± 54 32 ± 9 94 ± 29 133 ± 35 129 ± 64 54 ± 15
Lipid 19 ± 6 75 ± 32 52 ± 24 53 ± 19 100 ± 55 82 ± 56 95 ± 53 74 ± 58
Glucagon (pg/ml)
Arterial
Saline 35 ± 7 83 ± 32* 80 ± 27 88 ± 45 80 ± 45 56 ± 21 55 ± 21 71 ± 41
Lipid 51 ± 11 95 ± 5* 86 ± 12* 74 ± 7 74 ± 12 69 ± 13 65 ± 7 66 ± 7
Portal
Saline 60 ± 19 143 ± 56 110 ± 50 124 ± 75 119 ± 68 104 ± 71 80 ± 38 103 ± 58
Lipid 70 ± 9 126 ± 18* 101 ± 13 99 ± 9* 100 ± 14 85 ± 9 93 ± 20 96 ± 17
Values are means ± SE.  Basal period values are an average of samples taken at -40 and 0 min.  * P < 0.05 vs. respective control levels.  
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CHAPTER V 
 
THE EFFECTS OF REPEATED ELEVATIONS OF FFA AND INCREASED 
LIVER TRIGLYCERIDES ON HEPATIC AND PERIPHERAL INSULIN 
SENSITIVITY 
 
Aim 
The goal of Specific Aim III was to examine whole body insulin sensitivity 
following treatment regimens to induce hepatic steatosis (see Chapter IV):  a 10% 
fructose diet (4-mo), repeated elevations of FFA for 3-h/d for 15-d, or repeated elevations 
of FFA (3-h/d for 15-d) in the presence of a MTP inhibitor, CP-346086.  The 10% 
fructose diet did not increase liver triglycerides even after four months of treatment; thus 
the protocol was terminated due to the insignificant effect on hepatic lipid metabolism.  
Although whole body insulin sensitivity was assessed after 4-mo of treatment, the 
statistical power (n=2/group) was too low to draw any conclusions.   
As demonstrated in Specific Aim II, repeated elevations of FFA for 3-h/d for 15 d 
(Treatment 1, Lipid) did not chronically alter hepatic triglyceride content; however, 
simultaneous elevation of hepatic FFA flux and inhibition of hepatic triglyceride export 
(Treatment 2, Lipid + CP-346086) resulted in a two-fold increase in liver triglycerides.  
Although it is well established that both acute and chronic increases of FFA cause insulin 
resistance, it remains unclear if recurring elevations of plasma FFA levels, such as might 
occur during the postprandial period in type 2 diabetes, can alter insulin sensitivity.  For 
that reason, even though repeated elevations of FFA did not result in a rise in hepatic 
triglycerides, it was of interest to evaluate insulin sensitivity following the treatment 
regimen. To assess whole body insulin sensitivity, a two-step hyperinsulinemic-
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euglycemic clamp was performed on the day immediately following completion of the 
15-d treatment period used to induce hepatic steatosis in the dog.  
 
Experimental Design 
Nineteen male mongrel dogs received treatment with saline (n=7), 20% Intralipid 
+ heparin for 3-h/d for 15-d (Lipid, n=7), or 20% Intralipid + heparin for 3-h/d for 15-d in 
the presence of an MTP inhibitor, CP-346086 (Lipid + CP-346086). Approximately 15-h 
following the final infusion (18 h after feeding), a two step hyperinsulinemic-euglycemic 
clamp was performed.  Each experiment consisted of a tracer and dye (ICG) equilibration 
period (-140 to -40 min), a basal period (-40 to 0 min), and an experimental period (0 to 
240 min).  At -140 min, a priming dose of [3-3H] glucose (33.3 μCi) was given and a 
constant infusion of [3-3H] glucose (0.35 μCi/min) was begun to allow the assessment of 
hepatic glucose production.  At the same time a constant infusion of ICG (0.07 mg/min) 
was started to assess hepatic blood flow.  A somatostatin infusion (0.8 μg·kg-1min-1) was 
started at 0 min to inhibit endogenous insulin and glucagon secretion.  A constant 
intraportal infusion of glucagon (0.55 ng/kg/min; Bedford Laboratories, Bedford, OH) 
was given (t = 0 min) to replace endogenous glucagon secretion.  Endogenous insulin 
secretion was replaced by two rates of insulin infusion, 600 μU/kg/min from 0 to 120 min 
and 2000 μU/kg/min from 120 to 240 min.  In a normal overnight fasted dog under 
euglycemic conditions, 600 μU/kg/min of insulin should reduce net hepatic glucose 
output to approximately zero mg/kg/min while 2000 μU/kg/min should shift the liver to a 
low rate of net hepatic glucose uptake (NHGU) ().  It should also cause a significant 
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increase in non-hepatic glucose uptake of ~12 mg/kg/min.  A fifty percent solution of 
dextrose was administered peripherally during the experimental period in order to 
maintain euglycemia.   Plasma glucose concentrations were measured every 5 minutes to 
assess the need for glucose infusion.  Arterial blood samples were taken every 10 min 
during the basal period and every 15 min during the experimental period for the 
assessment of glucose and [3-3H]- glucose.  For the measurement of acetoacetate, FFA, 
and glucagon, arterial, portal vein, and hepatic vein samples were taken at -40 and 0 min 
during the basal period and every hour during the experimental period.  For all other 
parameters, arterial, portal vein, and hepatic vein samples were taken at -40 and 0 min 
during the basal period and every 30 min for the last 90 min of each step of the 
experimental period.  The total blood volume withdrawn did not exceed 20% of the dog’s 
total blood volume and each volume of blood taken was replaced with two volumes of 
0.9% saline.  
Immediately following the last blood withdrawal, each animal was anesthetized 
with pentobarbital sodium.  The animal was then removed from the harness while the 
hormones and glucose continued to be infused.  A midline laparotomy incision was 
made, and clamps cooled in liquid nitrogen were used to freeze sections of all seven 
hepatic lobes in situ.  Each hepatic biopsy was placed in liquid nitrogen and stored at –
70°C.  For histological examination, liver samples were frozen in embedding medium 
(Tissue-Tek, O.C.T. Compound) and stored at -70°C.  Approximately 2 min elapsed 
between the time of anesthesia and the time of tissue excision. All animals were then 
euthanized.   
 
137 
Results 
Hormone levels and hepatic blood flow.  Hepatic sinusoidal levels of plasma glucagon 
remained basal throughout the study in all groups (Fig. 5.1).  Arterial plasma insulin 
levels increased from basal values of ~ 7 ± 1 to ~11 ± 0.5 as a result of a 600 μU/kg/min 
insulin infusion in Step 1 of the experimental period in all groups (Fig. 5.2).  During Step 
2, a 2000 μU/kg/min insulin infusion increased arterial plasma insulin levels to 51 ± 4, 42 
± 4, and 40 ± 6 μU/ml in the Saline, Lipid, and Lipid + CP-346086 groups, respectively 
(P = 0.049 Lipid vs. Saline, P = 0.017 Lipid + CP-346086 vs. Saline, Fig. 5.2).  Despite 
the moderate differences in arterial plasma insulin levels, there were no significant 
differences in hepatic sinusoidal insulin levels among the groups (Fig. 5.2). Arterial 
plasma cortisol, plasma epinephrine and norepinephrine, and hepatic blood flow 
remained basal and unchanged in all groups throughout the study (data not shown).    
Glucose levels and glucose infusion rates.  In all three groups, arterial plasma glucose 
(mg/dl) was successfully clamped in Step 1 (~110) and Step 2 (~109) of the experimental 
period at levels similar to those observed during the control period (~112, Fig. 5.3).  In 
the Saline group, the glucose infusion rate required to maintain euglycemia in response to 
an insulin infusion rate of 600 μU/kg/min was 2.2 ± 0.2 mg/kg/min.  That rate rose 
significantly to 15.3 ± 1.5 mg/kg/min when the insulin infusion was increased to 2000 
μU/kg/min (Step 2, Fig. 5.3).  However, in the Lipid group, the glucose infusion 
(mg/kg/min) only reached rates of 1.3 ± 0.3 in Step 1 and 11.1 ± 1.4 in Step 2 of the 
experimental period (both P < 0.05 vs. Saline and Lipid + CP-346086, Fig. 5.3).  
Interestingly, the glucose infusion rates required to maintain euglycemia in the Lipid + 
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CP-346086 group (3.0 ± 0.7 and 16.5 ± 2.7 mg/kg/min in Step 1 and Step 2, respectively, 
Fig. 5.3) were not different from those seen in the Saline group. 
Glucose metabolism.  Basal rates of net hepatic glucose output (NHGO, mg/kg/min) 
were similar in all three groups (Saline= 2.2 ± 0.6, Lipid= 1.9 ± 0.3, Lipid + CP-346086= 
1.9 ± 0.4, Fig. 5.4).  In the Saline group, 600 μU/kg/min of insulin suppressed NHGO to 
0.0 ± 0.3 mg/kg/min while infusion of insulin at 2000 μU/kg/min of insulin stimulated 
net hepatic glucose uptake (NHGU) of -1.2 ± 0.5 mg/kg/min (Fig. 5.4).  Insulin only 
suppressed NHGO in Step 1 of the Lipid and Lipid + CP-346086 groups to 0.9 ± 0.4  and 
0.7 ± 0.2 mg/kg/min, respectively (both P < 0.05 vs. Saline, Fig. 5.4).  Likewise, high 
levels of insulin tended to cause less NHGU in the lipid treated groups (~ -0.3 ± 0.2 
mg/kg/min) than in the Saline group (P< 0.01, Step 2, Fig. 5.4). Thus, repeated brief 
elevations in FFA resulted in decreased insulin sensitivity in the liver. 
Basal net hepatic glycogenolytic (NHGLY) flux rates were 2.7 ± 0.6, 2.0 ± 0.5, 
and 1.6 ± 0.6 mg/kg/min in the Saline, Lipid, and Lipid + CP-346086 groups, 
respectively (Fig. 5.4).   Increases in insulin, in the Saline group, resulted in a fall in net 
NHGLY flux (mg/kg/min) by 2.4 ± 0.7 in Step 1 and actually caused net glycogen 
synthesis in Step 2 (both P < 0.05 vs. control period, Fig. 5.4).  In contrast, in the Lipid 
group, increases in plasma insulin levels only decreased NHGLY flux by 1.0 ± 0.8 
mg/kg/min in Step 1 and barely caused net glycogen synthesis in Step 2 (P < 0.05 vs. 
Saline, Fig. 5.4).  A similar trend was also observed in the Lipid + CP-346086 group, in 
which NHGLY flux decreased by 1.0 ± 0.5 mg/kg/min in Step 1 and minimum net 
glycogen synthesis occurred in Step 2 (Fig. 5.4).   
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In the Saline group, basal net hepatic gluconeogenic (NHGNG) flux was -0.5 ± 
0.3 mg/kg/min, a rate signifying a state of net glycolysis.  In contrast, in both of the lipid 
treated groups, rates of basal NHGNG flux (mg/kg/min) represented a state of net 
gluconeogenesis with a rate of 0.1 ± 0.3 in the Lipid group and 0.3 ± 0.3 in the Lipid + 
CP-346086 (both P < 0.05 vs. Saline, Fig. 5.4).  In response to low dose insulin, rates of 
NHGNG flux were not significantly altered.  All groups exhibited net gluconeogenesis 
during Step 2.  The positive values obtained for NHGNG flux in the Saline group in 
response to high levels of insulin were likely due to the inhibition NHGLY flux such that 
carbon in the glycolytic pathway was reduced. 
Non-hepatic glucose uptake (non-HGU) was basal (~2.0 mg/kg/min) in all three 
groups during the control period (Fig. 5.4).  Insulin infusion at 600 μU/kg/min did not 
alter non-HGU (mg/kg/min) in the Saline (2.4 ± 0.2) or Lipid (2.1 ± 0.2) groups but 
surprisingly increased it in the Lipid + CP-346086 group (3.6 ± 0.7, P < 0.05 vs. Saline 
and Lipid, Fig 5.4).  In Step 2, hyperinsulinemia significantly increased non-HGU to 14.4 
± 1.8 mg/kg/min in the Saline group.  However, in the Lipid group, non-HGU only 
increased to 9.9 ± 1.0 mg/kg/min (P < 0.05 vs. Saline and Lipid + CP-346086, Fig. 5.4), 
whereas it was similar to that seen in the Saline group in the presence of Lipid and the 
MTP inhibitor (17.9 ± 4.8 mg/kg/min, P < 0.05 vs. Lipid, Fig. 5.4). 
Arterial blood levels and net hepatic balance of lactate.  In the Saline group, basal 
arterial blood lactate levels and net hepatic lactate output (NHLO) were 653 ± 83 μmol/l 
and 7.5 ± 2.9 μmol/kg/min, respectively (Fig. 5.5).  Basal arterial lactate levels (μmol/l) 
were significantly decreased in the Lipid (433 ±33) and Lipid + CP-346086 (347 ± 51, P 
< 0.05 vs. Saline), groups in association with decreased basal NHLO (P < 0.05 vs. Saline, 
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Fig. 5.5).   In fact, repeated lipid treatment in the presence of CP-346086 resulted in net 
uptake of lactate by the liver (-1.5 ± 3.4 μmol/kg/min, P < 0.05 vs. Saline, Fig. 5.5).  
Arterial blood lactate levels were not significantly altered by elevated insulin levels in 
any group throughout the experimental period.  NHLB was suppressed by high dose 
insulin in the Saline group but no appreciable change was observed in the other two 
groups. 
Arterial plasma FFA and triglycerides and blood glycerol levels and net hepatic 
uptake.  In the Saline group, arterial plasma FFA levels (μmol/l) fell from 545 ± 103 to 
187 ± 26 in response to an insulin infusion rate of 600 μU/kg/min (Step 1), and to 46 ± 5 
when the insulin infusion was increased to 2000 μU/kg/min (Step 2, Fig. 5.6). However, 
in the Lipid group, plasma FFA levels (μmol/l) decreased from 711 ± 124 to 407 ± 122 
(P < 0.05 vs. Saline) in Step 1 and 76 ± 25 in Step 2 (Fig. 5.6).  Interestingly, FFA levels 
in the Lipid + CP-346086 group (564 ± 89 μmol/l) tended to drop to those seen in the 
Saline group with levels of 230 ± 89  and 45 ± 14 μmol/l in Step 1 and Step 2, 
respectively (Fig. 5.6).  Rates of net hepatic FFA uptake fell in parallel with the decline 
in plasma FFA levels in all three groups (Fig. 5.6). 
 Arterial blood glycerol levels (μmol/l) fell from 62 ± 9 to 30 ± 4 and 17 ± 3 due to 
increased insulin infusion rates in the Saline group (Fig. 5.6).  However, in the Lipid 
group, glycerol levels (μmol/l) decreased from 79 ± 14 to 55 ± 9 (P < 0.05 vs. Saline) in 
Step 1 and 33 ± 8 in Step 2 (Fig. 5.6).  Blood glycerol levels in the Lipid + CP-346086 
group (69 ± 13 μmol/l) tended to drop to those seen in the Saline group with levels of 38 
± 5  and 20 ± 3 μmol/l in Step 1 and Step 2, respectively (Fig. 5.6).  Rates of net hepatic 
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glycerol uptake fell in parallel with the decline in plasma glycerol levels in all three 
groups (Fig. 5.6). 
 Basal arterial plasma triglycerides were ~500 ± 40 μmol/l in the Saline and Lipid 
group and fell modestly in response to increased plasma insulin (Fig. 5.7).  Interestingly, 
basal triglycerides were higher in the Lipid + CP-346086 group (740 ± 92 μmol/l, P < 
0.05 vs. Saline and Lipid, Fig. 5.7), and fell significantly fell during the experimental 
period to levels similar to those seen in the other two groups.   
Arterial blood levels and net hepatic balances of β-OHB and acetoacetate.  Basal 
arterial blood β-hydroxybutyrate (β-OHB) levels were not significantly different among 
the Saline and Lipid groups (Fig. 5.8).  However, there was a tendency for basal arterial 
blood β-OHB levels to be higher in the Lipid + CP-346086 group compared to the Saline 
group (Fig. 5.8).  Rates of basal net hepatic β-OHB output (μmol/kg/min) in the Lipid 
(0.8 ± 0.2) and Lipid + CP-346086 (1.1 ± 0.3) groups, on the other hand, were 
significantly elevated compared to those in the Saline group (0.4 ± 0.04, P < 0.05, Fig. 
5.8).  Arterial blood levels and net hepatic outputs of β-OHB fell in response to increases 
in plasma insulin so that eventually they were no different from those in the Saline 
control (Fig. 5.8).  Arterial blood levels of acetoacetate were comparable among all 
groups.  Basal net hepatic output of acetoacetate tended to be higher in the Lipid + CP-
346086 group than in the Saline and Lipid groups.  Although rates of net hepatic outputs 
of acetoacetate fell in response to elevated insulin in all groups, rates remained higher in 
the Lipid + CP-346086 (NS) compared to the other groups (Fig. 5.8).  Thus, lipid 
treatment resulted in increased ketogenesis, particularly in the presence of the MTP 
inhibitor, consistent with excessive FA breakdown.   
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Arterial blood levels, net hepatic balances, and fractional extraction of gluconeogenic 
amino acids.  Basal arterial blood levels of total gluconeogenic amino acids were similar 
among all groups despite lower levels of the individual amino acids alanine and serine in 
the Lipid group and alanine alone in the Lipid + CP-346086 (Table 5.1).  Additionally, 
no differences in net hepatic balance or fractional extraction of individual or total amino 
acids were observed among groups during the control period (Table 5.1).  Interestingly, 
hepatic fractional extraction of total gluconeogenic amino acids was higher in the Lipid + 
CP-346086 group in response to low dose insulin than the other groups (P < 0.05 vs. 
Saline and Lipid, Table 5.1).  By Step 2 of the experimental period, net hepatic balance 
and fractional extraction of total gluconeogenic amino acids increased in response to 
elevated insulin levels regardless of treatment (P < 0.05, Table 5.1).  This in turn resulted 
in a fall in arterial blood levels of each gluconeogenic amino acid (P < 0.05, Table 5.1). 
 
Discussion 
The aim of the present study was to determine the effect of repeated elevations of 
circulating FFA on insulin sensitivity in the liver and peripheral tissues in the presence or 
absence of an MTP inhibitor.  Repeated elevations of FFA for 3-h/d for 15-d did not 
chronically alter hepatic triglyceride content (see Chapter IV); however, simultaneous 
elevations of hepatic FFA flux and inhibition of hepatic triglyceride export with CP-
346086 resulted in a two-fold increase in liver triglycerides.  Although it is well 
established that both acute and chronic increases of FFA cause insulin resistance, it 
remains unclear if a meal associated (3-h) elevation in plasma FFA levels can alter 
insulin sensitivity.  Thus we examined whole body insulin sensitivity following treatment 
143 
with saline, Intralipid/heparin (Lipid), or Intralipid/heparin in the presence of a 
microsomal triglyceride transfer protein inhibitor, CP-346086, for 3 h/d for 15 d.   
Approximately 15 h after the final treatment (18 h fast), a 2 step 
hyperinsulinemic-euglycemic clamp was performed to assess insulin sensitivity.  In the 
presence of basal glucagon and euglycemia, insulin was administered intraportally at 600 
μU/kg/min in step 1 (0 to 120 min) and 2000 μU/kg/min in step 2 (120 to 240 min).  In 
the normal overnight-fasted dog, 600 μU/kg/min of insulin should fully suppress net 
hepatic glucose output, while 2000 μU/kg/min should induce a low rate of net hepatic 
glucose uptake and marked non-HGU (47).  Our findings were three-fold: 1) brief 3-h 
elevations in FFA given daily for 3-h/d for 15-d can impair insulin action in liver, adipose 
tissue, and skeletal muscle, 2) the accumulation of hepatic triglycerides brought about by 
inhibition of VLDL export  does not worsen the effects of repeated elevations of FFA on 
the liver, and 3) the peripheral insulin resistance brought about by repeated elevations of 
FFA is not observed when the lipid treatment is administered in the presence of the MTP 
inhibitor, CP-346086.   
The present study confirmed previous findings that acute suppression of NHGO by 
insulin results from inhibition of glycogenolysis (Fig. 5.4, (25, 83, 106).  Boden et al. 
(25) showed in humans that, by 3-h, an acute administration of Intralipid and heparin 
reduced insulin suppression of glycogenolysis and therefore endogenous glucose 
production by 66 and 64%, respectively.  Here we show that repeated brief elevations of 
FFA daily over a 15-d period chronically reduced insulin suppression of net hepatic 
glucose production by ~40 % in the Lipid and Lipid + CP-3460686 groups compared to 
Saline control (Fig. 5.3).  This reduction resulted from insulin’s inability to suppress 
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NHGLY (Fig. 5.4).  Furthermore, higher insulin levels (~130 μU/ml) were less effective 
in stimulating NHGU in the lipid treated groups (both P ≤ 0.1 vs. Saline, Fig. 5.4).  As 
hepatic sinusoidal levels of plasma insulin and glucagon were successfully controlled 
throughout the study, the reduction in hepatic insulin action was due to the 15-d lipid 
treatments.  
Repeated brief elevations of FFA altered basal NHGNG flux in both lipid treated 
groups.  As expected in a 18-h fasted dog, net hepatic glycolysis was present during the 
basal period in the Saline group (117).  Interestingly, following 15-d of lipid treatment, 
NHGNG flux had shifted to net gluconeogenesis.   A possible explanation for this 
difference in basal NHGNG flux is suggested by the higher rates of hepatic production of 
ketone bodies observed in both Lipid groups compared to the Saline group (Fig. 5.8).  It 
has been proposed (132, 186, 221) that increased fatty acid oxidation subsequently raises 
intracellular citrate levels, leading to decreased PFK-1 and increased P1,6P2ase activities, 
and thus suppression of glycolysis and/or stimulation of gluconeogenesis.  When glucose 
is being produced via glycogenolysis, as seen here in the basal period, some of the 
glycogenolytically-derived carbon enters the glycolytic pathway and exits the liver as 
lactate, and an increase in net hepatic lactate output occurs (49, 117).  In the present 
study, an increase in hepatic ketone production was associated with suppressed hepatic 
lactate output during the basal period of both of the lipid treated groups.  Thus, as 
increased basal hepatic ketone production positively correlated with changes in basal 
NHGNG flux in both of the lipid groups, it is likely a new steady state had been 
achieved, whereby the daily elevated hepatic FFA load was compensated for by an 
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increase in the removal of hepatic lipids via mitochondrial β-oxidation and ketogenesis, 
which in turn inhibited glycolysis and/or stimulated gluconeogenesis.   
Insulin resistance was also induced in peripheral tissues following 15-d of 
repeated brief elevations of FFA.  In response to an insulin infusion of 600 μU/kg/min, 
arterial blood glycerol levels fell to a significantly lesser degree in the Lipid group than in 
the Saline group.  Interestingly, arterial blood glycerol levels remained elevated in Step 2 
despite such high levels of insulin.  This observation is of particular significance as 
suppression of lipolysis is the most sensitive response to the action of insulin (270).  
Although glycerol is a better indicator of lipolysis, arterial plasma FFA levels also fell 
less in response to low dose insulin in the Lipid group than they did in the Saline group.  
Levels were comparable during high insulin infusion (Fig. 5.6).  These findings suggest 
that insulin’s ability to suppress lipolysis in adipose tissue was significantly impaired.  As 
FFA have been shown to mediate insulin inhibition of hepatic glucose production, the 
lack of their suppression might explain the defect in insulin action at the liver in response 
to low dose insulin.   
Additionally, non-hepatic glucose uptake was reduced by ~30 % in the Lipid 
group compared to Saline group in response to high dose insulin (Fig. 5.4).  Of note, the 
lower arterial plasma insulin levels observed in the Lipid group than in the Saline group 
in Step 2 (Fig. 5.2) are presumably due to two outliers.  If these particular dogs are 
omitted from data analysis, plasma insulin levels (μU/ml) would be 46 ± 2 in the Lipid 
compared to 51 ± 4 in the Saline group.  In that case, non-HGU (mg/kg/min) would be  
9.9 ± 1.3 (Lipid) as opposed to 14.4 ± 1.8 (Saline).  Therefore, differences in non-HGU 
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are most likely attributable to repeated elevations of FFA and not to the apparent 
reduction in circulating insulin. 
Interestingly, the induction of insulin resistance in both adipose tissue and skeletal 
muscle brought about by repeated elevations of FFA was not observed when the lipid 
infusion was administered in the presence of the MTP inhibitor, CP-346086.  Arterial 
plasma FFA and blood glycerol levels in the group receiving the inhibitor fell to levels 
similar to those seen in the Saline group in response to insulin throughout the 
experimental infusion (Fig. 5.6).  Furthermore, non-hepatic glucose uptake was 
comparable between the Lipid + CP-346086 and Saline groups.  It should be noted that, 
in Step 2 of the experimental period, arterial plasma insulin levels were slightly lower 
(Fig. 5.2) in the Lipid + CP-346086 group than in the Saline group, strengthening the 
conclusion that the MTP inhibitor prevented loss of peripheral insulin sensitivity. 
The lack of peripheral insulin resistance observed following combined treatment of 
lipid and CP-346086 was most likely a result of a less pronounced increase in FFA 
during the lipid infusion, compared to lipid treatment alone.  Simultaneous infusion of 
Intralipid and heparin is a common research tool used to acutely raise circulating FFA.  
Heparin administration increases plasma levels (over 100-fold) of the lipolytic enzyme, 
lipoprotein lipase (LPL), which results in hydrolysis of triglycerides from chylomicrons 
and VLDL particles and consequently increases circulating levels of FFA (170).   LPL 
does not distinguish between exogenous and endogenous triglycerides.  Therefore, the 
level of FFA observed during combined Intralipid and heparin infusions is the result of 
hydrolysis of triglycerides from both sources.  As MTP is thought to play a pivotal role in 
the assembly and secretion of apoB-containing lipoproteins, and CP-346086 was 
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administered at the time of feeding, both VLDL and chylomicron secretion were 
presumably inhibited postprandially in the liver and small intestine, respectively.  
Therefore, it is possible that inhibition of apo-B lipoprotein secretion by CP-346086 
during the lipid infusion resulted in a blunting of the elevation of FFA, such that it was 
not sufficient to induce insulin resistance.  In keeping with this possibility, there was no 
evidence for elevation of FFA, glycerol, or triglycerides in the fasting state in the Lipid 
group, suggesting that the daily infusions of lipid and heparin had no prolonged effect on 
these parameters.  Morover, in the single dog examined following an acute infusion of 
Intralipid, FFA and glycerol levels returned to basal within an hour after the infusion 
ceased (Chapter IV). 
An alternative explanation could be that over a 24-h period, reduction of circulating 
lipoprotein triglycerides and subsequent lipid uptake by peripheral tissues prevented the 
FFA-induced insulin resistance observed in adipose tissue and skeletal muscle.  We have 
no data regarding the full 24-h response, but the elevation of plasma triglycerides in the 
basal state and the fact that the basal FFA levels were not reduced in the group receiving 
the inhibitor suggest that the latter alternative is unlikely. 
There is a large body of evidence which strongly suggests that elevated plasma FFA 
levels are a major cause of insulin resistance in obesity and type 2 diabetes.  It has been 
hypothesized that acute elevations in FFA impair insulin action via oxidative and/or non-
oxidative mechanisms.  As alluded to above, FFA compete with glucose for substrate 
oxidation which consequently leads to the inhibition of glycolysis and could therefore 
reduce peripheral glucose uptake and/or stimulate hepatic gluconeogenesis.  An 
alternative hypothesis, as proposed by Shulman (252) and Boden (19), is that elevations 
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of intracellular FA metabolites (diacylglycerol, fatty acyl CoA, and ceramides) following 
increased FFA delivery activate PKC.  PKC then leads to decreased activity of the insulin 
receptor and IRS-1 and consequently results in decreased PI3K activity and reduced 
insulin-stimulated muscle glucose transport.   Although this mechanism has primarily 
been established in muscle, studies have indicated that a similar mechanism may also 
occur in liver (28, 156) and adipose tissue (104).   
More recently, it has been suggested that FFA-induced hepatic (28, 36) and peripheral 
(194, 208) insulin resistance is associated not only with elevations of intracellular  FFA 
metabolites but also activation of proinflammatory signaling pathways (JNK and 
IkB/NFκB) and increased expression of proinflammatory cytokines such as TNF-α and 
IL-6.  Activation of an inflammatory state is thought to play an important role in insulin 
resistance and is thus an important link to the pathogenesis of type 2 diabetes.  As 
increases in proinflammatory gene expression are associated with insulin resistance in the 
liver and peripheral tissues, it is probable that a sub-acute inflammatory response was 
induced following repeated lipid treatment.  Indeed, IKK-β activation in insulin resistant 
hepatocytes and adipocytes is associated with macrophage infiltration and 
proinflammatory cytokine release which could promote local and potentially systemic 
inflammation.  Additionally, acute infusion of Intralipid has been shown to activate the 
NFκB pathway in mouse (36, 150) and human (150, 302), and the associated insulin 
resistance has been shown to be ameliorated by salicylate.  Thus, it would be of particular 
interest to assess markers of inflammation following repeated elevations of FFA.  
Although markers of inflammation were not evaluated in the current study, it is possible 
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that recurring elevations of FFA induced a sub-acute inflammatory response that resulted 
in chronic insulin resistance. 
Accumulation of intracellular triglycerides in liver and skeletal muscle has been 
strongly implicated in the development of insulin resistance; however to date, their 
putative role is based solely upon correlative results.  It is proposed that the triglycerides 
themselves do not alter insulin action but rather provide a reservoir of FFA and/or FA 
metabolites that arise during lipid synthesis or hydrolysis and thus impair insulin 
signaling via activation of PKC, JNK, and/or IKK-β.  The present study supports this 
hypothesis, given that the accumulation of hepatic triglyceride content in the Lipid + CP-
346086 group did not result in a greater reduction of hepatic insulin action compared to 
the Lipid group (Fig. 5.4).  Moreover, as a single 3-h treatment of elevated FFA resulted 
in a two-fold rise in hepatic triglycerides (Chapter IV, Fig. 4.5) that was not present 
following the 15-d treatment regimen, it is possible that a compensation of the liver 
during the chronic treatment allowed it to remove accumulated hepatic lipids that would 
have impaired insulin suppression of NHGO.  The fact that basal hepatic β-OHB 
production was elevated in both of the lipid groups following the 15-d treatment, albeit in 
the presence of normal basal plasma FFA levels, strongly suggests that the liver does 
indeed compensate for a positive triglyceride balance.  Therefore, it is possible that 
hepatic triglyceride hydrolysis and subsequent increases in intracellular FFA and/or FA 
metabolites and impaired insulin signaling via activation of PKC, JNK, and/or IKK-
β contribute to the insulin resistance associated with steatosis. 
In conclusion, the present study is the first to show that repeated brief daily elevations 
of FFA induce insulin resistance in liver, skeletal muscle, and adipose tissue.  This 
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finding suggests that recurring elevations of FFA, such as might occur during the 
postprandial period in type 2 diabetes, could progressively lead to chronic insulin 
resistance.  In addition, we show that accumulation of hepatic triglycerides does not 
worsen the effects of repeated elevations of FFA.  We speculate that it is rather the 
compensatory mechanism(s) of the liver to remove excess lipids that results in hepatic 
insulin resistance.   And lastly, peripheral insulin resistance was not present following 
combined lipid and CP-346086 treatment which was likely owing to a less significant rise 
in FFA during the lipid infusion as less lipoprotein-associated triglycerides were 
available for hydrolysis.  However, it could be that accumulation of hepatocellular 
triglycerides reduce circulating lipids and thus serve to prevent induction of peripheral 
insulin resistance.  Although we can not draw any definitive conclusions from this 
particular finding, it raises the question as to whether normalization of the increased 
postprandial VLDL production observed in type 2 diabetes would improve insulin 
sensitivity.
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Figure 5.1:  Hepatic sinsusoidal levels of plasma glucagon. Hepatic sinusoidal levels 
of plasma glucagon during a 2 step hyperinsulinemic-euglycemic clamp in conscious 18 
h fasted dogs. Insulin was infused intraportally at 600 μU/kg/min in Step 1 and 2000 
μU/kg/min in Step 2.  The clamp was performed following treatment with saline, 
Intralipid/heparin (Lipid), or Intralipid/heparin in the presence of a MTP inhibitor, CP-
346086 for 3h/d for 15-d.  Values are means ± SE.  Control period values are an average 
of samples taken at -40 and 0 min. Values for Steps 1 and 2 of the experimental period 
are an average of the 3 samples taken during the last h of each step at 30 min intervals.   
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 Figure 5.2:  Arterial and hepatic sinsusoidal levels of plasma insulin.  Arterial (A) 
and hepatic sinusoidal levels (B) of plasma insulin during a 2-step hyperinsulinemic-
euglycemic clamp in conscious 18 h fasted dogs. Insulin was infused intraportally at 600 
μU/kg/min in Step 1 and 2000 μU/kg/min in Step 2.  The clamp was performed following 
treatment with saline, Intralipid/heparin (Lipid), or Intralipid/heparin in the presence of a 
MTP inhibitor, CP-346086 for 3h/d for 15-d.  Values are means ± SE.  Control period 
values are an average of samples taken at -40 and 0 min. Values for Steps 1 and 2 of the 
experimental period are an average of the 3 samples taken during the last h of each step at 
30 min intervals.  * P < 0.05 vs. Saline    
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Figure 5.3:  Arterial plasma levels of glucose and glucose infusion rates.  Arterial 
plasma levels of glucose (A) and glucose infusion rates (B) during a 2-step 
hyperinsulinemic-euglycemic clamp in conscious 18 h fasted dogs.  Insulin was infused 
intraportally at 600 μU/kg/min in Step 1 and 2000 μU/kg/min in Step 2.  The clamp was 
performed following treatment with saline, Intralipid/heparin (Lipid), or 
Intralipid/heparin in the presence of a MTP inhibitor, CP-346086 for 3 h/d for 15-d.  
Values are means ± SE.  Control period values are an average of samples taken at -40 and 
0 min. Values for Steps 1 and 2 of the experimental period are an average of the 3 
samples taken during the last h of each step at 30 min intervals.  * P < 0.05 vs. Saline  
@ P < 0.05 vs. Lipid 
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Figure 5.4:  Net hepatic glucose balance, glycogenolytic (GLY) and gluconeogenic 
(GNG) fluxes, and non-hepatic glucose uptake.  Net hepatic glucose balance (A) and 
glycogenolytic flux (B), gluconeogenic flux (C), and non-hepatic glucose uptake (D) 
during a 2-step hyperinsulinemic-euglycemic clamp in conscious 18 h fasted dogs.  
Insulin was infused intraportally at 600 μU/kg/min in Step 1 and 2000 μU/kg/min in Step 
2.  The clamp was performed following treatment with saline, Intralipid/heparin (Lipid), 
or Intralipid/heparin in the presence of a MTP inhibitor, CP-346086 for 3 h/d for 15-d.  
Positive and negative values of net hepatic glucose balance represent net output and net 
uptake, respectively.  Positive and negative values of net hepatic GLY flux represent net 
glycogenolysis and net synthesis, respectively.  Positive and negative values of net 
hepatic GNG flux represent net gluconeogenesis and net glycolysis, respectively.  Inset:  
Change in net hepatic GLY from control period during hyperinsulinemic-euglycemic 
clamp.  Values are means ± SE.  Control period values are an average of samples taken at 
-40 and 0 min. Values for Steps 1 and 2 of the experimental period are an average of the 
3 samples taken during the last h of each step at 30 min intervals.  * P < 0.05 vs. Saline 
@ P < 0.05 vs. Lipid  
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Figure 5.5:  Arterial blood levels and net hepatic balance of lactate.  Arterial blood 
levels (A) and net hepatic balance (B) of lactate during a 2-step hyperinsulinemic-
euglycemic clamp in conscious 18 h fasted dogs.  Insulin was infused intraportally at 600 
μU/kg/min in Step 1 and 2000 μU/kg/min in Step 2.  The clamp was performed following 
treatment with saline, Intralipid/heparin (Lipid), or Intralipid/heparin in the presence of a 
MTP inhibitor, CP-346086 for 3 h/d for 15-d.  Positive and negative values of net hepatic 
lactate balance represent net output and net uptake, respectively.  Control period values 
are an average of samples taken at -40 and 0 min. Values for Steps 1 and 2 of the 
experimental period are an average of the 3 samples taken during the last h of each step at 
30 min intervals.  * P < 0.05 vs. Saline @ P < 0.05 vs. Lipid. 
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Figure 5.6:  Arterial plasma FFA and blood glycerol levels and net hepatic uptakes.  
Arterial plasma FFA levels (A), net hepatic FFA uptake (B), arterial blood glycerol levels 
(C), and net hepatic glycerol uptake (D) during a 2-step hyperinsulinemic-euglycemic 
clamp in conscious 18 h fasted dogs.  Insulin was infused intraportally at 600 μU/kg/min 
in Step 1 and 2000 μU/kg/min in Step 2.  The clamp was performed following treatment 
with saline, Intralipid/heparin (Lipid), or Intralipid/heparin in the presence of a MTP 
inhibitor, CP-346086 for 3 h/d for 15-d.  Control period values are an average of samples 
taken at -40 and 0 min. Values for Steps 1 and 2 of the experimental period are an 
average of the 3 samples taken during the last h of each step at 30 min intervals.   
* P < 0.05 vs. Saline.  
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Figure 5.7:  Arterial plasma triglyceride levels.  Arterial plasma triglyceride levels 
during a 2-step hyperinsulinemic-euglycemic clamp in conscious 18 h fasted dogs.  
Insulin was infused intraportally at 600 μU/kg/min in Step 1 and 2000 μU/kg/min in Step 
2.  The clamp was performed following treatment with saline, Intralipid/heparin (Lipid), 
or Intralipid/heparin in the presence of a MTP inhibitor, CP-346086 for 3 h/d for 15-d.  
Control period values are an average of samples taken at -40 and 0 min. Values for Steps 
1 and 2 of the experimental period are an average of the 3 samples taken during the last h 
of each step at 30 min intervals.  * P < 0.05 vs. Saline @ P < 0.05 vs. Lipid 
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Figure 5.8.  Arterial blood levels and net hepatic outputs of β-OHB and 
acetoacetate.  Arterial blood levels (A) and net hepatic balance (B) of β-OHB and 
arterial blood levels (C) and net hepatic output (D) of acetoacetate during a 2-step 
hyperinsulinemic-euglycemic clamp in conscious 18 h fasted dogs.  Insulin was infused 
intraportally at 600 μU/kg/min in Step 1 and 2000 μU/kg/min in Step 2.  The clamp was 
performed following treatment with saline, Intralipid/heparin (Lipid), or 
Intralipid/heparin in the presence of a microsomal triglyceride transfer protein inhibitor, 
CP-346086 for 3 h/d for 15 d.  Values are means ± SE.  * P < 0.05 vs. Saline.  @ P < 
0.05 vs. Lipid. 
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CHAPTER VI 
 
SUMMARY AND CONCLUSIONS 
 
Although diabetes mellitus was long considered a disease of minor significance to 
world health, it is now the most common disease in the world. In fact, over the past two 
decades an explosive increase has been observed in the number of people diagnosed with 
diabetes worldwide.  The epidemic is chiefly of type 2 diabetes and is largely due to the 
escalating rates of obesity.  Analyses by the International Obesity Task force indicate that 
approximately 58% of diabetes mellitus globally can be attributed to weight gain.  More 
specifically, in western countries, around 90% of type 2 diabetes cases are attributable to 
weight gain. 
Weight gain leads to insulin resistance and consequently hyperglycemia due to 
increase hepatic glucose production and decreased peripheral glucose uptake.  Insulin 
resistance places a greater demand on the pancreatic capacity to produce insulin. 
Although the primary cause of the disease is unknown, the major causative link between 
type 2 diabetes and obesity is an elevation of circulating (free fatty acids, FFA) and 
intracellular lipids.  To optimize therapy with insulin sensitizing agents, it would be 
useful to understand how increased lipids contribute to insulin resistance.  Therefore, the 
goal of this dissertation was to gain a better understanding of how changes in lipid 
metabolism alter glucose homeostasis.   
Glucose homeostasis reflects a delicate balance between glucose production and 
glucose uptake. This balance is best demonstrated during periods following food 
consumption and fasting when plasma glucose levels remain in a narrow range.  
161 
Following an overnight fast (post absorptive state), the liver is the major contributor of 
endogenous hepatic glucose production and is thus the principal organ which delivers 
glucose to both the non-insulin-sensitive (nervous, red blood cells, skin, smooth muscle) 
and the insulin sensitive (muscle and fat) tissues.  Following a meal (postprandial state) 
minimization of postprandial hyperglycemia results from the suppression of endogenous 
glucose production and stimulation of glucose uptake (110). Thus, the factors that 
regulate balance between glucose production and glucose uptake are extremely important 
to glucoregulation.   
 Glucoregulatory hormones tightly control glucose production and uptake by their 
direct actions on glucose metabolism and indirect actions on both lipid and protein 
metabolism.  Three main glucoregulatory hormones are insulin, epinephrine, and 
glucagon.  Insulin, secreted by the β-cells of the pancreas, rises in response to 
hyperglycemia, rapidly suppressing hepatic glucose production, and stimulating glucose 
uptake in peripheral tissues.   On the other hand, epinephrine and glucagon, secreted from 
the adrenal medulla and pancreatic α-cells, respectively, rise in response hypoglycemia 
acting on the liver to stimulate hepatic glucose production.  Additionally, the metabolic 
effects of insulin and epinephrine on lipid and protein metabolism in peripheral tissues 
indirectly mediate their glucoregulatory action.    
In fact, our laboratory (255) and others (2, 109, 225) have shown that the main 
substrate responsible for the reduction in insulin’s indirect effect on HGP is FFA.  Insulin 
inhibits lipolysis and thus decreases the plasma FFA levels.   Cellular uptake of FFA 
subsequently increases FA oxidation and alters enzymatic activity of glucose metabolic 
pathways by increasing P1,6P2ase and decreasing PFK-1 activities, thereby 
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simultaneously stimulating GNG and hindering glycolysis.  Thus, the antilipolytic effects 
of insulin mediate its ability to suppress HGP by reducing GNG.   
Likewise, the lipolytic action of epinephrine influences its ability to stimulate 
HGP.  The direct action of epinephrine on the liver results in the stimulation of GLY, 
however, Chu et al. (53) have shown that in the presence of elevated FFA epinephrine’s 
glycolytic effect is limited but its gluconeogenic action is augmented.  Thus, 
epinephrine’s ability to release FFA from adipose tissue mediates its action on the liver 
by stimulating hepatic GNG.  The simultaneous inhibition of glycolysis causes an 
increase in intracellular G6P and could possibly result in the inhibition of GLY.   
Although glucagon receptors are located on adipocytes and glucagon has been 
shown to be capable of stimulating lipolysis in vitro, the hormone has little to no effect 
on adipose tissue in vivo.  Since the direct actions of both epinephrine and glucagon on 
HGP are mediated by cAMP, it could be hypothesized that elevations in FFA would alter 
hepatic glucagon action in a similar manner to that seen with epinephrine.   In overt type 
2 diabetes, lower plasma insulin levels during the postprandial period results in a 
decreased insulin effect at both the pancreatic α-cell and adipocyte, contributing to the 
elevation of glucagon and FFA levels (75, 243).   As an insufficient decrease in HGP is 
thought to be a main contributor of the postprandial hyperglycemia observed in type 2 
diabetes, it is possible that elevated levels of glucagon and FFA could be responsible for 
the increase in glucose production by the liver in these patients.  Therefore the goal of 
Specific Aim I was to determine how elevations in glucagon and FFA interact to acutely 
regulate HGP.  Our findings indicate that elevated FFA inhibit the glycogenolytic effects 
of glucagon, as they do the glycogenolytic effect of epinephrine.  However, this effect is 
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short-lived compared to epinephrine.  In contrast to the results with the combination of 
elevated FFA and epinephrine, an increase in FFA does not augment glucagon-stimulated 
hepatic gluconeogenesis.  One possible explanation for this could be that the potency of 
glucagon to stimulate glycogenolysis and thus force carbon down the glycolytic pathway 
is greater than that of epinephrine.  This would override FFA’s ability to inhibit 
glycolysis or fuel gluconeogenesis.  Therefore, the question arises as to whether 
epinephrine levels of equal biological effectiveness to the glucagon dosage used in this 
study would prevent FFA-stimulated gluconeogenesis.   
 Although postprandial levels of glucagon and FFA are elevated in individuals 
with type 2 diabetes, our results suggest that their interaction alone does not potentiate 
HGP nor do FFA alter the mechanisms by which glucagon stimulates HGP.  Therefore, it 
is likely that lower levels of insulin as well as elevated levels of glucagon and FFA are 
responsible for the increases in HGP observed during the postprandial period of patients 
with type 2 diabetes.   
Even though elevated postprandial FFA may not alter glucagon action in type 2 
diabetes, there is strong evidence for elevated fasting and postprandial FFA levels in type 
2 diabetes and those at risk for the disease.  Both acute (20, 26, 229, 257) and chronic 
(20, 237) elevations of FFA have been shown to induce insulin resistance.  Actually, it 
has been estimated that elevated plasma FFA account for the entire insulin resistance in 
non-diabetic obese patients and ~50% of the insulin resistance in obese patients with type 
2 diabetes (19).  The mechanism(s) by which elevations in FFA impair insulin action is 
unclear however it has been hypothesized that insulin resistance occurs via oxidative 
and/or non-oxidative mechanisms.  As alluded to above, FFA compete with glucose for 
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substrate oxidation which consequently leads to the inhibition of glycolysis and could 
therefore reduce peripheral glucose uptake and/or stimulate hepatic gluconeogenesis.  An 
alternative hypothesis, as proposed by Shulman (252) and Boden (19), is that elevations 
of intracellular FA metabolites (diacylglycerol, fatty acyl CoA, and ceramides) following 
increased FFA delivery activate PKC.  PKC then leads to decreased activity of the insulin 
receptor and IRS-1 and consequently results in decreased PI3K activity and reduced 
insulin-stimulated muscle glucose transport.   Although this mechanism has primarily 
been established in muscle, studies have indicated that a similar mechanism may also 
occur in liver (28, 156) and adipose tissue (104).   
More recently, it has been suggested that FFA-induced hepatic (28, 36) and 
peripheral (194, 208) insulin resistance is associated not only with elevations of 
intracellular  FFA metabolites but also activation of proinflammatory signaling pathways 
(JNK and IkB/NFκB) and increased expression of proinflammatory cytokines such as 
TNF-α and IL-6.  Activation of an inflammatory state is thought to play an important role 
in insulin resistance and is thus an important link to the pathogenesis of type 2 diabetes.  
Additionally, acute infusion of Intralipid has been shown to activate the NFκB pathway 
in mouse (36, 150) and human (150, 302), and the associated insulin resistance has been 
shown to be ameliorated by salicylate.   
Accumulation of intracellular lipids, specifically, triglycerides in liver and 
skeletal muscle has also been strongly implicated in the development of insulin 
resistance.  Interestingly, an increase in triglycerides in skeletal muscle shows a stronger 
correlation with insulin resistance than elevated levels of plasma FFA (152, 195, 202).  
Accummulation of hepatic triglycerides, or hepatic steatosis, has a very robust 
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association with hepatic insulin sensitivity; in fact, studies have indicated that insulin 
resistance is more closely related to changes in hepatocellular than intramyocellular 
triglyceride content (11, 173, 242).  It is proposed that the triglycerides themselves do not 
alter insulin action but rather provide a reservoir of FFA and/or FA metabolites that arise 
during lipid synthesis or hydrolysis and thus impair insulin signaling via activation of 
PKC, JNK, and/or IKK-β.  Although there is a strong correlation with increased 
triglyceride content in non-adipose tissues (152, 195, 202)  and type 2 diabetes it unclear 
whether the accumulation of intracellular lipid is a cause of or result of the decreased 
insulin response.  The putative role of triglyceride accumulation in non-adipose tissues is 
based solely upon correlative results.  Therefore, one remains unconvinced regarding the 
importance of triglyceride accumulation as a direct cause of insulin resistance and a 
contributor to the pathogenesis of diabetes. Since our laboratory uses the conscious dog 
as an experimental model due to its good reflection of glucose metabolism in humans and 
allowance for invasive experimental design, the goal of Specific Aim II was to create a 
canine model of hepatic steatosis.  In attempt to do so, lipid metabolism was altered by 3 
different treatments: 1) a 10% fructose diet, 2) elevating hepatic FFA flux, or 3) elevating 
hepatic FFA flux while simultaneously inhibiting triglyceride export from the liver using 
the microsomal triglyceride transfer protein inhibitor, CP-346086.  A 10% fructose diet 
given over a four month period and repeated elevations of FFA (3-h/d for 15-d) were not 
successful in elevating hepatic triglycerides.  However, as triglyceride levels were 
elevated 2-fold following the combined lipid and CP-346086 treatment we were thus 
successful in creating a canine model of hepatic steatosis.   
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Although it is well established that both acute and chronic increases of FFA cause 
insulin resistance, it remains unclear if recurring elevations of plasma FFA levels, such as 
might occur during the postprandial period in type 2 diabetes, can alter insulin sensitivity.  
For that reason, even though repeated elevations of FFA did not result in a rise in hepatic 
triglycerides, it was of interest to evaluate insulin sensitivity following the treatment 
regimen. Therefore the goal of Specific Aim III was to examine whole body insulin 
sensitivity following treatment regimens to induce hepatic steatosis.   
Interestingly, repeated brief elevations of FFA also altered the mechanisms by 
glucose is produced by the liverin the basal state in both of the lipid treated groups.  In a 
normal 18-h fasted dog, glucose is produced primarily via hepatic glycogenolysis and a 
state of net hepatic glycolysis is present (117).  However, following the 15-d of lipid 
treatment, HGP resulted from both glycogenolysis and gluconeogenesis as NHGNG flux 
had shifted from a net glycolysis to net gluconeogenesis.   A possible explanation for this 
difference in basal NHGNG flux is suggested by the higher rates of hepatic production of 
ketone bodies observed in both Lipid groups compared to the Saline treatment.  As 
mentioned above, increased fatty acid oxidation subsequently raises intracellular citrate 
levels, leading to decreased PFK-1 and increased P1,6P2ase activities, and thus 
suppression of glycolysis and/or stimulation of gluconeogenesis.  Thus, as increased 
basal hepatic ketone production positively correlated with changes in basal NHGNG flux 
in both of the lipid groups, it is likely a new steady state had been achieved, whereby the 
daily elevated hepatic FFA load was compensated for by an increase in the removal of 
hepatic lipids via mitochondrial β-oxidation and ketogenesis, which in turn inhibited 
glycolysis and/or stimulated gluconeogenesis.   
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Furthermore, our results show for the first time that repeated daily elevations of FFA 
induce chronic insulin resistance in liver, skeletal muscle, and adipose tissue.  This 
finding suggests that recurring elevations of FFA, such as might occur during the 
postprandial period in type 2 diabetes, could progressively lead to chronic insulin 
resistance.  In addition, we show that accumulation of hepatic triglycerides does not 
worsen the effects of repeated elevations of FFA.  We speculate that it is rather the 
compensatory mechanism(s) of the liver to remove excess lipids that results in hepatic 
insulin resistance.   Therefore, it is possible that hepatic triglyceride hydrolysis and 
subsequent increases in intracellular FFA and/or FA metabolites and impaired insulin 
signaling via activation of PKC, JNK, and/or IKK-β contribute to the insulin resistance 
associated with steatosis.   
 Taken together, this dissertation clearly demonstrates that elevations of circulating 
and intracellular lipids alter glucoregulatory hormone action.  We have shown that acute 
elevations of FFA affect hormone (insulin, epinephrine and glucagon) regulated hepatic 
glucose production by altering the mechanisms by which glucose is produced by the 
liver.  Our findings also suggest that compensatory increases in triglyceride hydrolysis by 
the liver also alter mechanisms of basal hepatic glucose production and reduce insulin’s 
ability to suppress glycogenolysis.  And lastly, this work suggests that repeated brief 
elevations, such as might occur during the postprandial period in type 2 diabetes, could 
progressively lead to chronic insulin resistance.  Although several mechanism(s) have 
been proposed by which elevated circulating and intracellular lipids alter glucoregulatory 
hormone action (particularly for that of insulin), the means by which changes in lipid 
metabolism alter glucose homeostasis still remains unclear.  Elucidating the biochemical 
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and molecular mechanisms by which a dysregulation of lipid metabolism could interact 
with glucoregulatory hormones and cause harmful metabolic effects is of particular 
interest in order to optimize insulin sensitizing agents and thus ultimately better the lives 
of those affected with type 2 diabetes. 
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